ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES

Abstract: This invention relates to compounds of formula (I) which are useful in association with a pharmaceutical carrier as antiatherosclerotic agents. In addition, various compounds of formula (I) are useful inhibitors of cell proliferation.

Description: ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZ0PYRAN-4-0NES AND 2-AMINO-l,3-BENZOXAZINE-4-ONES BACKGROUND OF THE INVENTION The present specification provides methods for use of pharmacologically active substances. Further the present specification provides novel compositions of matter and novel methods of their preparation. Atherosclerosis in mammals is a disease characterized by the deposition of atherosclerotic plaque on arterial walls. While atherosclerosis exhibits many varied forms and consequences, typical consequences of atherosclerotic diseases include angina pectoris, myocardial infarction, stroke and transient cerebral ischemic attacks. Other forms of atherosclerotic diseases include certain peripheral vascular diseases and other ischemias (e.g., bowel and renal) . Medical science now recognizes that certain forms of athero¬ sclerosis may be preventable or reversible. Agents capable of preventing or reversing atherosclerosis are characterized as exhibit¬ ing antiatherosclerotic activity. Since serum lipids have a recognized association with atherogenesis, an important class of antiatherosclerotic agents are those with serum lipid-modifying effects. Serum lipids implicated in atherogenesis include serum cholesterol, serum triglycerides, and serum lipoproteins. With respect to serum lipoproteins, at least three different classes of these substances have been characterized; high density lipoproteins (HDL's), low density lipoproteins (LDL's), and very low density lipoproteins (VLDL's). HDL's are often referred to as alphalipoproteins, while LDL's and VLDL's are referred to as beta- lipoproteins. The enhancement of HDL levels (hyperalphalipoprotein- emic activity) is postulated to have direct antiatherosclerotic effects. See Eaton, R.P. , J. Chron. Dis .31:131-135 (1978). In contrast, agents which reduce serum LDL's and serum VLDL's (hypobeta- lipoproteinemic agents) are also associated with antiatherogenic effects. See Haust, M.D. , "Reaction Patterns of Intimal Mesenchyme to Injury and Repair in Atherosclerosis" , Adv. Exp. Med. Biol. 43:35- 57 (1974), which postulates that serum LDL is a factor in athero¬ sclerotic lesion formation. Numerous animal models have been developed for assessing antiatherosclerotic activity. Principal among these are models for assessing hypolipoproteinemic activity in the rat and antiatherosclerotic activity in the Japanese quail. For a description of the operation of the hypobetalipoproteinemic rat model, refer to the known methods of Schurr, P.E., et al. , "High Volume Screening Procedure for Lypobetalipoproteinemia Activity in Rats", Adv. Exp. Med. Biol. 67: Atherosclerotic Drug Discovery, pp. 215-229, Plenum Press (1975). For a description of the Japanese quail model, see Day, C.E. et al. , "Utility of a Selected Line (SEA) of the Japanese Quail (Corturnic Cortumix japonica) for the Discovery of New Anti-Atherosclerosis Drugs", Laboratory Animal Science 27:817-821 (1977). 2-Aminochromones (4H-l-benzopyran-4-ones) are known in the literature. For example, the antiallergic activity of 2- aminochromones has been described in the literature by Mazzei, Balbi, Ermili, Sottofattori and Roma (Mazzei, M. , Ballbi, A., Ernili, A., Sottofattori, E., Roma, G. , Farmaco. Ed. Sci.. (1985) 40, 895 and Mazzei, M. , Ermili, A., Balbi, A., Di Braccio, M. , Farmaco. Ed. Sci.. (1986), 41, 611; CA 106:18313w). The CNS activity of 2-amino- chromones has also been described (Balbi, A., Roma, G., Ermili, A., Farmaco. Ed. Sci., (1982) 37, 582; Ermili, A., Mazzei, M. , Roma, G. , Cacciatore, C, Farmaco. Ed. Sci., (1977), 32, 375 and 713). The nitro derivatives of various 2-aminochromones have recently been described (Balbi, A., Roma, G. , Mazzei, M. , Ermili, A., Farmaco. Ed. Sci., (1983) 38, 784) and Farmaco. Ed. Sci., 41(7), 548-57. 2-Amino- 3-hydroxychromones are described in DE 2205913 and GB 1389186. U.S. Patent 4,092,416 (see also DE 2555290 and CA 87:102383r) discloses various benzopyrone derivatives exhibiting anti-allergic activity, including 2-{2-[4-(2-methoxyphenyl)-piperazinyl-1]-ethyl)- 5-methoxy-4-oxo-4H-l-benzopyran and 2-{2-[4-(2-methoxyphenyl)- piperazinyl-1]-ethyl)-5-(2-hydroxypropoxy)-4-oxo-4H-l-benzopyran. JA-025657 and JP-259603 descrive various 2-amino-3-carboxamide derivatives and 3-phenyl (optionally substituted)-2-aminochromone derivatives as useful as oncostatic and immunosuppressive agents. The pharmacomodulation of -adrenergic blocking agents by a series of benzopyrans, including 2-(l-piperidinylmethylene)-4H-l- benzopyran-4-one, is described in Eur. J. Med. Chem. , 1987, 22(6), 539-44; CA 109:92718k. Structurally, the closest compounds in the literature to 2-(4- morpholinyl)-4H-l-benzopyran-4-one (Cpd 2) is believed to be the 3- hydroxy, 3-methoxy and 3-acetyloxy analogues (i.e., 2-(4- morpholinyl)-3-hydroxychromone, 2-(4-morpholinyl)-3-methoxychromone and 3-(acetyloxy)-2-(4-morpholinyl)chromone) reported by Eiden and Docher (Eiden, F. , Dolcher, D. , Arch. Pharm. (Weinheim Ger.) (1975) 308, 385) and DE 2205913; CA 83(11) :96942w and CA79(19) :115440s. 6,7-dimethoxy-2-(4-morpholinyl)chromone is disclosed in J. Chem. Soc, Perkins Trans. 1, (2), 173-4; CA78(9) ;58275v. 3-Acetyl-2-(4- morpholin l)chromone is disclosed in Arch. Pharm. 316(1), 34-42; CA98(15):12915g. 3-hydroxy-2-[4-(2-hydroxyethyl)-l-piperazinylj-4H-l-benzopyran- 4-one and 3-hydroxy-2-(4-methyl-l-piperazinyl)-4H-l-benzopyran-4-one are disclosed in Arch. Pharm 308(5), 385-8; CA83(11) :96942w. 5,8- dimethoxy-2-(4-methyl-l-piperazinyl)-4H-l-benzopyran-4-one is disclosed in J. Heterocycl. Chem., 18(4), 679-84; CA95(17) :150348v. The synthesis of 2-aminochromones from the corresponding 2- sulphonyl and 2-sulphinyl analogues has been reported by Bantick and Suschitzky (Bantick, J.R., Suschitzky, J.L., J. Heterocyclic Chem., (1981) 18, 679). Also described in this report is the preparation of the HCL and H2SO4 salts of several 2-aminochromones. The anti-platelet activity of some 2-(dialkylamino)chromones, namely: 2-(diethylamino)-5,6-dimethyl-4H-l-benzopyran-4-one, 2-(diethylamino)-6,7-dimethyl-4H-l-benzopyran-4-one, 2-(diethyl- amino)-7-hydroxy-5-methyl-4H-l-benzopyran-4-one, 2-(diethylamino)-5- hydroxy-7-methyl-4H-l-benzopyran-4-one, 2-(diethylamino)-6-chloro-8- isopropyl-4H-l-benzopyran-4-one, 2-(diethylamino).-5,7-methoxy-4H-l- benzopyran-4-one, 2-(ethylamino)-5-hydroxy-4H-l-benzopyran-4-one, 2-(ethylamino)-7-hydroxy-4H-l-benzopyran-4-one, 2-(diethylamino)-7- hydroxy-6-nitro-4H-l-benzopyran-4-one, 2-(diethylamino)-4H-l-benzo- pyran-4-one, 2-(dimethylamino)-7-methoxy-4H-l-benzopyran-4-one, 2-(diethylamino)-7-methoxy-4H-l-benzopyran-4-one, 2-(1-pyrrolidinyl)- 7-methoxy-4H-l-benzopyran-4-one, 2-(l-piperidinyl)-7-methoxy-4H-l- benzoρyran-4-one, 2-(diethylamino)-7-hydroxy-4H-l-benzopyran-4-one, 2-(1-piperdinyl)-7-hydroxy-4H-l-benzopyran-4-one, 2-(ethylamino)-7- methoxy-4H-l-benzopyran-4-one, 2-(diethylamino)-5-hydroxy-4H-l- benzopyran-4-one, 2- (diethylamino)-5-methyl-8-isopropyl-4H-1-benzo- pyran-4-one, and 2- (diethylamino)-3-(4-morpohoinomethyl)-7-methoxy- 4H-l-benzopyran-4-one, was reported by Mazzei et al. in Eur. J. Med. Chem. 23, 237-242 (May-June 1988); CA 110:75246h. The literature on the use of an ynamine in the synthesis of a 2- aminochromones has been reported by Tronchet, Bachler and Bonenfant (Tronchet, J.M. J., Bachler, B. , Bonenfant, A., Helv. Chim. Acta. (1976), 59, 941). In this report, a 2-amino-3-glycosylchromone was prepared. 2-Amino-l,3-benzoxazin-4-ones are also known in the literature. Specifically, 2-morpholinyl-4H-l,3-benzoxazin-4-one (Cpd 98) and 8- methyl-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one (Cpd 84) are described in Netherlands patent application 6,412,966 (see also U.S. 3,491,092), and in the literature (Grigat, E. , Putter, R. , Schneider, K. , Wedemeyer, K. , Chem. Ber. , (1964) 97, 3036). The fungicide and analgesic activity of 2-aa_ino-l,3-benzoxazin- 4-ones are also claimed by Sankyo in Japn. Tokkyo Koho 79 20,504 (CA 91:157755b) and in Japan (Kokai 72, 17,781 (CA 77:140107e). These patents appear to cover 2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one (Cpd 98) and 6,7-substituted-2-(4-morpholinyl) analogues for the above indications. The synthesis of 2-dialkylamino-l,3-benzoxazin-4-ones has been described by Kokel et al (see Tet. Letters (1984) 3837) . 2-N-Alkyl and 2-N-aryl-l,3-benzoxazin-4-ones have been described by Palazzo and Giannola (Palazzo, S., Giannola, L.I., Atti. Accad. Sci. Lett. Arti Palermo, Parte 1, (1976) 34(2), 83-7). 2-Benzamidino-l,3-benzoxazin-4-one have been described by Brunetti, H. , and Luthi, C.E. (in Helv. Chim. Acta., (1972) 55, 1566). BRIEF DESCRIPTION OF THE INVENTION This invention relates to compounds of the Formula I which are useful in association with a pharmaceutical carrier as antiatherosclerotic agents. In addition, various compounds of the Formula I are useful inhibitors of cell proliferation and/or platelet aggregation. DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are represented by Formula I wherein X is N, or CZ where Z is H, C1-C5 alkyl, amino (-NH2) or a halogen atom; when X is CZ, Y is selected from the group consisting of "( CH 2)n NR 9 R 10 wherein R9 and R^Q, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Ro and Rχo are not both hydrogen; (b) c l _c 12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -Cθ2(Cχ-C alkyl); (d) -(CH2) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -Cθ2 Cχ-C4alkyl)] , (e) -(CH2) n ρyridinyl or (f) wherein R9 and Rχθ, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of 0 - C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo, trifluoromethyl, -(CH2)q0H, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 c l _c 4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-l-piperazine, 4-(cycloC3- Cgalkyl)-l-piperazine, 4-phenyl-l-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 Ci- C4 alkyl, C1-C alkoxy, halo or trifluoromethyl) or 4- pyridinyl-1-piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C alkoxy, halo, OH, trifluorometh l, -CH 2 0 H , -C0 2 H, -CO2CH3 or -CO2CH2CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- meth lhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydrox )pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5, Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, C -Cg alkyl, -(CH2 n hen l [wherein phenyl is optionally substituted with one, 2 or 3 C -C alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -Cθ2(Cχ-C4alk l ] , -(CH 2 ) n naphthyl, -(CH2) n pyridinyl, -(CH2)qNRgR θ' "CH-CH-phenyl [wherein phenyl is optionally sub- stituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C 4 alkyl)] , -CH2-CH-CH 2 , -CH-CH-CH3, -O-CH2-CH-CH2, -C-=C-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -Cθ2 C 1 -C4al yl)] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -O-(CH 2 )pNR9R 10 , -O-CH2CH(0CH 3 )2, -0-(CH 2 )pOR 15 [wherein R 5 is selected from C1-C5 alkyl, -(CH2 n phe yl [phenyl optionally substituted with one, 2 or 3 C -C alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cχ-C4alkyl)] , -(CH 2 ) n ρyridin-l-yl or -(CH 2 ) p piperidin-l-yl] , -(CH 2 ) n C(0)- (CH 2 ) n R 9 , -(CH 2 ) n C(0)0-(CH 2 )pR9, -(CH )n C(O)O-(CH 2 ) p NR 9 R 10 , -(CH 2 ) n C(O)(CH 2 ) tl NR 9 R 10 , N0 2 ,-0-(CH 2 ) n C(0)-(CH 2 )pR 9 , -0-(CH 2 ) n C(0)0-(CH 2 ) p R9, -0-(CH 2 ) n C(0)-(CH 2 ) n NR 9 R 10 , -NR 9 R 10 , -N(R 9 )(CH 2 ) n C(0)-(CH 2 ) n R 10 , -N(R 9 )-(CH2 n C O O-(CH2) n 10. N(R9)(CH 2 ) n C(0)-(CH 2 ) n NR 9 R 10 , -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 alkyl, C -C alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C alkyl ] , -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0- (CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(R 9 ) (CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl, -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NR 9 -(CH 2 ) n naphth l, halo (fluoro, chloro, bromo, iodo) , OH, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)R 9l -(CH 2 ) q OC(O)-NR 9 R 10 , .(1-cyclohexyl-lH-tetrazol- 5-yl)C 1 -C 4 alkoxy, - [1-(C 1 -C 5 alkyl)-lH-tetrazol-5-yl]C 1 -C4 alkoxy, - [l-( p henyl)-lH-tetrazol-5-yl]Cχ-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, Cχ-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl)], - [l-(pyridinyl)-lH-tetrazol-5-yl]C 1 -C 4 alkoxy, - [1-(1-phenylethyl)-lH-tetrazol-5-yl]C_-C4 alkoxy, -C1-C4 alkoxyl, or a group of Formula II (see Formula Sheet) wherein R' is methyl or carboxy, R' ' is hydrogen and R' ' ' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], alkyl, -(CH 2 ) n C0 2 H, -CH 2 SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(0H) , CH2OH, H 2 N(CH )4-(optionally in protected form) or H 2 NC(NH)NH(CH 2 )3 (optionally in protected form); with the overall proviso that when Y is other than -(C^^morpholinyl, at least one member of R5, Rg, R7 or Rg is other than hydrogen, C > Cg alkyl, NO2, OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH 2» or dimethyamino; with the further proviso that when Y is 4-morpholinyl, the compound is other than: 6,7-dimethoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-l-benzopyran-4-one, N-cyclohexyl-2- [ [8-methyl-2- (4-morpholinyl)-4-oxo-4H-l- benzopyran-7-yl]oxy] -acetamide, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-l-benzopyran-7- yl]oxy] -N-phenyl-acetamide, 6- [ (1-cyclohexyl-1H-tetrazol-5-yl)methoxy] -2- (4-mor- pholinyl)-4H-l-Benzopyran-4-one, 2- [ [8-methyl-2- (4-morpholin l) -4-oxo-4H-l-benzopyran-7- yl]oxy] -N-(1-phenylethyl)-acetamide; with the further provisio that when Y is dimethylamino, the compound is other than: 2 - (Dimethylamino) -8-methyl-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester, (Dimethylamino)-4-oxo-4H-l-benzopyran-6-yl carbamic acid dimethyl ester, 2-(Dimethylamino)-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester; when X is N, Y is selected from the group consisting of - RgRχo wherein Rg and Rχø, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Rg and R o are not both hydrogen; (b) C -C 2 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or ■ -CC^CC!-C4alkyl ; (d) -(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, Cχ-C4 alkoxy, halo, OH, trifluoromethyl or- C02(C -C4alk l ] , (e) -(CH2) n pyridinyl or (f) wherein Rg and o » taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C^-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C ~ C4 allsyl, C -C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of Ci -C4 alkyl, C -C4 alkoxy, halo, trifluoromethyl, -(CH2)q0H, -C0 2 H, -C0 2 CH3 j -C0 2 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo or trifluoromethyl) , (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-l-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C-^-C^ alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl, -CH2OH, -C0 2 H, -C0 2 CH 3 or -CO2CH2CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- meth lhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5, R , R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, C -Cg alkyl, -(CH2 n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -Cθ2(C -C4 lkyl)] , -(CH 2 ) n naphth l, -(CH 2 ) n pyridinyl, -(CH 2 )qNRgR o > -CH-CH-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C -C alkyl, C -C alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl)] , -CH 2 -CH-CH 2 , -CH-CH-CH3, -O-CH2-CH-CH2, -C*C-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C -C4 allsyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cχ-C4alkyl)] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -O-(CH 2 )pNR9R 10 , -O-CH2CH(0CH 3 ) 2 , -0-(CH 2 )pOR 15 [wherein R^5 is selected from C -C5 alkyl, -(CH ) n phenyl [phenyl optionally substituted with one, 2 or 3 C -C4 alkyl, C -C alkoxy, halo, OH, trifluoromethyl or -C0 2 (C -C alk l) ] , -(CH 2 ) n pyridin-l-yl or -(CH 2 ) p piperidin-l-yl] , -(CH 2 ) n C(0)- (CH 2 ) n Rg, -(CH 2 ) n C(0)0-(CH 2 ) p R9, -(CH )n C(0)0-(CH 2 ) p NRgR 10 , -(CH 2 ) n C(0) (CH 2 ) n NR 9 R 10 , N0 2 , -0-(CH 2 ) n C(0)-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p R9, -0-(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 , -NRgR 10 , -N(Rg)(CH2) n C(O)-(CH2) n R 10 , -N(Rg)-(CH 2 ) n C(0)0-(CH 2 ) n R 10 , N(Rg)(CH2) n C(0)-(CH2) n NR 9 R 10 , -0-(CH 2 ) n ρhenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C alkoxy, halo, OH, trifluoromethyl or -C02(C -C4alkyl) , -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0- (CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(Rg)(CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl, -0-(CH 2 ) n pyraziny1, -0-(CH 2 ) n naph hyl, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthy1, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl. -0-(CH 2 ) n C(0)NRg-(CH 2 ) n naphthyl, halo (fluoro, chloro, bromo, iodo) , OH, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q OC(0)-NRgR 10 , .(1-cyclohexyl-lH-tetrazol- 5-yl)C 1 -C 4 alkoxy, -[l-(C 1 -C 5 alkyl)-lH-tetrazol-5-yl]C 1 -C 4 alkoxy, -[l-( p henyl)-lH-tetrazol-5-yl]C -C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl)] , -[l-(pyridinyl)-lH-tetrazol-5-yl]C 1 -C 4 alkoxy, -[1-(1- phenylethyl)-lH-tetrazol-5-yl]C -C4 alkoxy, or -C1-C4 alkoxyl, or a group of Formula II (see Formula Sheet) wherein R' is methyl or carboxy, R' ' is hydrogen and R' ' ' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], Cι-C 5 alkyl, -(CH 2 ) n C0 2 H, -CH 2 SH, -CH SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(0H) , CH 2 0H, H 2 N(CH 2 )4-(optionally in protected form) or H 2 NC(NH)NH(CH 2 ) 3 (optionally in protected form); n is 0-5, preferably 0 or one; p is 2-5, preferably 2 or 3; q is 1-5, preferably 1 or 2; and pharmaceutically acceptable salts thereof. X is preferably CZ where Z is H or C -C5 alkyl, more preferably H or methyl, most preferably H. When X is CZ, Y is preferably selected from the group consiting of -(CH ) n NRgRχo wherein Rg and R o» taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of: (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of 0 - C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C2-C alkyl, Cχ-C4 alkoxy, halo, OH, -CH 2 OH, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C -C alkyl, C1-C4 alkoxy, halo, trifluorometh l, -(CH 2 )qOH, -C0 2 H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), and (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo, trifluoromethyl, -CH2θ H ,- C0 2 H, -C0 2 CH 3 or -C0 2 CH 2 CH3. When X is CZ wherein Z is H or C -C5 alkyl (most preferably H) , Y is more preferably selected from the group consisting of -(CH2) n NRgR o wherein n is 0 or 1 (most preferably 1) and Rg and Rχo» taken together with N, form: (aa) morpholine (preferably 4-morpholine) optionally substituted with one or two members selected from the group consisting of C^-C4 alkyl or phenyl (wherein phenyl is optionally substituted with one or 2 C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl) ; and preferably, at least one member selected from R5, Rg, R or Rg is selected from: the group consisting of -(CH2 pphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or ] , -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH 2 ) q NR 9 R 10 , -CH-CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C^- C alkyl)], -CH 2 -CH=CH 2 , -CH=CH-CH 3 , -0-CH 2 -CH=CH 2 , -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, Cχ-C^ alkoxy, halo, OH, trifluoromethyl or -C0 (Cχ- C4al yl)], -0(CH 2 )p(N-methylpiperdin-3-yl) , -O-(CH 2 )pNRgR 10 , -0-CH2CH/0CH3)2 ι -0-(CH 2 )pORχ5 [wherein R 5 is selected from C ~ C5 alkyl, -(CH 2 ) n phenyl [phenyl optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl)] , -(CH 2 ) n pyridin-l-yl or -(CH 2 ) p piperidin-l- yl], .(CH 2 ) n C(0)-(CH 2 ) n Rg, -(CH 2 ) n C(0)0-(CH 2 ) p Rg, -(CH n C(0)0- (CH 2 ) p NR 9 R 10 , -(CH 2 ) n C(0)(CH 2 ) n NR 9 R 10 , -0-(CH 2 ) n C(0)-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 , -NRgR 10 , -N(Rg)(CH 2 ) n C(0)-(CH 2 ) n R 10 , -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n R 10 , N(Rg)(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 , -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 - C 4 alkyl)], -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(Rg)(CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH2) n quinolinyl, -0-(CH2) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg-(CH^naphthyl, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q 0C(0)-NRgR 10 , .(1-cyclohexyl- lH-tetrazol-5-yl)C -C4 alkoxy, -[l-(C -C5alk l)-lH-tetrazol-5- yl]C -C alkoxy, -[l-( p henyl)-lH-tetrazol-5-yl]C 1 -C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C - C4alk l ], -[l-(pyridinyl)-lH-tetrazol-5-yl]C -C4 alkoxy, -[l-(l-phenylethyl)-lH-tetrazol-5-yl]C -C4 alkoxy, or -C -C4 alkoxyl; more preferably, (i) R5, Rg, R7 and Rg are each hydrogen; or (ii) R5, Rg, and Rg are each hydrogen, and R7 is selected from: -0-(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo or tri¬ fluoromethyl) , -C=C-phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), or -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C^- C4 alkoxy, halo or trifluoromethyl); or (iii) R 5 and Rg are hydrogen, Rg is hydrogen, halo or C -C 5 alkyl, and R 7 is selected from: -0-(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C^-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -0-(CH 2 ) n pyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), -0-(CH 2 ) n naphthyl, -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), -(CH 2 )ppyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH 2 ) p (l-piperidinyl) , -(CH 2 )p(l-pyrrolidinyl) or - [(l-cyclohexyl-lH-tetrazol-5- l)C -C4 alkoxy; or (iv) R5, R7 and Rg are each hydrogen, and Rg is -NH-C(0)-0-CH 2 phenyl. X is most preferably CH. Y is most preferably 4-morpholinyl. Rg is preferably hydrogen or C -C5 alkyl, more preferably hydrogen or methyl. Accordingly the present invention includes the novel 2- amino(4H)-l-benzopyran-4-ones and 2-aminoalk 1(4H)-l-benzopyran-4- ones of Formula I when X is CZ and the antiatherosclerotic utility of said compounds as well as the antiatherosclerotic utility of the known compounds of Formula I, including the 2-amino-l,3-benzoxazine- 4-ones of Formula IB. The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e. , the prefix C^-Cj indicates a carbon atoms content of the integer "i" to the integer "j " carbon atoms, inclusive. Thus, C -C3 alkyl refers to alkyl of 1-3 carbon atoms, inclucive, or methyl, ethyl, propyl, and isopropyl. With respect to the above, C -C4 alkyl is methyl, ethyl, propyl, or butyl, including isomeric forms thereof.. Similarly, C^-C alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, and isomeric forms thereof. The term "halo" includes fluoro, chloro, bromo and iodo. Examples of C^-Cg alkylthiomethyl are methylthiomethyl, ethylthiomethyl, propylthiomethyl, butylthiomethyl, pentylthiomethyl, hexylthiomethyl, and heptylthiomethyl, and isomeric forms thereof. Examples of C -Cg alkoxymethyl are methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, and heptoxymethyl, and isomeric forms thereof. Examples of heterocylic amines corresponding to heterocyclic amine rings according to -NRgN o are: 4-morpholine, 4-phenyl-1-piperazine, 4-(2-pyridinyl)-1-piperazine, 2,6-dimethyl-4-morpholine, 1-pyrrolidine, 4-methyl-l-piperazine, 1-piperidine, 4-phenyl-1- iperidine thiazolidine, 3-piperidine methanol, 2-piperidine methanol, pipecolic acid, 3-piperidine ethanol, 2-piperidine ethanol, 1-piperazine propanol, p-piperazinoacetophenone, 4-phenyl-1,2,3,6-tetrahydropyridine, 4-phenylpiperidine, proline, 1-(3-hydroxy)pyrrolidine, tetrahydrofurylamine, pyrrolidimethanol, 3-pyrroline, thiazolidine-4-carboxylic acid, thiomorpholine, nipecotamide, 2-meth lpiperidine, 3-methylpiperidine, 4-methylpiperidine, N-methylpiperazine, 1-methylhomopiperazine, 1-acetylpiperazine, N-carboethoxypiperazine, 3-methylpiperazine-2-carboxylic acid, 2-methylpiperazine, 2,3,5,6,-tetramethylpiperazine, 1,4-dimethylpiperazine, 2,6-dimethylpiperazine, 2-methyl-l-phenylpiperazine, l-(l-phenylethyl)piperazine, 1-(2-pyrazinyl)piperazine, 1-cyclopropylpiperazine, 1-cyclobutylpiperazine, 1,2,3, -tetrahydroisoquinoline, imidazole, homopiperdine, and pharmaceutically acceptable salts and hydrates thereof. Examples of -0(CH 2 )p(N-methylpiperdin-3-yl) include (2-(N- meth lpiperdin-3-yl)ethyl)ox , (3-(N-methylpiperdin-3-yl)propy)loxy, (4-(N-meth lpiperdin-3-yl)butyl)oxy. Examples of -0-(CH2)pNR R 10 include (2-(l- piperidinyl)ethyl)oxy, (2-(4-morpholinyl)ethyl)oxy, (2-(l- pyrrolidinyl)ethyl)oxy, (3-(N-methylpiperazinyl)propyl)oxy, (4-(N- ethy1-N-phenylamino)butyl)oxy, (5-(diethylamino)pentyl)oxy, (2-(4- benzylpiperazinyl)ethyl)oxy, and (3-(N,N-diisoρropyl)propyl)oxy. Examples of 0-(CH )p0R 5 include (2-methoxyethyl)oxy, (3- butoxypropyl)oxy, (4-phenoxybutyl)oxy, (2-benzyloxyethyl)oxy, (2-(2- (l-piperidinyl)ethoxy)ethyl)oxy and (3-(3-picolylmethoxy)propyl)oxy. Examples of -(CH 2 ) n pyridinyl include 2-pyridyl, 3-pyridylmethyl and 4-pyridylethyl. Examples of -(CH 2 ) n piperdinyl include 1-piperidinyl, 1- peiperidinylmethyl, 2-(l-piperidinyl)ethyl and 3-(l- piperidinyl)propyl. Examples of -(CH2)qNR9R10 include (l-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 3-(l-pyrrolindinyl)propyl and 4-(l- piperazinyl)butyl. Examples of -(CH 2 ) n C(0)-(CH 2 ) n Rg include acetyl, acetylmethyl, methylacetylmethyl, methylacetylethyl, phenylacetyl, phenylacetylmethyl, 2-(phenylacetyl)ethyl, 2-pyridylacetyl, 3- pyridylacetylmethyl, 3-(t-butylacetyl)propyl and 4- (ethylacetyl)bu yl. Examples of τ(CH ) n C(0)0- (CH ) p Rg include carbomethox , carbomethoxymethyl , 2 -(carbomethoxy) ethyl, carbophenylmethoxy , carbophenylmethoxymethyl, 2- (carbo(3-pyridyl)methoxy)ethyl, carboethoxymethyl and 3-(carbopropoxy)propoxy. Examples of - (CH 2 ) n C(O)Q-(CH 2 ) p NRgR 10 include - G (0)0- (CH 2 ) 2 N(ethyl) 2 , - (CH 2) C(0)0=(CH 2 ) 2 N(CH 3 ) (phenyl) , - (CH 2 )3C(0)0- (CH 2 ) 3 (l-pyrrolidine) , -(CH 2 ) 3 C(0)0-(CH 2 ) 2 (l-piperidinyl) , and -(CH 2 )C(0)0-(CH 2 ) 2 (4-morpholinyl) . Examples of -(CH 2 ) n C(0) (CH 2 ) n NRgR o include - (CH 2 )C(0) (CH 2 )N(ethyl) 2 , - (CH 2 ) 2 C(0) (CH 2 ) 2 N (methyl) (phenyl) , -C(0) (1-pyrrolidine) , - CH 2 2C(0) (CH 2 )3(l-piperidine) , and -(CH2)3C(0) (CH 2 ) (4-morpholine) . Examples of -0-(CH2) n C(0)-(CH 2 ) p Rg include -0-(CH 2 )C(0)- (CH 2 )(CH 3 ), -0-C(0)-(CH 2 ) 2 (CH 3 ), -0-(CH 2 ) 3 C(0) -(CH 2 )phenyl, -0-(CH 2 ) 2 C(0)-(CH 2 ) 3 (2-pyridyl), -0-(CH 2 )C(0)-(CH 2 ) 2 (3-pyridyl) and -0-(CH 2 ) 4 C(0)-(CH 2 )4(t-butyl) . Examples of -0- (CH 2 ) n C(0)0- (CH 2 ) p Rg include -0-(CH 2 )C(0)0- (CH 2 )(CH 3 ), -0-C(0)0-(CH 2 ) 2 (CH 3 ), -0-(CH 2 )2C(0)0-(CH 2 )3(phenyl) and -0-(CH 2 )3C(0)0-(CH 2 )2(3-pyridyl). Examples of -0-(CH 2 ) n C(0) - (CH 2 ) n NRgR 10 include -0- (CH 2 )C(0) - (CH 2 )N(CH 3 ) 2 , -0-C(0)-(CH 2 )(l-pyrrolidine), -0-(CH 2 )C(0)-(l- piperidine) , -0- (CH 2 ) 2 C(0) - (CH 2 ) (1-N-methylpiperazine) , -0- (CH 2 ) 2 C(0) -(CH 2 ) 2 (4-morpholine) , -0- (CH 2 ) C (0) - (CH2) 3 (cyclohexylamine) , -0- CH2) 2 C (°) - (CH 2 ) 3(t-butylamine) , -0-(CH 2 )C(0)-(CH 2 ) 2 (l-phenylethylamine). -0- (CH 2 )C(0) - (CH 2 ) 2 (aniline), -0-(CH 2 )C(0)-(CH 2 ) (L-phenylalanine ethyl ester) and -0- (CH 2 ) 2 nC(0) - (CH 2 ) 3 (3-pyridylamine) . Examples of -N(Rg) (CH 2 ) n C(0)-(CH 2 ) n R 10 include -N(CH 3 )C(0)- (CH 3 ), -N(H)(CH 2 ) 2 C(0)-(CH 2 ) (phenyl), -N(H) (CH 2 )C(0) -(CH 2 ) 2 (3- pyridyl) and -N(CH 3 ) (CH 2 )3C(0)-(CH 2 ) (CH 3 ) . Examples of -N(Rg)- (CH 2 ) n C(0)0-(CH 2 ) n Rιo include -N(H)-(CH 2 )C(0)0-(CH 3 ), -N(H)-(CH 2 ) 2 C(0)0-(CH 2 ) (benzyl), -N(H)- (CH 2 ) 2 C(0)0-(CH 2 )(3-pyridyl) and -N(CH 3 )-(CH 2 )C(0)0-(CH 2 ) 2 (t-butyl) . Examples of -N(Rg) (CH 2 ) n C(0)-(CH 2 ) n NRgR 10 include -N(H)(CH 2 )C(0)-(CH 2 )N(CH 3 ) 2f -N(H)C(0) -(CH 2 ) (1-pyrrolidine) , -N(H)(CH 2 ) 2 C(0)-(CH 2 ) 2 (l-piperidine), and -N(CH 3 ) (CH 2 )C(0) - (CH 2 ) 2 (4- morpholine) . Examples of -0- (CH 2 ) n phenyl include 2- (4- trifluoromethylphenyl)ethoxy, 4-chlorophenoxy, 4- fluorophenylmethoxy, 3-(4-methoxyphenyl)propoxy, 4-(2-methyl-4- fluorophenyl)butoxy, 2-(2-methoxyphenyl)ethoxy, 3- methoxyphenylmethoxy, 4-carbomethoxyphenylmethox , 2-(3,4- dichlorophenyl)ethoxy, 4-ethoxyphenylmethoxy, 3-(4- nitrophenyl)propoxy, 4-t-butylphenylmethoxy, 4- benzyloxyphenylmethoxy and 2-(3-triflouromethylphenyl)ethox . Examples of -0-(CH 2 ) n pyridine include 2-pyridylox , 3- pyridylmethoxy and 2-(4-pyridyl)ethoxy. Examples of -0(CH 2 ) n C(0)-(CH 2 ) n pyridine include -0(CH 2 )C(0)- (CH 2 )(2-pyridine), -0(CH 2 ) 3 C(0)-(CH 2 )(3-pyridine) and -0(CH 2 ) 2 C(0)- (CH 2 )3(4-pyridine) . Examples of -0-(CH 2 ) n C(0)0-(CH2) n pyridine include -0(CH 2 )C(0)0-(CH 2 )(2-pyridine), -0(CH 2 )3C(0)0-(CH 2 ) (3-pyridine) and -0(CH 2 ) 2 C(0)0-(CH 2 ) 3 (4-pyridine). Examples of -0(CH ) n C(0)-N(Rg)(CH 2 ) n pyridine include -0(CH 2 )C(0)-N(CH 3 ) (CH 2 )(2-pyridine) , -0(CH 2 ) 2 C(0)-N(CH 3 )(CH 2 ) (3- pyridine) and -0(CH 2 )C(0)-N(benzyl)(CH 2 ) 2 (4-pyridine) . Examples of -0-(CH2) n quinoxalinyl include 2-quinoxalinyloxy, 2- quinoxalinylmethoxy and 2-(2-quinoxalinyl)ethoxy. Examples of -0-(CH2) n quinolinyl include 2-quinolinyloxy, 2- quinolinylmethoxy and 2-(2-quinolinyl)ethoxy. Examples of -0-(CH2) n pyrazinyl include 2-pyrazinyloxy, 2- pyrazinyImethoxy and 2-(2-pyraziny1)ethoxy. Examples of -0-(CH2) n naphthyl include 1-naphth loxy, 2- naph h lme hoxy and 2-(1-naphthyl)ethox . Examples of -0-(CH 2 ) n C(0)-(CH 2 ) n naphthyl include -0-(CH 2 )C(0)- (CH 2 )(l-naphthyl), -0-(CH 2 )2C(0)-(CH 2 )(2-naphthyl) , -0-C(0)-(CH 2 ) (1- naphthyl) and -0-(CH 2 )2C(0)-(CH 2 ) 2 (2-naphthyl) . Examples of -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl include -0-(CH 2 )C(0)0-(CH 2 )(l-naphthyl), -0-(CH 2 ) 2 C(0)0-(CH 2 ) (2-naphthyl) , -0-C(0)0-(CH 2 )(l-naphthyl) and -0-(CH 2 )2C(0)0-(CH 2 )2<2-naphthyl) . Examples of -0- (CH 2 ) n C(0)NRg- (CH2) n naphth l include -0- (CH 2 )C(0)N(H) (CH 2 ) (1-naphthyl) , -0- (CH 2 )C(0)N(CH 3 ) (CH 2 ) 2 (2 - naphthyl) and -0- (CH 2 ) C(0)N(benzyl) (CH 2 ) 3 (l-naphthyl) . Examples of - (CH 2 ) q -0H include hydroxymethyl , hydroxyethyl and hydroxybutyl . Examples of (CH 2 ) q OC(0)R 9 include (CH 2 )0C (0)methyl , (CH 2 ) 2 0C(0)ethyl, CH 2 30C(0)phenyl, CH 2 )4θC(0)(3-pyridyl) and (CH 2 )OC(0)thiophene. Examples of -(CH 2 ) q OC(0)-NRgR 10 include -(CH 2 )0C(0)-N(CH 2 ) 2 , -(CH 2 ) 2 0C(O)-N(ethyl) 2 , -(CH 2 ) 3 0C(0)-(l-pyrrolidine) , -(CH 2 )4θC(0)- (1-piperidine) and -(CH 2 )0C(0)-N-benzylamine. Examples of _(l-cyclohexyl-lH-tetrazol-5-yl)Cχ-C4 alkoxy, -[1- (Cχ-C5alkyl)-lH-tetrazol-5-yl]Cχ-C4 alkoxy include _(l-cyclohexyl-lH- tetrazol-5-yl)methoxy, _.(l-cyclohexyl-lH-tetrazol-5-yl)ethoxy, - [1- (methyl)-lH-tetrazol-5-yl]methoxy, - [1-(cyclopropyl)-1H-tetrazol-5- yl]ethoxy, -[l-(l-tert-butyl)-lH-tetrazol-5-yl]propoxy and -[1- (cyclopenyl)-1H-tetrazol-5-yl]methoxy. Examples of -[l-( p henyl)-lH-tetrazol-5-yl]C -C4 alkoxy (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) include -[l÷(phenyl)-lH-tetrazol-5- yljmethoxy, -[l-( p henyl)-lH-tetrazol-5-yl]ethoxy, -[l-(4- methoxy p henyl)-lH-tetrazol-5-yl]methoxy, -[1-(4-fluorophenyl)-1H- tetrazol-5-yl]propox . Examples of -[1-(pyridinyl)-1H-tetrazol-5- l]Cχ-C4 alkoxy or -[l-(l-phenylethyl)-lH-tetrazol-5-yl]Cχ-C4 alkoxy include -[l-(2- pyridinyl)-1H-tetrazol-5-yljmethoxy, -[1-(3-pyridinyl)-lH-tetrazol-5- yl]ethoxy, -[l-(4-pyridinyl)-lH-tetrazol-5-yl]propoxy, -[1-(1- phenylethyl)-1H-tetrazol-5-yl]methox , -[1-(1-phenylethyl)-1H- tetrazol-5-yl]ethox . The tertiary amines and aromatic heterocyclic amines of the subject specification and claims include the N-oxides thereof. Pharmaceutically acceptable salts means salts useful for administering the compounds of this invention and include hydrochlor- ide, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propion- ate, lactate, maleate malate, succinate, tartrate, and the like. These salts may be in hydrated form. The compounds of Formula I are all characterized by pronounced antiatherogenic activity, rendering these compounds useful in the treatment and prophylaxis of atherosclerosis. Various compounds including 2-(4-morpholinyl)-4H-benzopyran-4- one (Cpd #2) , 2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one (Cpd #98) , 8- methyl-2-(4-morρholinyl)-4H-l,3-benzoxazin-4-one (Cpd #84), 2-(l-(4- thiomorpholinyl) ) -4H-l, 3-benzoxazin-4-one (Cpd #95) and 2- (4-methyl- l-piperazinyl)-4H-l,3-benzoxazin-4-one (Cpd #96) reduced arterial cholesterol accumulation in the SEA Japanese quail model. The reduction in arterial cholesterol was accompanied with reduced serum cholesterol levels with Compounds 84 and 95, but not with Compounds 2, 98 and 96. In normal cholesterolemic SEA Japanese quail, Compound 84 also lowered serum cholesterol. For a description of the Japanese quail model, see Day, CE. et al., "Utility of a Selected Line (SEA) of the Japanese Quail (Coturnic Coturnix japonica) for the Discovery of New Anti-Atherosclerosis Drugs", Laboratory Animal Science 27:817- 821 (1977). Preferred antiatherosclerotic compounds include Compounds 2, 3, 19, 51, 72, 76, 84, 95, 96, 98, 112, 139, 163, 164, 171 and 204. In addition, various compounds of Formula I are also potent inhibitors of cell proliferation and are contemplated as useful in the treatment of proliferative diseases such as cancer, rheumatoid arthritis, psoriasis, pulmonary fibrosis, scleroderma, cirrhosis of the liver and for the improved utilization of artificial prosthetic devices such as arterial grafts. These agents may also be useful in the prevention or treatment of obstruction or restenosis of arteries by subsequent administration of drug in cases such as by-pass surgery, coronary by-pass surgery, balloon angioplasty (and other procedures directed at re-establishing patency in occluded or partly occluded vessels, i.e atherectomy, laser or ultrasonic procedures), transplants, and post-thrombotic re-stenosis. Compounds of Formula I which are inhibitors of cell proliferation are those active in the test procedure described in Pledger W.J., Stiles CD., Antniades H.N. , Scher CD., [Proc. Natl. Acad. Sci (USA) (1977). Examples of inhibitors of cell proliferation include Compounds 1-14; 16-17; 19-23; 25 and 26; 28; 30-34; 36-39; 42; 46-48; 51, 52; 54-56; 58-76; 81, 100-103; 105-112; 120-122; 125- 133; 135-145; 149; 155 and 156; 158-160; 163; 165 and 166; 171; 173- 180, 183-190, 193, 204, 206 and 207. In addition, various compounds of Formula I are also inhibitors of ADP induced platelet aggregation and are useful in the prevention or treatment of thrombotic diseases and related complications by, for example, inhibition or reversal of platelet aggregation, or platelet adhesion or blood coagulation. Compounds of Formula I which are inhibitors of platelet aggregation are those active in the test procedure described in Born, G.R. , Cross M.J., J. Physiol., 168, p. 178 (1963). Examples of inhibitiors of ADP induced platelet aggreation include: Compounds 2- 3, 5-6, 9-11, 13, 20-22, 25-26, 28, 31-32, 34, 36-39, 31, 36-38, 51- 53, 56, 58-59, 63, 65, 69, 72-76, 80, 100, 102, 104, 106-107, 109- 113, 115, 116, 118, 120-123, 125-131, 133, 136-140, 147, 149, 154- 160, 162-167, 169, 171, 172, 178, 181-188, 192-198, and 207. Accordingly, in using compounds of Formula I for the prevention or treatment of atherosclerotic disease or thrombotic diseases, an oral route of administration, either by conventional oral dosage forms or by mixture with food, represents the preferred method of their systemic administration. Alternatively, however, these compounds may be administered by other convenient routes of administration whereby systemic activity is obtained. These other routes of administration would include rectal, vaginal, subcutaneous, intramuscular, intravenous, and like routes. In using compounds of Formula I for use in angioplasty, an oral route of administration represents the preferred method of their systemic adminstration. Alternatively, however, these compounds may be administered by other convenient routes of administration whereby systemic activity is obtained. The patient or animal being treated must be given periodic doses of the drug in amounts effective to reduce serum and/or arterial cholesterol, and reduce arterial atherosclerotic lesion size (as determined by angiogram, ultrasound, NMR, etc.); or, by the irihibi- tion or reversal of platelet aggregation, platelet adhesion or blood coagulation; or, by preventing arterial occlusion in vascular trauma associated with procedures such as by-pass grafts, coronary by¬ passes, angioplasty, post- hrombotic re-stenosis and transplants. Such effective dosages are readily determined by methods known in the art. For example, small daily doses of the drug ( e.g., 0.01-200 mg/kg) may be administered initially with higher succeeding doses until levels of serum and/or arterial cholesterol are favorably affected. By this regimen, a compound of Formula I is administered initially at doses as low as about 0.01 mg/kg per patient per day, with increasing doses up to about 200 mg/kg per patient per day. In the event the antiatherogenie response in a patient being treated at a dose of 200 mg/kg per day is insufficient, higher doses are also utilized to the extent patient tolerance permits further increases in dose. While the preferred dosage regimen is with single daily dosing of patients, also preferred for obtaining more uniform serum levels of drug are multiple dosages per day (e.g., up to 4-6 times daily). Accordingly, when 4 daily doses of drug are to be administered, each such dose may be about 50 mg/kg per patient per dose, or higher depending on tolerance. Similar doses are employed in hon-human mammals, e.g. 0.01-200 mg g/day. Charts A-1 herein describe various methods by which the compounds of Formula I are prepared. With respect to these Charts, X, Y, R5, R6, R7, Rg, R9 and R o are as defined above. With respect to Chart A, the compounds of Formula I are prepared by mixing the salicylic acid ester with the morpholine ynamine neat, or in an organic solvent, with stirring. After several minutes, a tertiary amine base, e.g. TEA (triethylamine) , is added and the reaction stirred for a period of time. The product can be isolated by recrystallization or column chromatograph . With respect to Chart B, the compounds of Formula I are prepared by reaction of a ortho-hydroxyacetophenone with an amideacetal, e.g., N,N-dimethylformamide dimethylacetal, to yield a vinylogous amide. Treatment of that amide with a halogen (Br, Cl, I or F) in an organic solvent such as CHCI3 or CHCN then affords a 3-halochromone. Treatment of that halochromone with amines, either neat or in the presence of organic solvents, then yields the desired 2-amino- chromone. With respect to Chart C, the compounds of Formula I are prepared by treating a ortho-hydroxyacetophenone with carbon disulfide in the presence of base followed by treatment with acid which yields the 2- mercaptochromone. Treatment of the resulting mercaptan with the appropriate amine then affords the desired 2-aminochromone. With respect to Chart D, the compounds of Formula I are prepared by hydrogenation of the corresponding benzylmethoxy analogues which are prepared by the methods described in Charts A,B and C, followed by alkylation of the resulting phenol. With respect to Chart E, these compounds can be prepared by treatment of a o-hydroxy acetophenone with an iminium salt such as morpholine-4-phos ene iminium chloride, in the presence of boron trifluoride etherate. Subsequent hydrolysis and alkylation yields the desired compounds. With respect to Chart F, these compounds can be prepared by the treatment of an o-hydroxy acetophenone containing a trifluoromethyl sulfonate group with an iminium salt such as 4-morpholine dichloromethyleniminium chloride, in the presence of boron trifluoride etherate. Subsequent hydrolysis and alkylation yields the 2-aminochromone. Treatment of the 2-aminochromone with an acetylene in the presence of a palladium catalyst such as (bis)triphenylphosphine palladium dichloride and copper iodide yields a 2-aminochromone with a substituted acetylene. Hydrogenation of the acetylene yields the desired derivative. With respect to Chart G, the treatment of an o-hydroxy acetophenone containing a halogen group with an iminium salt such as 4-morpholine dichloromethyleniminium chloride, in the presence of boron trifluoride etherate. Subsequent hydrolysis and alkylation yields the 2-aminochromone. Treatment of the 2-aminochromone with a tetraalkyl tin reagent in the presence of a palladium catalyst such as (bis)triphenylphosphine palladium dichloride and a salt such as lithium chloride affords a 2- aminochromone substituted with an alkyl s bs ituent. With respect to Chart H, the compounds of formula I are prepared by treating 4-benzyloxy-2-hydroxy-3-methylacetophenone with sodium hydride, then ethyl α-methylthioacetate and finally acid to yield 7- benzyloxy-8-methyl-2-methylthiomethyl-4H- [1] -benzopyran-4-one. Treatment of that compound with methyl iodide affords the corresponding 7-benzyloxy-8-methyl-2-iodomethyl-4H-[1]-benzopyran-4- one. Treatment of that compound with the appropiate amine then afforded the compounds of formula I. Compounds of formula I were also prepared by treating a formula I compound such as 7-benzyloxy-8- methyl-2-(4-morpholiniylmethyl)-4H-[l] -benzopyran-4-one with a transition metal catalyst in an atmosphere of hydrogen to yield 7- hydroxy-8-methyl-2- (4-morpholiniylmethyl)-4H-[l]-benzopyran-4-one. Alkylation of that phenol with the appropiate group also afforded compounds of formula I. Alternatively, compounds of formula I can also be prepared by hydrogenation of a s_ benzyloxy 2-amino-4H-l-benzopyran-4-one followed by alkylation of the resulting phenol as illustrated in chart I . The synthesis of the compounds of the present invention is more completely understood by the following examples: Procedure 1: Preparation of 1-ethynyl morpholine. Part A: Preparation of trichloroacetylmorpholine. Morpholine (4.0 mL, 45 mmol) is dissolved in EtOAc (50 mL) and saturated K2C03 (40 mL) added. The mixture is cooled in an ice bath and trichloroacetyl chloride (5.0 mL, 45 mmol) added drop-wise. The reaction is stirred for 20 min then diluted with EtOAc (200 mL) and washed with aq. K2C03 (20 mL) , water (2 X 50 mL) and brine (30 mL) . The organic layer is dried over MgS04. Rotary evaporation gives trichloroacetylmorpholine. Mp - 80-l β C 1H NMR (300 MHz, CDC13) 3.81-3.76 (m) UV (EtOH) 224 (4.520) IR (mull) 2955, 2926, 2859, 1657, 1431, 1270, 1239, 1116, 962, 852, 848, 842, 810, 777 MS m/e (relative intensity) 233 (12), 231 (12), 115 (8), 114 (100), 86 (10), 70 (67), 56 (26), 42 (20), 28 (18), 27 (8) HRMS calc'd. for C6H8N02C13: 230.9621; found: 230.9629; anal, calc'd. for C6H8N02C13: C, 31.00, H, 3.47, N, 6.02, Cl, 45.75; FOUND: C, 31.15, H, 3.43, N, 6.07, Cl, 45.88. Part B: Preparation of tricholorvinylmorpholine. Trichloroacetylmorpholine (8.3 g, 36 mmol) is dissolved in toluene and triphenylphosphine (9.44 g, 36 mmol) added. The mixture is brought to reflux for 1.5 h, then cooled and solvent removed in vacuo. The residue is fractionally distilled at reduced pressure to o give trichlorovinylmorpholine. BP - 85-7 C, 20 mm Hg. Part C: Preparation of the morpholine ynamine. Trichlorovinylmorpholine (5.50 g, 24.5 mmol) is dissolved in an¬ hydrous ether (30 mL) under a nitrogen atmosphere. The mixture is cooled to -30"C and butyllithium (50 mL, 1.5 M, 75 mmol) added slowly, then the mixture is allowed to warm to 23 oC for 2 h. The mixture is cooled to -30 oC again and poured into cold 20 % ammonium hydroxide (20 mL) , ether (50 mL) added and the solutions quickly separated. The organic layer is filtered through anhydrous K2C03 (5 cm) and concentrated in vacuo to a yellow orange oil that is fractionally distilled (0.9 mm Hg, BP - 53 β C) to give the ynamine, 1- ethynyl morpholine, as a colorless oil (1.1 g, 40%). IR (film) 2970, 2940, 2870, 2137, 1647, 1458, 1382, 1272, 1123cm- 1 . ^-H-NMR (CDC1 3 , 5) 3.81, 3.12, 2.36. Example 1: Preparation of 6-chloro-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one, Compound 1 The methyl ester of 5-chlorosalicylic acid (2.00 g, 10.7 mmol) is mixed with ethynyl morpholine (neat, 1.00 g, 9.00 mmol) dropwise. The reaction is exothermic. When the mixture cools, triethylamine (TEA, 1 drop) is added and the liquid mixture immediately crystall¬ ized. The mixture is chromatographed (flash, Si0 2 , CH 2 Cl 2 /EtOH, 95:5) to yield 6-chloro-2-(4-morpholinyl)-4H-lbenzopyran-4-one (1.07 g, 45%). Mp 194-5°C; IR (mull) 2949, 2946, 2869, 2855, 1640, 1615, 1566, 1464, 1450, 1437, 1345, 1246, 1118, 822, 787 cm -1 ; 1H-NMR (CDCI3, 200 MHz, 5) 8.11 (d, J - 2.5 Hz, 1 H) , 7.49 (dd, J - 8.7, 2.5 Hz, 1 H), 7.23 (d, J - 8.7 Hz, 1 H) , 5.49 (s, 1 H) , 3.85-3.82 (m, 4 H), 3.53-3.50 (m, 4 H) ; UV (EtOH) λ max (ε) 217 (31,360), 230 (24,900), 245sh (12,100), 290sh (11,170), 301 (15,810), 315 (16,070); Mass Spectrum: ions at m/e (relative intensity) 267 (35) , 265 (100) , 210 (24) 209 (22), 208 (74), 207 (31), 180 (47), 154 (27), 126 (19), 52 (21); High resolution MS calc'd. for C 13 H 12 N03Cl: 265.0506. Found: 265.0512. Anal, calc'd. for C 13 H 1 N03C1: C, 58.77; H, 4.55; N, 5.27; Cl, 13.34. Found: C, 58.52; H, 4.66; N, 5.11; Cl, 13.58. Following the general procedure of Example 1, but employing the appropriate o-hydroxy salicylic methyl ester in place of the methyl ester of 5-chlorosalicylic acid and, depending upon the reactivity of the methyl ester, carried out either neat, in methylene chloride, toluene or triethylamine, .there are prepared the following products: Cpd 2 2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 160-61 β C; Cpd 4 7-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 160-1"C (from CH 2 Cl 2 /Et0H) ; Cpd 5 8-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 190-1°C (from CH 2 C1 2 /Et 2 0) ; Cpd 6 6-Bromo-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 164-5°C (from CH 2 C1 2 /Et 2 0); Cpd 7 6-Fluoro-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 198-9°C (from CH 2 C1 2 /Et 2 0) ; Cpd 8 6-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 166-7 β C (from CH 2 Cl 2 /Et 2 0) ; Cpd 9 7-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 163-4°C (from CH 2 C1 2 /Et 2 0) ; Cpd 10 8-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 169-70 β C (from EtOAc/hexane) ; Cpd 11 6-Methoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 148-9 β C (from Et0H/CH 2 Cl 2 ) ; Cpd 12 7-Methoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 173-4 β C (from EtOH/hexane) ; Cpd 13 6-(Phenylmethoxy)-2-(4-morpholinyl)-4H-l-benzopyran-4- one, Mp 210-12°C; Cpd 14 8-(Phenylmethoxy)-2-(4-morpholinyl)-4H-l-benzopyran-4- one , Mp 192 -4° C ; Cpd 15 [ 2 - (4 -morpholinyl) -4 - oxo -4H- l -benzopyran-6-yl] -1 , 1- dimethylethyl carbamic acid ester ; Cpd 16 6 - (3 -pyridinecarboxamide ) - 2 - (4-morpholinyl ) - 4H- 1 - b enz opyr an - 4 - one . Example 17 Preparation of 2-(Morpholinyl)-6-nitro-4H-l-benzo- pyran-4-one, Compound #17 The ethyl ester of 5-nitro salicylic acid (634 mg, 3.0 mmol) is dissolved in TEA (2.0 mL) and the morpholine ynamine added. The mixture is then stirred for 48 h. The reaction is diluted with EtOAc (200 mL) and washed with water (5 X 25 mL) , brine (30 L) and dried ( gS04) . Evaporation of the solvent yields product which is chro at- ographed (silica gel [50 g] ; 4% EtOH/CH 2 Cl 2 ) to afford 182 mg (22%) of the desired product. MP - 258-9'C; 1H NMR (CDC13, 300 MHz) 9.05 (d, J - 2.9 Hz, 1 H), 8.44 (dd, J - 8.7, 2.9 Hz, 1 H) , 7.46 (d, J - 9.3 Hz, 1 H), 5.69 (s, 1 H) , 3.91-3.86 (m, 4 H) , 3.61-3.56 (m, 4 H) ; UV (EtOH) 226 (23,700), 234sh (19,000), 282 (17,600), 316 (15,000); LRMS m/e (rel. intensity) 277 (28), 276 (100), 261 (38), 219 (80), 218 (53), 191 (38), 172 (19), 55 (30), 53 (35), 41 (31); IR (mull) 2954, 2924, 2856, 1637, 1627, 1604, 1565, 1447, 1422, 1347, 1253, 1126, 740, 638; HRMS calc'd. for C13H12N205: 276.0746; found: 276.0742; anal calc'd. for C13H12N205: C, 56.52, H, 4.38, N, 10.14; found: C, 56.32, H, 4.52, N, 10.16. Example 18 : Preparation of 2- (4-Morpholinyl) -4H-pyrano [ 2 , 3b ] pyridin-4-one , Compound 18 The methyl ester of 2-hydroxy-3-carboxypyridine (300 mg, 1.9 mmol) is dissolved in toluene (2.0 mL) and a solution of the morpholine ynamine (250 mg, 2.2 mmol) in toluene (2.0 mL) added dropwise at 23°C The reaction is then warmed to 100°C for 24 h. The mixture is cooled and purified by flash chromatography (CH2CI2/ EtOH, 95:5) to give the chromone as pale yellow crystals (270 mg, 63 %). Mp 190-l β C; IR (mull) 2924, 2868, 2855, 1652, 1639, 1611, 1590, 1557, 1463, 1405, 1250, 1120, 788, 602 cm' 1 ; ^-H NMR (CDCI3, 200 MHz, S) 8.60 (s, 1 H), 8.57 (dd, J - 3.2, 2.4 Hz, 1 H), 7.45 (m, 1 H) , 5.56 (s, 1 H), 3.92-3.87 (m, 4 H) , 3.68-3.63 (m, 4 H) ; UV (EtOH) λ max (ε) 215 (16,740), 243 (10,250), 281sh (8,330), 289 (10,500), 320 (15,320); Mass spectrum: ions at m/e (relative intensity) 233 (14), 232 (100), 217 (17), 175 (37), 174 (39), 146 (15), 122 (17), 79 (34), 53 (15), 42 (14); Anal, calc'd. for C 12 H 12 N 2°3 : c > 6 2.06; H, 5.21; N, 12.06. Found: C, 61.85; H, 5.15; N, 11.88. Example 19 Preparation of 6-([[phenylmethoxy]carbonyl]amino)-2- (4-morpholinyl)-4H-l-benzopyran-4-one, Compound 19 2-Hydroxy-5-([[phenylmethoxy]carbonyl]amino)benzoic acid methyl ester (1.0 g, 3.3 mmol) is added to CH2C1 2 (1 ml) and cooled to 0 β C To that solution is added the ynamine (366 mg) neat and dropwise followed by several drops of TEA. The reaction solution turns yellow and after stirring at room temperature for 18 hr is heated at 80 β C (oil bath) for 6 hr. A solid fills the flask. The reaction is diluted with CH 2 C1 2 and the solid collected on a filter to yield 350 mg (19.4%) of the desired product. An analytical sample was prepared by recrystallization from CH3CN. Mp 245-50 β C; IR (mull) 3263, 2947, 2925, 2921, 2867, 2854, 1716, 1638, 1623, 1577, 1564, 1558, 1464, 1456, 1453, 1404, 1246, 1231, 1121, 731 cm "1 ; ^-NMR (CDCI3, δ 8 - 15 (d, 1H, J-2 Hz), 7.95 (s, 1H) , 7.87 (s, 1H) , 7.3 ( , 7H) , 5.42 (s, 1H, vinyl), 5.2 (s, 2H), 3.7 (m, 4H) , 3.4 (m, 4H) ; UV (EtOH λ max (ε) 231 (27,520), 246 (34,960), 300 sh (16,300), 307 (17,830), 320 si sh (12,800); Mass spectrum: ions at m/e (relative intensity) 380 (17), 335 (12), 272 (100), 215 (69), 187 (44), 161 (32), 108 (79), 91 (87), 79 (99), 53 (32), 44 (50); Anal. Calc'd. for: C 21 H 20 N 2 0 5 : C, 66.31; H, 5.26; N, 7.36. Found: C, 66.40; H, 5.28; N, 7.30. Example 20: Preparation of 8-Methoxy-2-(4-morpholinyl)-4H-l- benzopyran-4-one, Compound 20 Method A: 3-Methoxy salicyl chloride (750 mg, 4 mmol) is dissolved in THF (4mL) and cooled to 0 β C The morpholine ynamine (445 mg, 4.0 mmol) is dissolved in THF (4 mL) and then added dropwise to the cooled solution of the acid chloride. A white precipitate forms immediately and after stirring for 20 minutes, TEA (0.60 mL) , 4.5 mmol) is added and the reaction temperature raised to 23°C After refluxing for 20 minutes the reaction is cooled to room temperature and the THF removed .in vacuo. The crude reaction mixture is filtered and the filtrate chro atographed over silica gel (5% Et0H/CH 2 Cl ) to afford, after recrystallization, 115 mg (12%) of the desired product. Mp 184-6°C; IR 2952, 2925, 2870, 2855, 1642, 1625, 1618, 1581, 1575, 1463, 1455, 1410, 1350, 1250, 1244, 1116, 773 cm" 1 ; UV (EtOH) λ max (ε) 212 sh (20,710), 236 (25,000), 250 sh (12,000), 301 (17,800); 1H-NMR (CDC13) 7.74 (dd, 1H, J - 2 and 8 Hz) , 7.27 (t, 1H, J - 8 Hz), 7.10 (dd, 1H, J - 2 and 8 Hz), 5.52 (s, 1H) , 3.96 (s, 3H) , 3.88 (m, 4H) , 3.55 (m, 4H) ; Mass spectrum: ions at m/e (relative intensity) 261 (100), 204 (63), 203 (19), 176 (27), 122 (33), 77 (26), 55 (26), 57 (32), 43 (37); Anal, calc'd. for C 14 H 15 N0 4 ; C, 64.35; H, 5.76; N, 5.36. Found: C, 64.39; H, 5.83; N, 5.74. Method B: 3-Methoxy methyl salicylate (547 mg, 3.0 mmol) is dissolved in TEA (4.0 L) and the morpholine ynamine (400 mg, 3.7 mmol) is added. The mixture is stirred for 48 h, then diluted with EtOAc (200 mL) and washed with water (5 X 20 mL) , brine (30 mL) and dried (MgSU4) . Evaporation in vacuo affords 690 mg of crude product. Chromatography (silica gel [50 g] ; 4% Et0H/CH 2 Cl 2 ) affords the desired product (160 mg; 20%) . Example 21: Preparation of 3-Amino-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one, Compound 21 Part A: 2-(4-morpholinyl)-4H-benzopyran-4-one (2.00g, 8.00 mmol) is dissolved in CH 2 C1 2 (12 mL) and nitric acid (5.00 mL, 24 mmol) added dropwise with stirring at 23°C. After 2H, the mixture is warmed to 60 C and three drops of sulfuric acid added. The reaction gradually turns red and a brown gas is evolved. After about 4 hrs the starting material is consumed as evidenced by TLC (Et0Ac/CH 3 0H, 9/1). The reaction mixture is poured onto ice (30 mL) and yellow crystals precipitated almost immediately. The crystals are filtered and washed with cold water. The crude product is dissolved in ethyl acetate (200 mL) and the remaining precipitate is removed by filtration. The EtOAc layer is washed with saturated NaHC03 ( 2 x 30 mL) and brine (50 mL) then dried (M S04 . Rotary evaporation yields 1.44g (60%) of 2-(4-morpholinyl)-3-nitro-4H-lbenzopryan-4-one. The 2-(4-morpholinyl)-3-nitro-4H-l-benzopyran-4-one is further purified by column chromatography over silica gel (EtOAc) to give analytical material. Mp 206-8°C; IR (mull) 2954, 2925, 2869, 2856, 1646, 1620, 1599, 1575,1487, 1467, 1445, 1435\ 1422, 1379, 1341, 1325, 1116 cm "1 ; -NMR (CDC1 3 , 5) 8.23 (dd, J - 1.9, 8.9 Hz, 1H) , 7.65 (ddd, J - 2.1, 7.3, 10.2, 1H), 7.39 ( , 2H) , 3.90 (m, 4H) , 3.62 ( , 4H) ; MS m/e (rel intensity) 276 (78), 201 (36), 187 (38), 121 (100), 120 (56), 92 (30), 79 (23), 77 (21), 73 (22), 42 (25); UV (EtOH) λ max (ε) 230 (15,730), 286 (17,000), 295sh (14,760), 360sh (1,840); Anal, calc'd. for C 13 H 12 N2θ5: C, 56.52; H 4.38; N, 10.14. Found: C, 56.53; H, 4.56; N, 9.79. Part B: 2-(4-Morpholinyl)-3-nitro-4H-l-benzopyran-4-one (500 mg) is dissolved in EtOAc (30 mL) . Palladium on carbon (10 %, 100 mg) is added under a nitrogen atmosphere. The mixture is fixed to a Parr hydrogenator at 30 psi for 4 hr, then filtered (Celite, 1 cm) and solvent removed in vacuo. The product is purified by flash chromatography (EtOAc) to give 3-Amino-2-(morpholinyl)-4H-l-benzo- pyran-4-one (419 mg, 94%). Mp 140-l β C; IR (mull) 2954, 2925, 2856, 1621, 1607, 1551, 1466, 1423, 1382, 1277, 1271, 1240, 1115, 952, 762 cm' 1 ; NMR (CDCI3, S) 8.24 (dd, J - 7.8, 2.0 Hz, 1 H) , 7.60 (ddd, J - 6.8, 6.7, 1.8 Hz, 1 H) , 7.38 (br.d, J - 7.8 Hz, 2 H) , 3.91-3.76 (m, 4 H), 3.52-3.47 (m, 4 H), 3.43 (br.s, 2 H) ; UV (EtOH) λ max (ε) 212 (19,150), 233 (15,180), 255sh (9,900), 300 (3,000), 356 (12,100); Mass spectrum:ions at m/e (relative intensity) 262 (21), 246 (100), 201 (21), 188 (18), 187 (40), 148 (88), 121 (52), 114 (21), 70 (36), 42 (17); Anal, calc'd. for ^3^4^03: C, 63.40, H, 5.73, N, 11.38; found: C, 63.48; H, 5.84; N, 11.46. Example 22: Preparation of 3-Chloro-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Compound 22 2-(4-Morpholinyl)-4H-benzoρyran-4-one (2.0 g, 8.0 mmol) is dissolved in CH 2 C1 2 (20 mL) . t-Butyl hypochlorite (1.0 mL, 8.5 mmol) is added dropwise at 23°C The reaction mixture is warmed slightly and is finished almost instantaneously. The solvent is removed in vacuo and the residue is taken up in EtOAc (200 mL) . The organic layer is washed with water (2 X 50 mL) and brine (80 mL) , then dried ( gSU ) . The solution is concentrated in vacuo giving colorless crystals which are recrystallized from EtOAc to give the desired product (1.86 g, 91%) Mp 127-8°C; IR (mull) 2962, 2923, 2856, 1635, 1612, 1597, 1562, 1555, 1466, 1457, 1325, 1233, 1119, 872, 762 cm *1 ; X H NMR (200 Mhz, CDC1 3 , δ) 8.20 (br d, J - 7.5 Hz, 1H) , 7.60 (ddd, J - 9.1, 6.7, 1.7 Hz, 1H) , 7.36 (m, 2 H) , 3.88 (m, 4H) , 3.74 ( , 4H) ; MS m/e (rel intensity) 267 (33), 266 (15), 265 (100), 231 (15), 230 (98), 209 (16), 207 (45),' 120 (27), 110 (19), 41 (16); UV (EtOH) λ max (ε) 214 (18,900), 238 (18,160), 300 sh (11,530); Anal, calc'd. for C 13 H 12 N0 3 C1: C, 58.76; H, 4.55; N, 5.27. Found: C, 58.82; H, 4.58; N, 5.37. Example 23: Preparation of 3-Bromo-2-(4-morpholinyl)-4H-1 benzopyran-4-one, Compound 23 2-(4-morpholinyl)-4H-benzopyran-4-one (2.0 g, 8.0 mmol) is dissolved in CH 2 C1 2 (20 mL) . N-Bromosuccinimide (1.6 g, 8.2 mmol) is added and the reaction mixture warmed slightly and the starting material disappears immediately as evidenced by TLC. The solvent is removed in vacuo and the colorless residue is taken up in EtOAc (200 mL) and washed with water (4 X 30 mL) , brine (50 mL) and dried (MgS04) . Rotary evaporation gives the desired product (2.27 g, 92%) as colorless crystals, mp: 145-6 βG ; IR (mull) 3337, 3016, 2922, 2871, 2855, 1698, 1609, 1585, 1502, 1462, 1378, 1367, 1341, 1303, 1295, 1260, 1234, 996, 812 cm "1 ; X H NMR (CDCI3, 5) 8.22 (dd, J - 7.9, 1.8 Hz, 1H), 7.63 (ddd, J - 8.2, 7.4, 1.4 Hz, 1H) , 7.44-7.28 (m, 2H) , 3.90-3.84 (m, 4H) , 3.76-3.69 (m, 4H) ; LRMS m/e (rel intensity) 311 (55), 309 (55), 253 (14), 231 (17), 230 (100), 172 (21), 121 (20), 120 (15), 110 (61), 41 (16); UV (EtOH) λ max (ε) 216 (18,400), 238 (18,600), 317 (17,040); High resolution MS calc'd. for C 13 H 12 N0 3 Br: 309.0001. Found: 308.9990. Anal, calc'd. for C 13 H 12 N0 3 Br: C, 50.34; H, 3.90; N.4.52. Found: C, 50.40; H.4.05; N, 4.46. - Relating to Chart B: Example 24 Preparation of 8-methyl-2-(4-morpholinyl)-7-(phenyl- methoxy)-4H-l-benzopyran-4-one (Cpd 24). Part A: 3-(Dimethylamino)-1- (2-hydroxy-3-methyl-4-benzyloxyphenyl)- Propen-1-one. 2-Hydroxy-3-methyl-4-(phenylmethoxy)-acetophenone (25 g, 98 mmol) and DMF-DMA (17.9 g, 150 mmol) is heated at 95-100°C for 2.75 h. The reaction is cooled to room temperature and excess reagent and CH3OH removed in vacuo to leave a dark solid. That solid is tritura- ted with ether at 0°C and filtered to yield 19.64 g (64.4 %) of the product as a yellow solid. The mother liquors (9.91 g) also con¬ tained product but is not isolated. An analytical sample is prepared by recrystallization from EtOAc/ Skelly-B. Part B: 3-Bromo-8-methyl-7-(phenylmethoxy)-[4H] -1-benzopyran-4-one. The vinylogous amide of Part A (19.0 g, 61 mmol) is dissolved in CHC1 3 and cooled to 0°C. Br 2 (9.75 g, 61 mmol), in CHCI3 (50 mL) , is added dropwise over a 5 minute period. After complete addition, the reaction is diluted with H 2 0 (200 mL) and vigorously stirred for 5 minutes. The CHCI3 layer is separated, dried (M S04) and solvent evaporated in vacuo to yield 23.1 g of crude product. Recrystalliza¬ tion from EtOAc afforded 15.2 g (66%) of analytically pure product. Part C: 8-Methyl-2-(4-morpholinyl)-7-(phenylmethoxy)-4H-l-ben- zop ran-4-one. The 3-bromochromone of Part B (1.0 g, 2.9 mmol) is dissolved in acetonitrile (35 mL) . Anhydrous potassium carbonate is added (371 mg, 2.9 mmol). Then morpholine (0.252 mg, 2.9 mmol) is added dropwise. Stirring is begun and the reaction warmed to reflux for 36 h. The acetonitrile is removed in vacuo and the organic material is taken up in ethyl acetate. The organic phase is washed with water and brine then dried ( gSθ4) . The solvent is removed in vacuo and the residue is chromatographed over silica gel ( CH 2 C1 2 /Et 2 0; 2/1) to give two main fractions. The first contained a 3-amino substituted product. The second fraction is a mixture of a ring contracted product and the desired 2-morpholinyl chromone. That mixture is rechromatographed (EtOAc/C^OH; 95/5) giving two fractions, the faster moving containing the ring-contracted product (211 mg, 21%) , Mp 171-2 β C; IR (mull) 2954, 2924, 2867, 2855, 1693, 1632, 1613, 1597, 1260, 1166, 1140, 1108, 1099, 749 cm -1 ; ^-H-JNMR (200 MHz, CDCI3, δ) 7.64 (dd, J - 8.57 Hz, 1.27, 1 H) , 7.49-7.41 (m, 5 H) , 6.89 (s, vinyl, 1 H) , 8.84 (d, J - 8.57 Hz, 1H) , 5.22 (s, 2 H) , 3.89-3.84 (m, 4 H), 3.79-3.76 (m, 4 H) , 2.30 (s, 3 H) ; UV (EtOH) λ max (ε) 204 (25,300), 205sh (24,500), 252 (8,550), 258 (8,670), 321 (18,900), 377 (33,100), 391 (29,300); High resolution MS calc'd. for C 21 H 21 N0 : 351.1470. Found: 351.1470. Anal, calc'd. for C 21 H 21 N0 4 : C, 71.78; H, 6.02; N, 3.99. Found: C, 71.60; H, 6.15; N, 3.96. On further elution, the desired 2-morpholinyl chromone (Cpd #24) is isolated (127 mg, 12%). Mp 181.5-182.5°C; IR (mull) 2953, 2925, 2864, 2857, 1637, 1612, 1592, 1575, 1413, 1274, 1272, 1251, 1240, 1119, 782 cm" 1 ; ^- R (200 MHz, CDC1 3 , δ) 8.00 (d, J - 9.1 Hz, 1 H) , 7.47-7.38 (m, 5 H) 6.98 (d, J - 9.1 Hz, 1 H) , 5.44 (s, 1 H) , 5.19 (s, 2 H), 3.89-3.84 (m, 4 H) , 3.54-3.49 (m, 4 H) , 2.33 (s, 3 H) ; UV (EtOH) λ max (ε) 111 (33,610) 239 (23,660), 291sh (13,980), 312 (26,160), 376 (509); High resolution MS calc'd. for C 21 H 2 ιN0 : 351.1470. Found: 351.1464. Anal, calc'd. for C 21 H 21 N0 4 : C, 71.78; H, 6.02; N, 3.99. Found: C, 71.79; H, 5.99; N, 3.98. Example 25 Preparation of 2-(4-morpholinyl)-5-(phenylmethoxy)-4H- l-benzopyran-4-one Compound 25 Part A: 6-Benzyloxy-2-hydroxyacetophenone 2,6-Dihydroxyacetophenone (84.48 g, 0.55 M) , benzyl bromide (95 g, 0.55 M) , and K C03 (120 g) is added to acetone (750 mL) . That mixture is heated at reflux under nitrogen with vigorous stirring (overhead stirrer) for 18 h. The reaction is then cooled to room temperature and filtered. The filtrate is evaporated in vacuo to yield an oily semi-solid. That material is dissolved in CH 2 C1 2 and washed with 1 N HCL. The CH2CI2 solution is dried (MgSθ4) and solvent removed in vacuo to yield a pale oil. That material is chromatographed over silica gel (400 g) eluting with CH2C1 2 to afford 72.8 g (54.5%) of the product. An analytical sample is prepared by recrystallization from EtOAc/Skelly-B. Part B: 3-(Dimethylamino)-1-(2-hydroxy-6-benzyloxyphenyl)-Propen-1- one A mixture of 6-benzyloxy-2-hydroxyacetophenone (15.0 g, 62 mmol) and N,N-dimethylformamide dimethylacetal (DMF-DMA; 10.71 g, 90 mmol) is heated under nitrogen at 100-10°C for 2 h. Within several minutes of placing the reaction vessel in the oil bath (already at 100°C) the initial heterogeneous mixture became homogeneous and very dark in color. After several additional minutes a solid began to separate from this solution and at the end of the reaction time the flask is filled with a yellow solid. The reaction is cooled to room tempera¬ ture and excess DMF-DMA and methanol is removed in vacuo. The resulting solid is filtered with the aid of ether and air dried to yield 15.41 g (83.7%) of pure product. An analytical sample is prepared by recrystallization from EtOAc. Part C: 5-Benzyloxy-3-bromo- [4H] -l-benzopyran-4-one The vinylogous amide of Part B (10.0 g, 33.6 mmol) is dissolved in CHC1 3 (150 mL) and cooled to 0°C Br 2 (5.38 g, 33.6 mmol) is added to the aforementioned solution in CHCI3 (50 mL) dropwise over 10 minutes. After complete addition the reaction is diluted with H 2 0 and vigorously stirred for 5 minutes. The organic layer is separated and washed with brine, dried (MgS04) , and evaporated to give a dark red oil. Chromatography over silica gel (400 g) eluting with 1% CH 3 0H/CH 2 C1 2 afforded, after recrystallization from EtOAc/Skelly-B, 4.76 g (42.8%) of the product. The 5-benzyloxy-3-bromochromone of Part B (3.31g, 10.0 mmol) is dissolved in acetonitrile (50 ' mL) . Anhydrous potassium carbonate (1.38g, 10.0 mmol) is added, then morpholine (1.02 mL, 11.0 mmol) is added. The mixture is heated to reflux for 72 h. The solvent is removed under vacuo and the residue is taken up in EtOAc (400 mL) and washed with water (3 X 50 mL) and brine (100 mL) , then dried (MgS0*4) . The solvent is removed in vacuo and the residue purified by flash chromatography (CHCI3/CH3OH, 99/1) giving three main fractions. The first fraction contained a 3-morpholinyl chromone (0.92g, 51%). Mp 122.5-124°C; IR (mull) 2956, 2924, 2856, 1641, 1604, 1464, 1459, 1269, 1235, 1180, 1115, 1070, 1064, 772, 699 cm" 1 ; -NMR (200 MHz, CDCI3, δ) 7.61 (dd, J - 6.7, 1.5 Hz, 1 H) , 7.59-7.29 (m, 5 H), 6.98 (dd, J - 8.2, 1.5 Hz, 1 H) , 6.77 (dd, J - 8.2, 1.5 Hz, 1 H), 5.31 (s, 2 H), 3.94-3.90 (m, 4 H) , 3.08-3.04 ( , 4 * H) ; UV (EtOH) λ max (ε) 244 (22,700), 249 (21,500), 336 (6,270); Anal. calc'd. for C 20 H 19 N0 4 : C, 71.20, H, 5.68, N, 4.15; found: C, 70.84, H, 5.75, N, 4.05. The second fraction contained a ring contracted product (0.60g, 33%). Mp 179-181 β C The last fraction contains the desired 2-morpholinyl chromone (Cpd #25) (0.29g, 16%). Mp 139-40°C; IR (mull) 2954, 2926, 2870, 2855, 1640, 1623, 1615, 1600, 1470, 1449, 1407, 1239, 1122, 745, 740 cm "1 ; ^- R (CDCI3, 200 MHz, δ) 7.65 (broad doublet, J - 7.2 Hz, 2 H), 7.47-7.30 (m, 4 H) , 6.92 (dd, J - 8.1, 0.9 Hz, 1 H) , 6.85 (br.d, J - 8.1 Hz, 1 H) 5.45 (s, 1 H) , 5.32 (s, 2 H) , 3.89-3.85 (m, 4 H) , 3.52-3.47 (m, 4 H) ; UV (EtOH) λ max (ε) 210 (32,900), 238 (23,500), 252sh (8,040), 260sh (5,650), 313 (18,460); Mass Spectrum: ions at m/e (rel intensity) 91 (100), 337 (66), 231 (36), 174 (33), 173 (16), 338 (16) 336 (15) , 218 (15) , 65 (14) , 146 (12) ; High resolution MS calc'd. for C 20 H 19 N0 4 : 337.1314. Found: 337.1312. Anal, calc'd. for c 20 H 19 NO 4 : - > 71 -20, H, 5.58, N, 4.16. Found: C, 71.05, H, 5.56, N, 4.17. Example 26: Preparation of 7,8-dimethoxy-2(4-morpholinyl)-4H-l- benzopyran-4-one, Compound 26 Part A: The 7,8-dimethoxy-3-bromochromone, R.B. Gam ill, Synthesis (1979), p. 901, (3.42g, 12.0 mmol) is dissolved in acetonitrile (100 L) and anhydrous potassium carbonate (1.66g, 12.0 mmol) is added. Morpholine (1.10 mL, 12.5 mL) is added dropwise and the reaction is warmed to reflux (82 C bath temperature) for 24 h. The acetonitrile is removed in vacuo, and the mixture is taken up in ethyl acetate (400 mL) . The solution is washed with water (2 x 50 mL) and brine (100 mL) , then dried (M S04) and concentrated in vacuo to give a yellow solid. Flash chromatography over silica gel (EtOAc/MeOH, 95/5) gave the 3-morpholinyl adduct (2.77g, 79%), the ring contracted product (0.24 g, 6.9 %) and 0.23 g of a mixture of the ring contracted and the 2-substituted product (79%) Mp 168-9°C; IR (mull) 2952, 2924, 2866, 2854, 1639, 1619, 1509, 1456, 1441, 1433, 1322, 1291, 1200, 1171 cm "1 ; X H-NMR (200 MHz, CDC1 3 , δ) 8.0 (d,lH, 7.56 (s,lH,-C(H)0Ar), 7.02 (d,lH,J-8 .9Hz), 4.0 (s,3 H, 0CH 3 ) , 3.98 (s, 3 H, OCH3), 3.91 (m, 4 H) , 3.08 (m, 4 H) , UV (EtOH) λ max (ε) 247 (30,060), 303 (7,490), 326 (3,990); High resolution MS calc'd. for C 15 H 17 N0 5 : 291.1107. Found: 291.1110. Anal, calc'd. for C 15 H 17 N0 5 : C, 61.85; H, 5.88; N, 4.81. Found: C, 61.79; H, 5.86; N, 4.74. Part B: The mixture of ring contracted and 2-morpholinyl chromone are rechromatographed (Si0 2 , CH2CI2/CH3OH, 98/2). The ring-contrac¬ ted product is recrystallized from EtOH to give pale yellow crystals, Mp 180-181°C The 2-morpholinyl chromone is recrystallized from EtOH to give the desired product (Cpd #26) (colorless crystals); Mp 194.5-5.5°C; X H-NMR (CDCI3. δ) 7.88 (d, J - 8.8 Hz, 1 H) , 6.97 (d, J - 8.8 Hz, 1 H), 5.43 (s, 1 H), 3.98 (s, 3 H) , 3.94 (s, 3 H) , 3.86 (m, 4 H) , 3.55 (m, 4 H). UV (EtOH) λ max (ε) 217 (27,140), 239 (23,530), 270 (6,700), 311 (23,530); High resolution MS calc'd. for C 15 H 17 N0 5 : 291.1107. Found: 291.1093. Anal, calc'd. for C 15 H 17 N0 5 : C, 61.85; H, 5.88; N, 4.81. Found: C, 61.85; H, 5.83; N, 4.78. Example 27: Preparation of 2-(4-methyl-l-piperazinyl)-4H-l- benzopyran-4-one, Compound 27 Following the general procedure outlined in Chart B, the title compound is prepared. Relating to Chart C: Example 28: Preparation of 8-methyl-7-(phenylmethoxy)-2-[4-(2- pyridinyl) -1-piperazinylJ -4H-benzopyran-4-one, Compound 28 Part A: Preparation of 8-Methyl-7-(Phenylmethoxy)-2-mercapto-4H-l- benzopyran-4-one. Potassium t-butoxide (65.5 g) is covered with 500 mL of benzene under nitrogen and that solution is placed in a water bath. 4'- Benzyloxy-2'hydroxy-3'-methylacetophenone (50.0 g) and carbon disulfide (14.82 g) are dissolved in 500 mL of benzene and added dropwise to the potassium t-butoxide solution over a one hour period. After complete addition the dark red paste is stirred at room temperature over night and then diluted with one liter of water. That mixture is poured into a separatory funnel and the organic layer discarded. The aqueous is diluted with 300 mL of 20% H2S04 and the solid that separated is collected on a filter and air dried to yield 31.Og of a yellow powder. MP 245 β C [D] ; 2954, 2916, 2869, 2855, 1619, 1602, 1542, 1499, 1462, 1455, 1377, 1305, 1280, 1113, 1076, 822 cm "1 ; UV (EtOH) λ max (ε) 208 (34260), 231 (24940), 252 (15070), 263 si sh (9470), 285 si sh (5030), 299 (4930), 353 (18200), 392 (6840); X H-NMR (DMSO-dg) δ 7.73 (d, 1H, J - 8.9 Hz), 7.45 (m, 5H, aromatic), 7.24 (d, 1H, J - 8.9 Hz), 6.58 (s, 1H, vinyl at C-3), 5.29 (s, 2H) , 2.29 (s, 3H, -CH3) ; Mass spectrum: ions at m/e (relative intensity) 298 (12), 207 (1), 179 (1), 149 (1), 121 (1), 91 (100), 65 (6), 43 (1). See Bantick, J.R. and Suschitzky, J.L. , J. Heterocyclic Chem. 18, 679 (1981). Part B: 8-Methyl-7-(phenylmethoxy)-2-mercapto-4H-l-benzopyran-4-one (2.0 g, 6.7 mmol), l-(2-pyridyl)piperazine (1.19 g, 7.3 mmol) and TsOH (25 mg) is added to toluene and heated at reflux for 20 hours. The reaction temperature is lowered to room temperature and the toluene removed in vacuo. The resulting dark oil is diluted with EtOAc and the resulting crystals collected on a filter to afford 2.42 g of product. MP 148-9 β C Following the general procedure of Example 28, but employing the appropriate amine in place of l-(2-pyridyl)piperazine there are prepared the following products: 8-Methyl-7-(phenylmethoxy)-2-(1-piperazinyl)-4H- benzopyran-4-one, Mp 165-70°C; 8-Methyl-7-(phenylmethoxy)-2-(1-pyrrolidinyl)-4H- benzopyran-4-one, Mp 190-3°C; 8-Methyl-7-(phenylmethoxy)-2-(1-piperidinyl)-4H- benzopyran-4-one, Mp 172-4 β C; 8-Methyl-2-(4-methyl-l-piperazinyl)-7-(phenylmethoxy)- 4H-benzopyran-4-one, Mp 180-l β C; 8-Methyl-7-(phenylmethoxy)-2-(2,6-dimethyl-4- morpholinyl)-4H-benzopyran-4-one, Mp 166-8 β C; 2-[4-(Hydroxyethyl)-1-piperazinyl]-8-methyl-7-(phenyl- methoxy)-4H-benzopyran-4-one monohydrochloride, M p 253-5 β C; Cpd 35 2- [4-(Diphenylmethyl)-l-piperazinyl] -8-methyl-7- (phenylmethoxy)-4H-benzopyran-4-one, Mp 90-5°C; Cpd 36 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-l-piperidinyl)- 4H-benzopyran-4-one, Mp 193-4"C; Cpd 37 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-l-piperazinyl)- 4H-benzopyran-4-one, Mp 153-4°C; and Cpd 38 2-(4-Hydroxy-l-piperdinyl)-8-methyl-7-(phenylmethoxy)- 4H-benzopyr n-4-one. Relating to Chart D and E: Example 39: Preparation of 7-hydroxy-2-(4-morpholinyl)-8-methyl- 4H-l-benzopyran-4-one, Compound 39 (according to Chart D). Part A: 8-Methyl-2-(4-morpholinyl)-7-(phenylmethoxy)-4H-l-ben- zopyran-4-one (8.59g, 24.4 mmol.) is suspended in 250ml of ethyl acetate. 9.9 ml of cyclohexene is added followed by 0.85g of 10% Palladium on carbon. The mixture is heated at reflux for 18 hours. The reaction is allowed to cool and filtered, the solid is taken up in methanol, decanted and filtered. The methanol is evaporated to give 4.71g (74%) of the phenol (mp > 250 C) . Alternate Part A: 2' ,4' , -Dihydroxy-3' -methyl-acetophenone (90% purity, 1.108g, 6 mmole) is suspended in 25ml 1,2-dichloroethane and the mixture is treated with boron trifluoride etherate (1.48ml, 12 mmole) while stirring in a 50ml one neck round bottom flask under nitrogen. The mixture is stirred for 30 min at room temperature and is subsequently treated with morpholine-4-phosgene iminium chloride (2.70g, 13.2 mmole). The reaction mixture is warmed to 70 C for 3h. The reaction is cooled to room temperature and the insoluble orange solid is collected by filtration and the filter cake is washed well with diethylether. The solid is taken up in 25ml acetonitrile in a 50ml one neck round bottom flask under nitrogen and the solution is cooled to 0 C. The mixture is treated with 2.5ml water and the reaction is stirred for 48h as the cooling bath expired. The acetoni¬ trile is removed in vacuo and the residue is carefully diluted with 75ml 2:1 saturated sodium bicarbonate/sodiu chloride. The mixture is extracted with 4 X 35ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to an amber solid. The solid is washed successively with ethylacetate and diethylether to afford 980mg (44%) of [8-methyl-2-(4-morpholinyl)-4- oxo-4H-l-benzopyran-7-yl]4-morpholinyl carboxylic acid ester (Cpd 100) M.P. 232-234 β C The carbamate (945mg, 2.51 mmole) is suspended in 9ml 2/1 methanol/water in a 25ml on neck round bottom flask under nitrogen. The suspension is treated with lithium hydroxide (236mg, 5.62 mmole) and the reaction mixture is stirred for 48h at room temperature. The methanol is removed in vacuo and the pH of the aqueous residue is adjusted to pH — 4.9 by the addition of 5% hydrochloric acid. The precipitated material is collected by filtra¬ tion and is dried in vacuo at 25 C to afford 569mg (87%) of phenol 39 (M.P. > 250 C) as a chalky grayish solid. Second Alternate Part A: 2' ,4' -Dihydroxy-3'-methyl-acetophenone (90% purity, 18.46g, 100 mmole) is suspended in 50ml diethylether in a 100ml one neck round bottom flask under nitrogen. The mixture is treated with boron trifluoride etherate (18.45ml, 150 mmole) and the reaction is stirred overnight at room temperature. The precipitated material is collected by filtration and the filter cake is washed well with fresh diethylether. The filtered material is air dried to afford 10.45g (47%) of difluoroboronate salt as a yellow solid. The difluoroboronate salt (10.45g, 47 mmole) is combined with morpholine-4-phosgene iminium chloride (21.2g, 104 mmole) in 125ml 1,2-dichloroethane in a 250ml one neck round bottom flask under argon. The reaction mixture is warmed to 70 C for 3h and is cooled to room temperature. The orange-yellow precipitate is collected by filtration and is washed successively with 1,2-dichloroethane and diethylether to provide 25.3g of an orange solid. The solid is suspended in 200ml acetonitrile in a 500ml one neck round bottom flask and the mixture is cooled to 0 C The cooled mixture is treated with 20ml water and after stirring 20 min at 0 C, the reaction mixture is stirred overnight at room temperature. The mixture is subsequently cooled to -33 C for 2h and the precipitated hydro- chloride salt is collected by filtration and is washed with 125ml ice cold acetonitrile. The filter cake is dried to provide 13.25g (69%) of the carbamate-chromone hydrochloride as a white solid. The filtrate is concentrated in vacuo to an amber syrup. The syrup is diluted with 100ml saturated sodium bicarbonate and the mixture is extracted with 4 X 50ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to a reddish oil which upon crystallization with ethylacetate yielded 875mg (5%) of carbamate-chromone as a yellow solid. Hydrolysis of the carbamate-chromone as described in method B affords the desired phenol. Part B: 7-Hydroxy-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one (0.50g, 1.91mmol) is suspended in 15ml of acetonitrile. 1.3g of potassium carbonate is added followed by 0.39g (2.1mmol) of alphabromo-p-xylene. The mixture is refluxed for 5 hours. 0.04 g of additional alkylating agent is added and the mixture is refluxed for 2 hours. The cooled mixture is diluted with 5ml of water and filtered. The white solid is washed with water and dried. The solid is recrystallized from ethyl acetate to afford 0.59g (84%) of the product 48 (mp 167.5-168°C) . Following the general procedure of Example 39 but employing the appropriate phenylmethoxy aminochromone in place of (7-phenyl- methoxy)-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one there are prepared the following products: Cpd 40 6-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 290-2°C; Cpd 41 7-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 42 5-Hydroxy-2-(4-morpholinyl)-4H-l-benzoρyran-4-one, Mp 295-7 β C; Cpd 43 8-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, Mp 300°C; Cpd 44 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one, Mp 224.5-225.5 β C; [ (8 -methyl- 2- (4-morpholinyl) -4H-l-benzopyran-7-yl)oxy) acetic acid lithium salt; [ [8-Methyl-2-(4-morpholinyl)-4-oxy-4H-l-benzopyran-7- yl]oxy]acetic acid methyl ester, Mp 181-2°C; 7- [ (4-Methoxyphenyl)methoxy] -8-methyl-2- (4-morpho linyl)-4H-l-benzopyran-4-one, Mp 171-2"C; 8-Methyl-7- [ (4-methylphenyl)methoxy] -2- (4-morpho linyl)-4H-l-benzopyran-4-one, Mp 167.5-8 β C; 7- [ (4-Chlorophenyl)me thoxy] -8-methyl-2- (4-morpho linyl)-4H-l-benzopyran-4-one, Mp 226-7 β C; 7- [ (4, 5-Dichlorophenyl)methoxy] -8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one, Mp 243-4 β C; 8 -Methyl- 2- (4-morpholinyl) -7- (2-pyridinylme thoxy) -4H- l-benzopyran-4-one; Mp 174-175.5; and 8-Methyl-7- [ [ (phenyl) carbonyl] oxy] -2- (4-morpho linyl)-4H-l-benzopyran-4-one, Mp 223.5-25°C 8-Methyl-7-(2-(4-methyl-(l-piperizinyl))ethyl)oxy-2- (4-morpholinyl)-4H-l-benzopyran-4-one, Mp 159.0- 159.5 β C Cpd 54 7- [[4-(l,l-Dimethylethyl)phenyl]methoxy]-8-methyl-2- (4-morpholinyl)-4H-l-benzopyran-4-one, Mp 218.5-220 β C; 8 -Methyl- 2- (4 -morpholinyl) -7- [ [4-phenylme thoxy) - phenyl]methoxy]-4H-l-benzopyran-4-one, Mp 110-111° C; 7- [ (3-Methoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl)-4H-l-benzopyran-4-one, Mp 153.5-155.5°C; 7- [ (4-Nitrophenyl)methoxy] -8-methyl-2- (4-morpholinyl) - 4H-l-benzopyran-4-one, Mp 285°C dec; 7- [ (2-Phenylethyl)methoxy] -8-methyl-2- (4-morpholinyl) - 4H-l-benzopyran-4-one, Mp 200.5-201.5°C dec; 7- [(2-Methoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl)-4H-l-benzopyran-4-one, Mp 202-203°C; 7 - [ (4-Ethoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl)-4H-l-benzopyran-4-one, Mp 186-188°C; 8-(4-Ethoxy-benzyloxy)-2-(4-morρholinyl)-4H-l-benzo- pyran-4-one, Mp 149.5-151.5°C; 2- (4-Morpholinyl) -8- (4-nitro -benzyloxy) -4H-l-benzo- ρyran-4-one, Mp 240-241°C; 8- (2-Methoxy-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one, Mp 149 - 150° C; Cpd 64 2-(4-Morpholinyl)-8-(2-phenyl-ethoxy)-4H-l-benzopyran- 4-one, Mp 131-132°C; Cpd 65 2- (4-Morpholinyl) - (2 - oxo-2-phenyl-ethoxy) -4H-1- benzopyran-4-one, Mp 200- 201.5° C; Cpd 66 8 - (4-Benzyloxy-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one, Mp 143.5- 145° C; Cpd 67 8- (4-Chloro-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one, Mp 208-209°C; Cpg 68 8- (4- t-Butyl-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one, Mp 165.5-166.5°C; Cpd 69 8- (3-Methoxy-benzyloxy) - 2- (4-morpholinyl) -4H-1- benzopyran-4-one, Mp 177 - 178° C; Cpd 70 8-(3,4-Dichloro-benzyloxy)-2-(4-morpholinyl)-4H-l- benzopyran-4-one, Mp 207-208°C; Cpd 71 8- (4-Methyl-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one, Mp 177-178 β C; Cpd 72 8- (4-Methoxy-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one, Mp 173.5-174.5°C; Cpd 73 2- (4-Morpholinyl) -8- (naphthyl-2-methyloxy) -4H-1- benzopyran-4-one, Mp 200.5 -201.5° C; Cpd 74 2- (4-Morpholinyl) -8- (naphthyl-1-methyloxy) -4H-1- benzopyran-4-one, Mp 192.5-193.5 β C; Cpd 75 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-2-methyloxy)- 4H-l-benzopyran-4-one, Mp 158.5-159.5°C; Cpd 76 8-Methyl-2- (4 -morpholinyl) -7-(naphthyl-l-methyloxy)- 4H-l-benzopyran-4-one, Mp 205.5-207°C; Cpd 77 2- (Dimethylamino) -8-methyl-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester. Cpd 78 2- (Dimethylamino) -4-oxo-4H-l-benzopyran-6-yl carbamic acid dimethyl ester, Mp 179.5- 80° C; Cpd 79 2- (Dimethylamino) -4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester, Mp 158-9°C; Cpd 80 2- (Dimethylamino) -4H-l-benzopyran-4-one, Mp 122- 23.5°C; Cpd 81 2- (Dimethylamino) -8-methyl-7- (phenylmethoxy)-4H-l- benzopyran-4-one, Mp 165-6°C. Cpd 102 8-Methyl-2-(4-morpholinyl)-7-(2-oxo-2-phenylethoxy)- 4H-l-benzopyran-4-one mp. 226.5-227.5 Cpd 103 6-Chloro-8-methyl-2-(4-morpholinyl)-7-(phenylmethoxy)- 4H-l-benzopyran-4-one mp. 207-209 Cpd 104 [ [2-(4-Morpholinyl)-4-oxo-4H-l-benzopyran-8-yl]oxy]- acetic acid, methyl ester mp. 192.5-193 Cpd 105 4-[[[8-Methyl-2-( -morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]methyl]-benzoic acid, methyl ester mp. 226- 228 Cpd 106 4- [ [ [2- (4-Morpholinyl) -4-oxo-4H-l-benzopyran-8- yl]oxy]methyll-benzoic acid, methyl ester mp. 207- 209 Cpd 107 8 - Me thyl - 2 - ( 4-morpholinyl ) - 7 - [ [ 3 - ( trifluoromethyl) phenyl ] me thoxy ] -4H- 1 -benzopyran-4- one mp. 194.5-195.5 Cpd 108 2- (4-Morpholinyl) -8- [ [3- (trifluoromethyl)- phenyl]methoxy]-4H-l-benzopyran-4-one mp. 204-204.5 Cpd 109 7-(Cyclohexylmethoxy)-8-methyl-2-(4-morpholinyl)-4H-l- benzopyran-4-one mp. 184.5-185.5 Cpd 110 8-Methyl-2-(4-morpholinyl)-7-(2-propenyloxy)-4H-l- benzopyran-4-one mp. 191-192 Cpd 111 2-(4-Morpholinyl)-7-(l-naphthalenylmethoxy)-4H-l- benzopyran-4-one mp. 195.2-195.8 Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- l-benzopyran-4-one mp. 182.5-184 Cpd 113 8-Methyl-2-(4-morpholinyl)-7-(4=pyrindinylmethoxy)-4H- l-benzopyran-4-one mp. 253.5-255.5 Cpd 115 8-methyl-2-(4-morpholinyl)-7-(2-quinoxalinylme hoxy)- 4H-l-Benzopyran-4-one, mp. 250.5-252.5 Cpd 116 8-methyl-2-(4-morpholinyl)-7-(pyrazinlymethoxy)-4H-l- Benzopyran-4-one, mp. 236-237 Cpd 117 8-methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- l-Benzopyran-4-one, N-oxide mp. 248-249.5 Cpd 118 8-methyl-2-(4-morpholinyl)-7-(3-pyridinylmethoxy)-4H- l-Benzopyran-4-one, N-oxide mp. 233.5-234 Cpd 119 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-l- benzopyran-4-one mp. 214-215 Cpd 120 3,3-Dimethyl-l-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- l-benzopyran-7-yl]oxy] -butan-2-one mp. 197-198 Cpd 121 1- [ [8-Methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy] -propan-2-one mp. 206.5 Cpd 122 1- [ [8-Methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzoρyran- 7-yl]oxy] -butan-2-one mp. 183-184 Cpd 123 8 -Methyl - 2 - (4-morpholinyl) -7 - (2-oxo-2- (2- naphthyl)ethoxy)-4H-l-benzopyran-4-one mp. 214.5- 215.5 Cpd 125 2- (4-Morpholinyl) -7- (2-pyrindinylmethoxy)-4H-l- benzopyran-4-one mp. 274-276 Cpd 126 2- (4-Morpholinyl) -7- ( 3 -pyrindinylmethoxy) -4H-1- benzopyran-4-one mp. 193-194 Cpd 127 2- (4-Morpholinyl) -8- (2 -pyrindinylmethoxy) -4H-1- benzopyran-4-one mp. 199-200 Cpd 128 2- (4-Morpholinyl) -8- (3 -pyrindinylmethoxy) -4H-1- benzopyran-4-one mp. 160-161 Cpd 129 8-methyl-2-(4-morpholinyl)-7-(2-quinolinylmethoxy)-4H- l-Benzopyran-4-one, mp. 223.5-224.5 Cpd 130 7 , 8- (Bis) -phenylme thoxy- 2- (4-morpholinyl) -4H-1- benzopyran-4-one mp. 165.5-167 Cpd 131 7,8-(Bis)-acetyloxy-2-(4-morpholinyl)-4H-l-benzopyran- 4-one mp. 231.5-233 Cpd 132 7, 8 -(Bis) -hydroxy- 2- (4-morpholinyl) -4H-l-benzopyran-4- one mp . >300 Cpd 133 7-Hydroxy-2- (4-morpholinyl) -8-phenylmethoxy-4H-l- benzopyran-4-one mp. 198-199 Cpd 134 7 , 8- (Bis) - (3 - trif luoromethyl)phenylmethoxy-2- (4- morpholinyl)-4H-l-benzopyran-4-one mp. 178.5-179.5 Cpd 135 8 - Hydr oxy - 2 - ( 4 - morphol inyl ) - 7 - ( 3 - trifluorometh l)phenylmethoxy-4H-l-benzopyran-4-one mp. 262-262.5 Cpd 136 7 - Hydr oxy - 2 - ( 4 -morphol inyl ) - 8 - ( 3 - trifluoromethyl)phenylmethoxy-4H-l-benzopyran-4-one mp. 236-237 Cpd 137 7-[3-(l-cyclohexyl-lH-tetrazol-5-yl)propoxyl-8-methyl- 2-(4-morpholinyl)-4H-l-Benzopyran-4-one, mp. 228- 230 Cpd 138 8-[3-(l-cyclohexyl-lH-tetrazol-5-yl)propoxy] -2-(4-mor- pholinyl)-4H-l-Benzopyran-4-one, mp. 185-186 Cpd 139 7- [ (l-cyclohexyl-lH-tetrazol-5-yl)methoxy] -8-methyl-2- (4-morpholinyl) -4H-l-Benzopyran-4-one, mp . 228 Cpd 140 8 - [ (l- cyclohexyl -lH-tetrazol-5-yl)methoxy] -2- (4-mor- pholinyl) -4H-l-Benzopyran-4-one, mp . 218 Cpd 141 2 - (4-morpholinyl) -8- [ (l-phenyl-lH-tetrazol-5-yl)oxy] - 4H-l-Benzopyran-4-one, mp . 214-215 Cpd 142 N- cyclohexyl - 2 - [ [ 2 - (4- morpholinyl ) - 4-OXO-4H-1- benzopyran- 8 -yl] oxy] -acetamide mp. 238-241 Cpd 143 N- (l , l-dimethylethyl) -2- [ [2- (4-morpholinyl) -4-oxo-4H- l-benzopyran-8-yl] oxy] -acetamide mp . 219-220 Cpd 144 2- [ [ 2- (4-morpholinyl) -4-oxo-4H-l-benzopyran-8-yl] -N- phenyl-acetamide mp. 225-228 Cpd 145 2-[[2-(4-morpholinyl)-4-oxo-4H-l-benzopyran-8-yl]oxy]- N-(l-phenylethyl)-acetamide mp. 178-180 Cpd 146 N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-7-yl]oxy]-acetamide mp. 255-256 Cpd 147 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]acetyl]-Phenylalanine, ethyl ester mp. 173- 175 Cpd 148 2- [ [8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]-N-phenyl-acetamide mp. 242-244 Cpd 149 8-methyl-2-(4-morpholinyl)-7-[(l-phenyl-lH-tetrazol-5- yl)oxy]-4H-l-Benzopyran-4-one, mp. 209-211 Cpd 150 6- [ (l-cyclohexyl-lH-tetrazol-5-yl)methoxy]-2-(4-mor- pholinyl)-4H-l-Benzopyran-4-one, mp. 215-217 Cpd 151 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]-N-(l-phenylethyl)-acetamide mp. 203-205 Cpd 152 2-[ [8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]-N-3-pyridinyl-acetamide mp. 243-245 Cpd 153 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]acetyl]-Phenylalanine mp. 259-262 Cpd 154 7- (2,2-dimethoxyethoxy) -8-methyl-2-(4-morpholinyl)- 4H-1-Benzopyran-4-one, mp. 168-169 Cpd 155 2-(4-Morpholinyl)-8-(2-propenyl)-4H-l-benzopyran-4-one mp. 145.5-146.5 Cpd 156 2-(4-Morpholinyl)-8-(l-propenyl)-4H-l-benzopyran-4-one mp. 163-164 Cpd 157 8-Formyl-2-(4-Morpholinyl)-4H-l-benzopyran-4-one mp. -43- 209-209.5 Cpd 158 2 - (4-morpholinyl) -8- (phenylamino )methyl-4H- 1 - benzopyran- 4 -one, mp. 226-227 Cpd 159 2- (4-morpholinyl) -8- (2E-phenyl) ethenyl-4H- 1 - benzopyran- 4 -one, mp.209 -209.5 Cpd 160 8-Hydroxymethyl-2- ( 4 -Morpholinyl) -4H-1 -benzopyran-4- one, mp. 243-243.5 Cpd 162 8-methyl-7- [ (l-methyl-3-piperidinyl)methoxy] -2- (4-mor- pholinyl)-4H-l-Benzopyran-4-one, mp. 159-161 Cpd 163 8-Methyl-2- ( 4 - morpholin l ) -7- (2- (1-piperi- dinyl)ethyl)oxy-4H-l-benzopyran-4-one mp. 154-156 Cpd 164 8 -Methyl - 2 - ( 4 - morpholinyl) - 7 - ( 2- (l - pyrrolidinyl)ethyl)oxy-4H-l-benzopyran-4-one mp. 136-138 Cpd 165 8-Methyl-2-(4-morpholinyl)-7-(2-(4-morpholinyl)ethyl)- oxy-4H-l-benzopyran-4-one mp. 170.5-172.5 Cpd 166 8 -Methyl-2 - ( 4 - morpholinyl ) - 7 - ( 3 - (1 -piperi- dino)propyl)oxy-4H-l-benzopyran-4-one mp. 144-145 Cpd 167 7-(2-Diethylaminoethyl)oxy-8-methyl-2-(4-morpholinyl)- 4H-1 -benzopyran- 4 -one mp. 162-162.5 Cpd 168 7 - [2- (ethylphenylamino)ethoxy] -8-methyl-2- (4-mor- pholinyl)-4H-l-Benzopyran-4-one, mp. 146-147 Cpd 169 7 - (2-Diisopropylaminoethyl)oxy-8-methyl-2- (4- morpholinyl)-4H-l-benzopyran-4-one mp. 136.5-138.5 Cpd 170 7 -Hydroxy- 8-methyl-2-(l-piperidinyl)-4H-l-benzopyran- 4-one mp. 278-284 Cpd 171 8-Methyl-2-(l-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- 1 -benzopyran- 4 -one mp. 144-158 Cpd 172 7-(2-(4~Benzyl-(l-piperizinyl))ethyl)oxy-8-methyl-2- (4 -morpholinyl) -4H-l-benzopyran-4-one mp. 138-139 Example 82: Preparation of 2-(4-Morpholinyl)-4H-l-benzoρyran- 4 -one, Compound 2 Part A: Potassium t-butoxide (134 g, 1.2 mole) is covered with benzene (1 L) in a flame dried round bottom flask equipped with an overhead stirrer, addition funnel, thermometer, and a nitrogen inlet. This suspension is maintained at 15°C. A solution of o -hydroxyaceto¬ phenone (54.4 g, 48.1 ml, 0.4 mole) and carbon disulfide (30.4, 24 ml, 0.4 mole) in benzene (700 ml) is slowly added over 1.3 hours, applying an ice bath periodically in order to maintain the temperature 18°C The slurry which forms is stirred at ambient temperature for one day. The reaction mixture is transferred to a separatory funnel containing water (4 L) and extracted with ether (4 x 250 ml) and EtOAc (3 x 250 ml) . The aqueous layer is acidified with 10% H 2 S04 (1 L) and stirred at ambient temperature overnight. The resulting solid is filtered off and dried in vacuo at 50°C overnight to yield 22.07 g of 2-mercapto-4H-l-benzopyran-4-one. Mp 207-8°C. Part B: Tosic acid (0.4g, 2 mmol) is added to a solution of 2-mercapto- 4H-l-benzopyran-4-one (3.56 g, 20 mmol) and morpholine (2.44 g, 2.44ml, 28 mmol) in benzene (400ml). After refluxing for 4 hours, the reaction mixture is transferred to a separatory funnel containing EtOAc and water. Extracting with EtOAc (2x) , washing with combined organic layers with water and brine, and filtering through sodium sulfate yields 4.56 of crude material after evaporation of the solvent. Flash chromatography over silica gel (300 g, 2.5% MeOH/CHCl 3 , 50 ml fractions) yields 2.07 g of 2-(4-Morpholinyl)-4H-l- benzopyran-4-one (44.8%, fractions 22-32). Mp 160-l β C. Example 83 Preparation of 6-Methyl-2-(4-morpholinyl)-4H-l,3- benzoxazin-4-one, Compound 83 The methyl ester of 5-methylsalicylic acid (2.73 g; 16.4 mmol) is dissolved in acetone (50 ml), cyanogen bromide (1.81g; 17.2 mmol) is added and the solution is cooled to 0°C Triethylamine (1.73 g; 18.2 mmol) is dissolved in acetone (5 ml) and added dropwise. Precipitation occurred rapidly and -the solid is removed by filtration. The filtrate is concentrated in vacuo to afford 3.41 g of the intermediate cyanoether. The cyanoether is dissolved in acetonitrile (50 ,1), morpholine (1.43 g; 16.4 mmol) is added in 5 ml of acetonitrile and the reaction is stirred for two hours at room temperature. Crystals form and the reaction mixture is cooled to 0°C, and washed with cold acetonitrile to afford 1.65 g (40.8%). Mother liquors are recrystallized from acetonitrile to afford 0.54 g (13.4%); mp 197-197.9°C; IR (mull) 2955, 2923, 2858, 1674, 1619, 1576, 1466, 1453, 1433, 1424, 1333, 1325, 1315, 1112, 817 cm' 1 ; X H- NMR (CDC1 3 , δ) 7.91 (d, J-1.4 Hz, 1 H, aromatic), 7.40 (d of d's, J-8.3 Hz, 1.9 Hz, 1 H, aromatic), 7.09 (d, J-8.4 Hz, 1 H, aromatic), 3.81 (broad s, 8H, morpholine methylenes) , 2.40 (s, 3 H, methyl); UV λ max (ε) 217sh(26,550) , 223sh(26,350) , 259(15,100), 296(4,250), 304sh(3,550) ; Mass spectrum, ions at m/e (relative intensity) 246(parent, 29), 218(10), 189(20), 134(base, 100), 106(18), 105(10), 78(12), 77(8), 28(19); Anal. Calc'd. for: C 13 H 14 N 2 θ3: C, 63.40; H, 5.73; N, 11.38. Found: C, 63.29; H, 5.92; N, 11.31. Following the general procedure of Example 83, but employing the appropriate o-hydroxy salicylic methyl ester in place of the methyl ester of 5-methylsalicylie acid there are prepared the following products: Cpd 84 8-Methyl-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one, Mp 229-231°C; Cpd 85 6-Bromo-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one, Mp 207-214°C; Cpd 86 7-Chloro-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one Mp 207-214°C; Cpd 87 6,8-Bis(l-methylethyl)-2-(4-morpholinyl)-4H-l,3- benzoxazin-4-one, Mp 120-120.5°C; Cpd 88 6-Fluoro-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one, Mp 220-231°C; Cpd 89 6-Dimethoxymethyl-2-(4-morpholinyl)-4H-l,3-benzoxazin- 4-one; Mpl01-108°C; Cpd 90 7-Methoxy-2-(4-morpholinyl)-4H-l,3-benzoxazin- 4-one, Mp 197-200°C; and Cpd 91 6-(Morpholin-l-yl)-pyrido(2,3-e)-l,3-oxazine-8-one Mp 181-184°C Following the general procedure of Example 83, but employing the appropriate o-hydroxy salicylic methyl ester in place of the methyl ester of 5-methylsalicylic acid and the appropriate heterocylic compound in place of morpholine there are prepared the following products: Cpd 92 8-Me hyl-2-(l-piperidinyl)-4H-l,3-benzoxazin-4-one,Mp 214.5-217.5°C; Cpd 93 8-Methyl-2-(l-pyrrolidinyl)-4H-l,3-benzoxazin-4-one, Mp 199.5-200.5°C; Cpd 94 2-(l-pyrrolidinyl)-4H-l,3-benzoxazin-4-one, Mp 163- 164° C; Cpd 95 2- (l- (4-Thiomorpholinyl) ) -4H-l, 3-benzoxazin-4-one, Mp 179-180°C; Cpd 96 2-(4-Methyl-l-piperazinyl)-4H-l,3-benzoxazin-4-one; Example 98: Preparation of 2=(4-Morpholinyl)-4H-l,3-benzoxazin-4- one, Compound 98 (Method A) Methyl salicylate (25 g, 0.164 M) and BrCN (18.08 g, 0.172 M) is added to dry acetone (500 mL) and cooled to O'C That mixture is then treated with TEA (17.37 g, 0.172M) in acetone (50 mL) dropwise over 20 minutes. A white precipitate separates from the solution. After stirring 1 hr the acetone is decanted and the precipitate washed with acetone. The filtrate is concentrated in vacuo and used without further purification. The above cyanoether (29.0 g, 0.164 M) is added to acetonitrile (300 mL) under an atmosphere of nitrogen. An acetonitrile solution of morpholine (14.26 g, 0.164 M) is then added dropwise over 30 minutes. The reaction becomes warm during addition. After stirring a total of 3 hrs the solvent is removed in vacuo to yield a tan solid which is washed with ether to yield 22 g (58%) of pure product. An analytical sample is prepared by re- crystallization from EtOAc. MP 184.5-86.0°C (lit. MP 187-9°C); 6 IR (CHC1 3 ) 2950, 2825, 2750, 1670, 1620, 1600, 1560, 1460, 1440, 1420, 1340, 1260, 1110, 980, 850 cm" 1 ; IH-4NMR (CDCI3) 8.25 (dd, 1H, J-1.5 and 6.0 Hz), 7.8-7.2 ( , 3H, aromatic), 3.80 (s, 8H); Mass spectrum: ions at m/e (relative intensity) 232 (47), 215 (13), 204 (20), 189 (11), 176 (14), 175 (56), 121 (35), 120 (100), 92 (46), 64 (14); UV (EtOH) λ max (ε) 210 (24,000), 218 (24,200), 240sh (11,200), 258 (14,750), 286 (4,850), 295 (3,900); Anal, calc'd. for C 12 H 12 N 2 0 3 : C, 62.06; H, 5.17; N, 12.06. Found: C, 61.70; H, 5.22; N, 11.99. Example 99: Preparation of 2-(4-Morpholinyl)-4H-l,3-benzoxazin-4- one, Compound 98 (Method B) Tosic acid (0.4g, 2 mmol) is added to a solution of 2-mercapto- 4H-l-benzopyran-4-one (3.56 g, 20 mmol) and piperidine (2.38 g, 2.77 ml, 28 mmol) in benzene (400ml). After refluxing for 5 hours, the reaction solution is evaporated in vacuo. The residue is transferred to a separatory funnel with methylene chloride and water. Extracting with methylene chloride, washing the organic layer twice with water, and filtering through sodium sulfate affords 2.80 g of crude material after evaporation of the solvent. Flash chromatography over silica gel (300 g, 7% MeOH/CH 2 Cl 2 ) affords 0.39 g of 2-(4-Morpholinyl)-4H- l,3-benzoxazin-4-one. Example 101 2-(4-Morpholinyl)-7-(phenylmethoxy)-4H-l-benzopyran-4- one, Compound 101 Prepared by the method outlined in Chart C Example 173 Preparation of 4' -Acetoxy-3' -methyl-2' -hydroxy- propiophenone (Relating to Chart E) Part A 2' ,4' -Dihydroxy-3'methyl-propiophenone (7.21 g, 40 mmole) is suspended in 200ml dichloromethane in a 500 ml one neck round bottom flask under nitrogen. The suspension is treated with diisopropyl- ethylamine (6.97 ml, 40 mmole) and the solution is cooled to 0°C. Acetyl chloride (3.26 ml, 46 mmole), in 80 ml dichloromethane, is added slowly dropwise to the reaction mixture (1 h) at 0 C. The mixture is warmed to room temperature and is stirred 20 min. The reaction is washed with 1 X 150 ml 5% hydrochloric acid and the organics are dried over magnesium sulfate. The mixture is concentrated in vacuo to a yellow oil which is crystallized and then recrystallized from ethanol to afford 7.2 g (81%) of the acetate as a white solid. Melting Point: 59-61 C Part B Preparation of 7-Acetoxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one (Cpd 173) 4' -Acetoxy-2' -hydroxy-3' -methyl-propiophenone (6.2 g, 27.9 mmole) is dissolved, in 60 ml diethyl ether in a 100 ml one neck round bottom flask under nitrogen. The solution is treated with boron trifluoride etherate and the reaction mixture is stirred overnight at room temperature. The precipitate is collected by filtration and is washed with 150 ml diethyl ether to afford 6.8 g (90%) of the boron difluoride complex as a yellow solid. The boron difluoride complex (1.05 g, 5.13 mmole) and 4-morpholine phosgene iminium chloride (1.25 g, 4.63 mmole) are combined in 12 ml 1,2-dichloroethanein a 25 ml one neck round bottom flask under nitrogen. The reaction mixture is warmed to 60 C for 3 h. The reaction is cooled to room temperature and the dichloroethane is removed in vacuo. The residual oil is taken up in 12ml acetonitrile in a 25 ml one neck round bottom flask. The mixture is warmed to 60°C, is diluted with 10 ml water, and is stirred for 5 min. The reaction mixture is immediately neutralized with 25 ml saturated sodium bicarbonate and the acetonitrile is removed in vacuo. The aqueous residue is extracted with 4 X 25 ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to afford 750mg (51%) of Cpd 173 as an orange solid. Melting Point: 142.5-144.5°C Part C Preparation of 3,8-dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-l- benzopyran-4-one (Cpd 174) The boron difluoride complex (prepared as in Part A above, 3.0 g, 11.1 mmole) is combined with 4-morpholine phosgene iminium chloride (2.5 g, 12.2 mmole) in 29 ml 1,2-dichloroethane in a 50 ml one neck round bottom flask under nitrogen. The reaction mixture is warmed to 60°C for 3.5 h and is cooled to room temperature. The dichloroethane is removed in vacuo and the oily residue is dissoved in 30 ml acetonitrile in a 100 ml one neck round bottom flask under nitrogen. The solution is warmed to 60°C, is diluted with 25 ml water, and is stirred for 5 min. The reaction mixture is immediately quenched with 30 ml saturated sodium bicarbonate and the acetonitrile is removed in vacuo. The aqueous residue is extracted with 4 X 25 ml dichloromethane and the combined organics are dried over magnesium sulfate. The dried organics are concentrated in vacuo to a yellow solid (2.82 g) which is dissolved in 30 ml methanol in 100 ml one neck round bottom flask under nitrogen. The solution is diluted with 15 ml water and the mixture is treated with lithium hydroxide (800 mg, 19.1 mmole). The reaction mixture is stirred Ih at room tempera¬ ture. The methanol is removed in vacuo and the pH of the aqueous residue is adjusted to 5 with 5% hydrochloric acid (pH meter) . The precipitated phenol is collected by filtration and is dried to afford 1.2g (40%) of Cpd 174. Melting Point: >300 C Part D Preparation of 7-benzyloxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one (Cpd 175) . 3, 8-Dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one (355 mg, 1.29 mmole) is suspended in 9 ml dry acetonitrile in a 25 ml one neck round bottom flask under nitrogen. The suspension is treated successively with potassium carbonate (1.1 g, 8.0 mmole) and -49- benzyl bromide (213 mg, 1.79 mmole). The reaction mixture is warmed to 60°C for 16 h and is cooled to room temperature. The volatiles are removed in vacuo and the residue is washed with 25 ml dichloro¬ methane. The insoluable material is removed by filtration and the filtrate is concentrated to a pale oil. The oil is crystallized from diethyl ether to afford 323 mg (69%) of Cpd 175 as a white solid. Melting Point: 136-137.5° C. Following the general procedure of Example 173, but starting with the appropriate 2' -hydroxypropiophenone, there are prepared the following products: Cpd 176 3 , 8 -Dimethyl- 2- ( -morpholinyl) -7- (naphthyl-1- methyloxy) -4H-1 -benzopyran- 4 -one mp. 204-206 Cpd 177 3 , 8-Dimethyl-7- (4-methoxy-benzyloxy) -2- (^-morpho¬ linyl) -4H-l-benzopyran-4-one mp. 141-142 Cpd 178 3,8-Dimethyl-2-(4-morpholinyl)-7-(2-phenyl-ethyloxy)- 4H-l-benzopyran-4-one mp. 160-161.5 Cpd 179 3,8-Dimethyl-7-(4-chlorobenzyloxy)-2-(4-morpholinyl)- 4H-l-benzopyran-4-one mp. 166-167.5 Cpd 180 3, 8-Dimethyl-2-(4-morpholinyl)-7-(3-trifluoromethyl- benzyloxy) -4H-l-benzopyran-4-one mp. 158.5-160 Cpd 181 7 - (Carbomethoxy-methoxyl) -3 , 8 - dime thyl - 2 - (4- morpholinyl)-4H-l-benzopyran-4-one mp. 174-175 Cpd 182 8-Hydroxy-3-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one mp. 239-240 Cpd 183 8-Benzyloxy-3-methyl-2-(4-morpholinyl)-4H-l-benzo- ρyran-4-one mp. 134-135 Cpd 184 3 -methyl-2- (4-morpholinyl) -8- (m- trifluoromethyl - benzyloxy) -4H-l-benzopyran-4-one mp. 160.5-161 Example 185 Preparation of C-7 alkyl, alkenyl and alkynylaryl substituents . (relating to Chart F) Part A Preparation of 2' -Hydroxy- 3 ' -methyl -4' -trifluormethanesul- f onyloxy-acetophenone . 2' ,4'-Dihydroxy-3'methyl-acetophenone (11 g, 60.2 mmole) is suspended in 300 ml dichloromethane in a 1000 ml one neck round bottom flask under nitrogen. The suspension is treated successively with pyridine (4.4 ml, 54 mmole) and N,N, dimethylamino -pyridine (730 mg, 6 mmole) and the solution is cooled to 0 β C Triflic anhydride (11 ml, 66.2 mmole), in 1 X 100 ml dichloromethane, is added slowly dropwise to the reaction mixture (30 min) . The reaction is stirred for 1 h at room temperature for 1 h and the mixture is washed with 2 X 200 ml 5% hydrochloric acid. The organics are dried over magnesium sulfate and are concentrated in vacuo to a yellow oil. The oil is distilled via kugelrhor under high vacuum (165 C) to provide 16.4 (91%) of triflate as a white solid. Melting Point: 60-64°C Part B Preparation of 8-methyl-2-(4-morpholinyl)-7-trifluormethane- sulfonyloxy-4H-1-benzopyran-4-one. 2' -Hydroxy-3'-methyl-4' -triflouromethanesulfon loxy-acetophenone (1.5 g, 5.03 mmole) is dissolved in 10 ml diethyl ether in a 25 ml one neck round bottom flask under nitrogen. The solution is treated with boron trifluoride etherate (0.9 ml, 7.5 mmole) and the reaction mixture is stirred for 6 h at room temperature. Approximately 1/2 the ether is removed in vacuo and the precipitate is collected by filtration. The pale solid is washed with cold diethyl ether to afford 1.1 g (63%) of difluoroboronate. Boron difluoride complex (1.1 g, 3.2 mmole) is combined with 4-morpholinophosgeniminium chloride (0.72 g, 3.5 mmole) in 12 ml 1,2-dichloroethane in a 50 ml one neck round bottom flask under nitrogen. The reaction mixture is warmed to 65 β C for 3 h and is cooled to room temperature. The precipitate is removed by filtration and is washed with diethyl ether to provide 1.35 g. The solid is supended in 12 ml acetonitrile in a 25 ml one neck round bottom flask under nitrogen. The suspension is stirred with 1.2 ml water for 48 h. The colorless solution is diluted with 10 ml saturated sodium bicarbonate and the acetonitrile is removed in vacuo. The aqueous residue is extracted with 4 X 25 ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to a red solid. The solid is recrystallized from ethyl acetate to afford 566 Eg (45%) of chromone- triflate as an off white solid. Melting Point: 151-155°C Part C Preparation of 8-methyl-7-(2-phenyl)ethynyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one (Cpd 185) . 8-Methyl-7-(trifluoromethanesulfonyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one (190 mg, 0.48 mmole) is suspended in 6 ml 1:1 ben- zene/triethylamine in a 15 ml screw cap pressure tube. The suspension is treated successively with phenyl acetylene (100 ul, 0.91 mmole), bis (triphenylphosphine) palladium dichloride (14 mg, 0.02 mmole), and cuprous iodide (2 mg, 0.01 mmole). The reaction mixture is warmed to 100-110°C overnight. The reaction mixture is cooled to room temperature and is again treated successively with phenyl acetylene (100 ul, 0.91 mmole), bis (triphenylphosphine) palladium dichloride (14 mg, 0.02 mole), and cuprous iodide (2 mg, 0.01 mmole). The reaction is heated to 110°C for 4 h and is cooled to room temperature. The volatiles are removed in vacuo to a black residue. The residue is chromatographed over 12 g silica gel (230- 400 mesh) eluting with 1% methanol/dichloromethane and collecting 3 ml fraction s for 48 fractions. Thereafter elution is carried out with 2% methanol/dichloromethane and 5 ml fractions are collected. Fractions 55-72 are combined and concentrated to provide 153 mg of a dark brown solid. The solid is recrystallized from ethyl acetate to afford 94 mg (56%) of Cpd 185 as a pale grey solid. Melting Point: 228.5-229.5°C Example 186 Preparation of 8-methyl-2-(4-morpholinyl)-7-(2- phenyl)ethyl-4H-l-benzopyran-4-one (Cpd 186). 8-Methyl-2-(4-morpholinyl)-7-(2-phenyl-ethynyl)-4H-l-benzopyran- 4-one (90 mg, 0.261 mmole) is dissolved in 90 ml 8:1 methanol/acetone in a Parr shaker bottle. The solution is treated with 18 mg 10% palladium on carbon and the reaction mixture is hydrogenated at 40 PSI for 2 h. The catalyst is removed by filtration through a 1" bed of celite and the filter cake is washed well with methanol. The filtrate is concentrated in vacuo to a yellow oil which crystallized from hexane to give 70 mg (77%) of Cpd 186 as a tan solid. Melting Point: 162-163°C Following the general procedures of Example 185, but starting with the appropriate 2' -hydroxyacetophenone, there are prepared the following products: Cpd 187 2-(4-Morpholinyl)-8-(2-phenyl)ethynyl-4H-l-benzopyran- 4-one mp. 196-197 Cpd 188 2-(4-Morpholinyl)-8-(2-phenyl)ethyl-4H-l-benzopyran-4- one mp. 110-112 Cpd 189 2 - ( 4 - Morpho l inyl ) - 8 - ( 2 - ( 3 - r i f luo r omethyl - ) phenyl )ethynyl-4H-l -benzopyran- 4 -one mp . 157.5- 158.5 Cpd 190 2- (4-Morpholinyl) - 8 - (2- (3- trifluoromethyl)phenyl) - ethyl-4H-l-benzopyran-4-one mp . 130-131 Cpd 192 8-Methyl-2- (4-morpholinyl) -7- (2- (l-naphthyl) )ethyl-4H- l-benzopyran-4-one mp. 188.5-189.5 Cpd 193 8-Methyl-2-(4-morpholinyl)-7-phenyl-4H-l-benzopyran-4- one mp. 194.5-195 Example 194 (Relating to Chart G) Part A Preparation of 4' -acetoxy-3' -iodo-2'-hydroxy-propiophenone 2' ,4' -dihydroxy-3'-iodoacetophenone (55.6 g, 0.2 ώol) is suspended in 600 ml of methylene chloride. Triethylamine (27.8 ml, 0.2 mol) is added and the cooled mixture (0°C) is treated dropwise with acetyl chloride (16.35 ml, 0.23 mol). The mixture is stirred at 0°C for 1 h and at ambient temperature for 2 h. The mixture is washed with 5% hydrochloric acid, dried owver magnesium sulfate and evaporated. The solid is recrystallized from ethanol to provide 48.39 g of the product. Part B Preparation of 7-acetyloxy-8-iodo-2-(4-morpholinyl)-4H-l- benzopyran-4-one (Cpd 194) 4'-Acetoxy-3' -iodo-2' -hydroxy-propiophenone (48.4 g, 0.15 mol) is suspended in 750 ml of ether and treated with boron trifluoride etherate (27.9 ml, 0.22 mol). The mixture is stirred overnight at ambient temperature, filtered and the solid is washed well with ether to afford 47.0 g of the boron difluoride complex. The complex is combined with 4-morρholine dichloromethyleniminium chloride in 400 ml of ethylene dichloride and heated at 70°C for 5 h and at 50°C for 16 h. The reaction is cooled to 0°C and the solid is filtered and washed well with ether (45 g) . The solid is suspended in 400 ml of acetonitrile, 40 ml of water is added and the mixture is stirred overnight at room temperature, heated at 50°C for 2 h and finally heated at 60°C for 30 min. The solvent is evaporated and the material is taken up in methylene chloride/ saturated sodium bicar¬ bonate. The aqueous layer is extracted twice with methylene chloride and the combined organics are dried over magnesium sulfate. Evapora- tion of the solvent and recrystallization from methanol gave 20.8 g (39%) of the chromone. The mother liquors contained 5.8 g of crude product from which a second recrystallization yielded 0.7 g. mp. 201.5-202.5 Part C Preparation of 8-ethyl-7-hydroxy-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one 7-Acetyloxy-8-iodo-2-(4-morpholinyl)-4H-l-benzopyran-4-one (2.07 g, 5.0 mmol) is combined with lithium chloride (0.64 g, 15 mmol) tetraethyltin (1.04 ml, 5.25 mmol) and (bis)triphenylphosphine palladium dichloride (70 mg, 0.10 mmol) in 20 ml of dimethylfor- mamide. The mixture is heated a 100°C for 40 min., poured into half saturated sodium chloride and extracted twice with methylene chlor¬ ide. The organics are washed twice with half saturated sodium chloride, dried over magnesium sulfate and evaporated. The material is taken up in 20 ml of methanol and 10 ml of water and treated with 0.63 g (15 mmol) of lithium hydroxide. The mixture is stirred at room temperature for 30 min. The solvent is evaporated, the mixture is diluted with water and extracted twice with ethyl acetate. The aqueous layer is acidified to pH 6.1 qirh 5% hydrochloric acid and the solid is filtered, washed with ether and dried to afford 0.98 gt (71%) of the product. Part D Preparation of 8-ethyl-2-(4-morpholinyl)-7-(3-pyrindinyl- methoxy)-4H-l-benzopyran-4-one (Cpd 195) 8-Ethyl-7-hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one (0.176 g, 0.64 mmol) and sodium hydride (0.105 g, 60%, 2.6 mmol) are combine in 4 ml of dimethylformamide and heated to 60°C for 20 min. 3-Picoyl chloride hydrochloride (0.321 g, 1.76 mmol) is added and the mixture is heated at 60°C for 1 h. The cooled mixture is poured into 2N sodium hydroxide and ice. The solid is filtered, washed well with water and ether and recrystallzed form ethyl acetate to provide 0.156 g of the product, mp.178-179 Following the general procedure of Example 194, but starting with the 2' -hydroxyacetophonone, there are prepared the following products: Cpd 196 8-Ethyl-2- (4-morpholinyl) -7-phenylmethoxy-4H-l- benzopyran-4-one mp. 153-154.5 8-Iodo-2- (4-morpholinyl) -7-phenylmethoxy-4H-1- benzopyran-4-one mp. 155-157 8-Ethyl-2- (4 -morpholinyl) -7-(2-(l-piperi- dinyl)ethyl)oxy-4H-l-benzopyran-4-one mp. 151-152 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 214-215 8-Iodo-7-hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4- one mp. 224-225 Example 201 (Relating to Chart H) Part A Preparation of 7-hydroxy-8-methyl-2-(l-piperidinyl)-4H-l- benzopyran-4-one (Cpd 201). Palladium black (225 mg) is added to a solution of the benzyl ether Cpd 31 (1.00 g, 2.86 mmol) in EtOAc (80 ml). After shaking in a Parr hydrogenation apparatus under 50 lbs pressure of hydrogen for 2 days, the catalyst is filtered off through a cintered glass funnel rinsing with EtOAc and MeOH. Evaporation of the solvent afforded 0.99 g ,of crude material. Flash chromatography (60 g silica gel, 10% Me0H/CH 2 Cl 2 ) afforded 0.83 g of the phenol. Recrystallization from MeOH/EtOAc at 4°C afforded 0.65 g (88%) of white crystalline title product, mp 278-284°C Part B Preparation of 7-(3-pyridinylmethoxy)-2-(l-piperidinyl)-8- methyl-4H-l-benzopyran-4-one, Cpd 202. A suspension of phenol Cpd 170 (130 mg, 0.5 mmol), 3-picolinyl ' chloride-HCl (161 mg, 1.0 mmol), and potassium carbonate (277 mg, 2.0 mmol) in dimethylformamide (5 ml) is stirred at 90°C After 7 days, the reaction mixture is evaporated down and then CHCI3 added. The solids are filtered off and the filtrate evaporated. Flash chromatography of the residue (15 g silica gel, 2% MeOH/CH 2 Cl , 6 ml fractions) afforded 18 mg (10%, fractions 37-52) of Cpd 202. mp 144- 58°C Example 203 Preparation of 7-phenylmethoxy-2-methylthiomethyl-8- methyl-4H-l-benzopyran-4-one, Cpd 203 (Relating to Chart I) Part A: Sodium hydride (50% oil dispersion washed 3x in hexane, 23.2 g, 0.48 mol) is stirred in THF (195 ml) under nitrogen in a flame dried 2 1 three-necked round bottom flask equipped with an addition funnel and a condensor. A solution of the 2-hydroxyaceto- phenone (25 g, 97.6 mmol) and ethyl α-thiomethyl- acetate (130.4 g, 123 ml, 0.9 mol) in THF (164 ml) is slowly dropped into the sodium hydride slurry. After about half of the reagent solution had been added the reaction is heated with a heating gun until the reaction had begun to reflux on its own. The remainder of the reagent solution is slowly added with stirring. After 10 min at ambient temperature and 1 h 40 min at reflux, the solution is evaporated in vacuo. The solution is transferred to a separatory funnel with methylene chloride/2N HC1 and shaken for about 10 min. Extraction with methylene chloride (2x) and drying over magnesium sulfate affords the crude 0-diketone which is not further purified. A biphasic solution of the ?-dikeone and 6N HC1 (250 ml) is stirred at ambient temperature overnight. Extraction with methylene chloride and drying over magnesium sulfate afforded 127.13g of crude material after evaporation of the solvent. Flash chromatography (700 g silica gel, 30-50% EtOAc/hexane) afforded 122 g of a mixture of the starting acetophenone, the thiomethylacetate, and some 3-diketone and 4.94 g Cpd 203 (15%). An analytical sample is recrystallized from ether/hexane to afford white crystalline title product. mp 110- 114°C Part B Preparation of 7-ρhenylmethoxy-2-iodomethyl-8-methyl-4H-l- benzopyran-4-one A solution of Cpd 203 (4.0 g, 12.3 mmol) in methyl iodide (12.5 ml) and CH 2 Cl 2 (8 ml) is stirred under reflux. After 3 days, the solution is cooled to 0°C and the yellow precipitate filtered off. The filtrate is evaporated down and the residue flash chromatographed (100 g silica gel, 40% EtOAc/hexane) to afford 1.48 g of 7- phenylmethoxy-2-iodomethyl-8-methyl-4H-l-benzopyran-4-one (30%) . An analytical sample is prepared by recrystallization from CH 2 Cl 2 /EtOAc/hexane to afford white crystalline title product. mp 144-7°C; Part C Preparation of 8-Methyl-2-(4-morpholinylmethyl)-7- (phenylmethoxy)-4H-1-benzopyran-4-one (Cpd 204) Morpholine (0.21 g, 2.5 mmol) is added to a stirring solution of 7-phenylmethoxy-2-iodomethyl-8-methyl-4H-1-benzopyran-4-one (1.0 g, 2.5 mmol) and triethylamine (0.25 ml, 2.5 mmol) in CHCI3 (12 ml). After stirring at ambient temperature for 2.5 h, the solvent is evaporated in vacuo. The residue is flash chromatographed (100 g silica gel, 50-100% Et0Ac/CH 2 Cl 2 , 45 ml fractions) to afford 0.72 g (79%) of the product. Recrystallization from ether afforded a white solid title product. MP 130-3°C Part D Preparation of 7-hydroxy-2-(4-morpholinylmethyl)-8-methyl-4H-l- benzopyran-4-one, Cpd 205 Palladium black (140 mg) is added to a solution of the benzyl ether Cpd 204 (0.65 g, 1.78 mmol) in EtOAc (50 ml). After shaking in a Parr hydrogenation apparatus under 50 lbs pressure of hydrogen for 23 h, the catalyst is filtered off through a cintered glass funnel rinsing with EtOAc and MeOH. Evaporation of the solvent afforded 0.49 g of crude material. Flash chromatography (100 g silica gel, 4% Me0H/CH 2 Cl 2 , 50 ml fractions) afforded 35 mg (5%, fractions 6-7) of the starting material and 0.33 g (68%, fractions 11-16) of the phenol. An analytical sample is prepared by recrystallization from EtOAc/ether/hexane at 4°C to afford white crystalline title product. MP 144-6°C; Part E Preparation of 7-[(l-cyclohexyl-lH-tetrazol-5-yl)methyoxy]-8- methyl-2-(4-morpholinylmethy)-4H-l-benzopyran-4-one, Cpd 206 A suspension of Cpd 205 (100 mg, 0.36 mmol), 5-(4- chloromethyl)-l-cyclohexyltetrazole [see e.g. Chem. Pharm. Bull. 31, 1151 (1983) " ] (146 mg, 0.73 mmol), and potassium carbonate (201 mg, 1.45 mmol) in acetonitrile (3 ml) is stirred at 60oC After 17 h, the reaction mixture is evaporated down and then CHCI3 added. The solids are filtered off and the filtrate evaporated. Flash chromatography of the residue (25 g silica gel, 3% Me0H/CH 2 Cl 2 , 15 ml fractions) afforded 134 mg (85%, fractions 5-6) of white crystalline title product. MP 193-5°C; Part F Preparation of 8-Methyl-2-(4-morpholinylmethyl)-7-(3- pyridin lmethoxy)-4H-l-benzopyran-4-one, Cpd 207 A suspension of Cpd 205 (50 mg, 0.18 mmol), 3-picolinyl chloride-HCl (58 mg, 0.36 mmol), and potassium carbonate (100 mg, 0.72 mmol) in acetonitrile (2 ml) is stirred at 60°C. After 2 days, the reaction mixture is evaporated down and then CHCI3 added. The solids are filtered off and the filtrate evaporated. Flash chromatography of the residue (20 g silica gel, 3% MeOH/C^C^, 10 ml fractions) afforded 45 mg (68%, fractions 17-25) of white crystalline title product which is recrystallized from ether, mp 105-8°C CHART B halogen/organic solvent CHART C acid HNRg io NRg io CHART D NRgRio g io CHART E 1. Δ 2. H 2 0 CHART F CHART G CHART H CHART I FORMULA IB FORMUIA (Continued) II

Claims: CLAIMS 1. A compound of Formula I wherein X is CZ where Z is H, C -C5 alkyl, amino (-NH 2 ) or a halogen atom; Y is selected from the group consisting of -(CH 2 ) n NRgRιo wherein Rg and Rio- being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Rg and Rχo are not both hydrogen; (b) C l -C 12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C^-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl) ; (d)- (CH2) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, tri¬ fluoromethyl or -Cθ2(Cι-C4alkyl)] , (e) -(CH 2 ) n pyridinyl or (f) wherein Rg and Rιo > taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Ci- C4 alkyl, C -C alkoxy, halo or trifluoromethyl (cc) 3-amino-1-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C alkyl, C1-C4 alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH 2 )q0H, -C0 2 H, -C0 2 CH3 -C0 2 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 ^1"^4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) , (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH 2 0 jj , -C0 2 H, -CO2CH3 or -CO2CH2CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- ethylho opiperazine, 4-phen l-1,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5, Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, C -Cg alkyl, -(CH2 n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C alkyl)] , -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH2)qNRgRιo, -CH-CH-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C -C4 alkyl, C1-C alkoxy, halo, OH, trifluoromethyl or -Cθ2 Cι-C alkyl)] , -CH 2 -CH=CH 2 , -CH-CH-CH3, -0-CH 2 -CH=CH 2 , -CsC-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl ] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -0-(CH 2 )pNR Rι 0 , -O-CH2CH ( 0CH 3 ) 2 , -0-(CH 2 )pORι 5 , -(CH 2 ) n C(0)-(CH 2 ) n Rg, -(CH 2 ) n C(0)0-(CH 2 ) p R 9 , -(CH n C(0)0- (CH 2 ) p NR 9 Rι 0 , -(CH 2 ) n C(0) (CH 2 ) n NRgR 10 , N0 2 ,-0-(CH 2 ) n C(0)- (CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)-(CH 2 ) n NR 9 Rι 0 , -NRgRiQ, -N(Rg)(CH 2 ) n C(O)-(CH 2 ) n Rι 0 , -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n Rι 0 , N(R 9 )(CH 2 ) n C(O)-(CH 2 ) n NRgRι 0 , -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι- C 4 alkyl)], -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine. -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine. -0(CH 2 ) n C(0)-N(Rg)(CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg-(CH 2 ) n nap th l, halo (fluoro, chloro, bromo, iodo) , OH, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)R 9 , -(CH 2 ) q 0C(0)-NRgRiQ, -d-cyclohexyl-lH-tetrazol- 5-yl)Cχ-C4 alkoxy, -[l-(Cι-C 5 alkyl)-lH-tetrazol-5-yl]C -C4 alkoxy, - [1-( p henyl)-1H-tetrazol-5-yl]C -C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, 0^04 alkoxy, halo, OH, trifluoromethyl or -^(Ci^alkyl)] , -[1-(pyridinyl)-lH-tetrazol-5-yl]Cι-C 4 alkoxy, -[1-(1- phenylethyl)-lH-tetrazol-5-yl]C -C4 alkoxy, -C -C4 alkoxyl, a group of Formula II wherein R' is methyl or carboxy, R' ' is hydrogen and R' ' ' is selected from benzyl [optionally substituted with one, . two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], Ci* C 5 alkyl, -(CH 2 ) n C0 2 H, -CH 2 SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH 3 CH(0H) , CH 2 0H, H 2 N(CH 2 )4-(optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form) ; with the overall proviso that when Y is other than -(CH2) n morpholinyl, at least one member of R5, Rg, R7 or Rg is other than hydrogen, C^-C alkyl, N0 2 , OH, C -C alkoxy, a halogen atom, phenyl, benzyl, 4-morpholin lmethyl, NH 2 , or dimethyamino; with the further proviso that when Y is 4- morpholinyl, the compound is other than: 6,7-dimethoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-l-benzopyran-4-one, N-cyclohexyl-2- [ [8-methyl-2- (4-morpholinyl)-4-oxo-4H-1- benzopyran-7-yl]oxy] -acetamide, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-l-benzopyran-7- yl]oxy] -N-phenyl-acetamide, 6- [ (1-cyclohexyl- 1H-tetrazol-5-yl)methoxy] -2-(4-mor- pholinyl)-4H-l-Benzopyran-4-one, 2- [ [8-methyl-2-(4-morpholinyl) -4-oxo-4H-l-benzopyran-7- yl]oxy]-N-(1-phenylethyl)-acetamide; with the further provisio that when Y is dimethylamino, the compound is other than: 2- (Dimethylamino) -8-methyl-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester, (Dimethylamino)-4-oxo-4H-l-benzopyran-6-yl carbamic acid dimethyl ester, 2-(Dimethylamino)-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester; Rl5 is selected from C1-C5 alkyl, -(CH 2 ) n phenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alk l ] , -(CH 2 ) n pyridin-l-yl or -(CH 2 ) p piperidin-l-yl; n is 0-5; p is 2-5; q is 1-5; and pharmaceutically acceptable salts and hydrates thereof. 2. A compound according to Claim 1 wherein Y is selected from the group consiting of -(CH 2 ) n NRgR Q wherein Rg and Rio. taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of: (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Cι~ C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C1-C alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C ] _-C4 alkyl, Ci-C4 alkoxy, halo, trifluoromethyl, -(CH 2 )qOH, -C0 2 H, -C0 2 CH3 -C0 2 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine, 4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH 2 0 H , -C0 2 H, -C0 2 CH 3 or -C0 2 CH 2 CH 3 . 3. A compound according to Claim 1 wherein Z is H or Cι-C5 alkyl. 4. A compound according to Claim 3 w herein Y is selected from the group consisting of -(CH2) n NRgRιo wherein n is 0 or 1, and Rg and R^0 > taken together with N, form 4-morpholine. 5. A compound according to Claim 4 wherein Z is H. 6. A compound according to Claim 5 wherein n is 0. 7. A compound according to Claim 2 wherein at least one member selected from R5, Rg, R7 or Rg is selected from: the group consisting of -(CH2) p phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl) ] , -(CH 2 ) n naphth l, -(CH 2 ) n pyridinyl, -(CH 2 ) q NR 9 R 10 , -CH-CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι- C 4 alky1) ] , -CH 2 -CH-CH 2 , -CH-CH-CH3, -0-CH 2 -CH-CH 2 , -C«C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl or -C0 (Cχ- C 4 alkyl)], -0(CH 2 )p(N-methylpiperdin-3-yl) , -0-(CH 2 )pNR 9 R 10 , -O-CH2CH ( 0CH 3 ) 2 . -0-(CH 2 )pOR 15 , -(CH 2 ) n C(0)-(CH 2 ) n Rg, -(CH 2 ) n - C(0)0-(CH 2 ) p Rg, -(CH )n C(0)0-(CH 2 ) p NRgRι 0 , -(CH 2 ) n C(0) (CH 2 ) n - NRgR 10 . -0-(CH 2 ) n C(0)-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)-(CH 2 ) n NR 9 R 10 , -NR 9 R 10 . -N(R 9 ) (CH 2 ) n C(0)- (CH 2 ) n Rι 0 . -N(Rg)-(CH 2 ) n C(0)0-(CH2) n Rιo. N(Rg)(CH 2 ) n C(0)- (CH 2 ) n NRgRιo, -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 Cι-C4alkyl)] , -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH2) n C(0)0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(Rg)(CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)- (CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NR 9 -(CH 2 ) n naphthyl, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q 0C(0)-NRgRi Q , .(l-cyclohexyl-lH-tetrazol-5-yl)Cι-C 4 alkoxy, -[l-(Cι-C 5 alkyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -[1-(phenyl)-lH-tetrazol-5-yl]C -C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl)] , -[1-(pyridinyl)-lH-tetrazol-5-yl]C -C4 alkoxy, -[1-(1- phenylethyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, or -C1-C4 alkoxyl. 8. A compound according to Claim 2, 3,. 4 or 6 wherein R5, Rg, R and Rg are selected from the following groups: (i) R5, Rg, R7 and Rg are each hydrogen; or (ii) R5, Rg, and Rg are each hydrogen, and R7 is selected from: -0-(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or tri¬ fluoromethyl) , -C»C-phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), or -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, Cι~ C4 alkoxy, halo or trifluoromethyl) ; or (iii) R5 and Rg are hydrogen, Rg is hydrogen, halo or C1-C5 alkyl, and R7 is selected from: -0-(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -0-(CH 2 ) n pyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -0-(CH 2 ) n naphthyl, -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH 2 ) p pyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C alkoxy, halo or trifluoromethyl), -(CH 2 ) p (l-piperidinyl) , -(CH2)p(l-pyrrolidinyl) or -[(l-cyclohexyl-lH-tetrazol-5- yl)Cι-C4 alkoxy; or (iv) R5, R7 and Rg are each hydrogen, and Rg is -NH-C(0)-0-CH 2 phenyl. 9. A compound according to Claim 1 selected from the group consisting of: Cpd 1 6-Chloro-2-(4-morpholinyl)-4H-l-benzo pyran-4-one; 2- (4 -morpholinyl) -4H-benzopyran-4-one; 8 -Methyl- 2 - (4 -morpholinyl) - (7 -phenylme thoxy) -4H- benzopyran-4-one ; 7-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 8-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-Bromo-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-Fluoro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 7-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 8-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-Methoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 7-Methoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-(Phenylmethoxy)-2-(4-morpholinyl)-4H-l-benzopyran-4- one; 8-(Phenylmethoxy)-2-(4-morpholinyl)-4H-l-benzopyran-4- one; [2- (4-morpholinyl) -4- oxo -4H-1 -benzopyran- 6 -yl] -1,1- dimethylethyl carbamic acid ester; 6 - (3-pyridinecarboxamide) -2- (4-morpholinyl) -4H-1- benzopyran-4-one ; 2-(4-Morpholinyl) -6-nitro-4H-l-benzopyran-4rone; 6- ( [ [Phenylmethoxy]carbonyl]amino)-2- (4-morpholinyl) - 4H- 1 -benzopyran- 4 - one ; 8-Methoxy-2- (4 -morpholinyl) -4H-1- benzopyran-4-one; 3-Amino-2-(4-morpholinyl) -4H-l-benzopyran-4-one; 3-Chloro-2-(4-morpholinyl) -4H-l-benzopyran-4-one; 3-Bromo-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 24 8-Methyl-2- (4-morpholinyl) - -(phenylmethoxy)-4H-1- benzopyran-4-one; Cpd 25 2-(4-Morpholinyl)-5-(phenylmethoxy)-4H-l-benzopyran-4- one; 7,8-Dimethoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 2-(4-Methyl-2-piperazinyl)-4H-l-benzopyran-4-one; 8-Methyl-7- (phenylmethoxy) -2- [4-(2-pyridinyl)-l- piperazinyl]-4H-benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(1-piperazinyl)-4H- benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(1-pyrrolidinyl)-4H- benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(1-piperidinyl)-4H- benzopyran-4-on ; 8-Methyl-2-(4-methyl-l-piperazinyl)-7-(phenylmethoxy)- 4H-benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(2,6-dimethyl-4- morpholinyl)-4H-benzopyran-4-one; 2-[4-(Hydroxyethyl)-1-piperazinyl]-8-methyl-7-(phenyl- methoxy)-4H-benzopyran-4-one monohydrochloride; 2-[4-(Diphenylmethyl)-1-piperazinyl]-8-methyl-7- (phenylmethoxy)-4H-benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-l-piperidinyl)- 4H-benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-l-piperazinyl)- 4H-benzopyran-4-one; 2-(4-Hydroxy-l-piperdinyl)-8-methyl-7-(phenylmethoxy)- 4H-benzopyran-4-one; 7-Hydroxy-S-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one; 6-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 7-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 5-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 8-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one; Cpd 45 [(8-methyl-2-(4-morpholinyl)-4H-l-benzopyran-7-yl)oxy] acetic acid lithium salt; Cpd 46 [ [8-Methyl-2-(4-morpholinyl)-4-oxy-4H-l-benzopyran-7- yl]oxy]acetic acid methyl ester; Cpd 47 7- [ (4-Methoxyphenyl)methoxy] -8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 48 8-Methyl-7-[(4-methylphenyl)methoxy] -2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 49 7-[(4-Chlorophenyl)methoxy] -8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 50 7- [ (4, 5-Dichlorophenyl)methoxy] -8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 51 8-Methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1 -benzopyran- 4 -one; Cpd 52 8-Methyl-7- [ [ (phenyl) carbonyl] oxy] -2- (4-morpho linyl) -4H-l-benzopyran-4-one; Cpd 53 7 -Methoxy- 8-methyl-2- (4 -morpholinyl) -4H-l-benzopyran- 4 - one ; Cpd 54 7- [ [4-(l,l-Dimethylethyl)phenyl]methoxy]-8-methyl-2- (4-morpholinyl) -4H-1 -benzopyran- 4 -one ; Cpd 55 8 -Methyl -2 - (4-morpholinyl) -7- [ [4 -phenylme thoxy) - phenyl] me thoxy] -4H-l-benzopyran-4-one; Cpd 56 7- [ (3-Methoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl)-4H-l-benzopyran-4-one; Cpd 57 7- [ (4-Nitrophenyl)methoxy]-8-methyl-2- (4-morpholinyl) - 4H-l-benzopyran-4-one; Cpd 58 7-[(2-Phenylethyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-l-benzopyran-4-one; Cpd 59 7- [ (2-Methoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl)-4H-l-benzopyran-4-one; Cpd 60 7 - [ (4-Ethoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl)-4H-l-benzopyran-4-one; Cpd 61 8- (4-Ethoxy-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpd 62 2- (4-Morpholinyl) -8- (4-nitro -benzyloxy) -4H-l-benzo- pyran-4-one; Cpd 63 8- (2 -Methoxy-benzyloxy) - 2- (4-morpholinyl) -4H-1- benzopyran- 4 - one ; Cpd 64 2-(4-Morpholinyl)-8-(2-phenyl-ethoxy)-4H-l-benzopyran- 4- one; Cpd 65 2- (4-Morpholinyl) - (2-oxo-2-phenyl-ethoxy) -4H-1- benzopyran-4- one ; Cpd 66 8- (4-Benzyloxy-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one ; Cpd 67 8- (4-Chloro-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpg 68 8- (4-t-Butyl-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one ; Cpd 69 8- (3-Methoxy-benzyloxy) - 2- (4-morpholinyl) -4H-1- benzopyran- 4- one; Cpd 70 8-(3 ,4-Dichloro-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyr n- 4 - one ; Cpd 71 8- (4-Methyl-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpd 72 8- (4-Methoxy-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one ; Cpd 73 2- (4-Morρholinyl) -8- (naphthyl-2-methyloxy) -4H-1- benzopyran-4 - one ; Cpd 74 2-(4-Morpholinyl)-8-(naphthyl-l-methyloxy)-4H-l- benzopyran-4-one; Cpd 75 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-2-methyloxy)- 4H-1-benzopyran-4-one; Cpd 76 8-Methyl-2- (4-morpholinyl)-7-(naphthyl-l-methyloxy)- 4H-1-benzopyran-4-one; Cpd 80 2-(Dimethylamino)-4H-l-benzopyran-4-one; and Cpd 81 2-(Dimethylamino)-8-methyl-7-(phenylmethoxy)-4H-1- benzopyran-4-one; Cpd 100 [8-methyl-2- (4-morpholinyl)-4-oxo-4H-l-benzopyran-7- yl]4-morpholinyl carboxylic acid ester; Cpd 101 2-(4-morpholinyl)-7-(phenylmethoxy)-4H-l-benzopyran-4- one; Cpd 102 8-Methyl-2- (4-morpholinyl)-7-(2-oxo-2-phenylethoxy)- 4H-l-benzopyran-4-one; Cpd 103 6-Chloro-8-methyl-2-(4-morpholinyl)-7-(phenylmethoxy)- 4H-l-benzopyran-4-one; Cpd 104 [ [2-(4-Morpholinyl) -4-oxo-4H-l-benzopyran-8-yl]oxy]- acetic acid methyl ester; Cpd 105 4-[[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7 -yl] oxy] methyl ] -benzoic acid methyl ester; Cpd 106 4- [ [ [2- (4-Morpholinyl) -4-oxo-4H-l-benzopyran-8- yl]oxy]methyl] -benzoic acid methyl ester; Cpd 107 8 - Me thyl - 2 - ( 4 - mo rphol inyl ) - 7 - [ [ 3 - ( rif luoromethyl)phenyl]me thoxy] -4H-l-benzopyran-4- one; Cpd 108 2- (4 -Morpholin l) -8- [ [3- (trifluoromethyl) - phenyl] me thoxy] -4H-l-benzopyran-4-one ; Cpd 109 7-(Cyclohexylmethoxy)-8-methyl-2-(4-morpholinyl)-4H-l- b enz opy r an - 4 - one ; Cpd 110 8-Methyl-2-(4-morpholinyl) -7- (2-propenyloxy)-4H-l- benzopyran-4-one ; Cpd 111 2- (4-Morpholinyl)-7-(l-naphthalenylmethoxy)-4H-l- benzopyran-4-one ; Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1 -benzopyran-4 - one ; Cpd 113 8-Methyl-2-(4-morpholinyl)-7-(4-pyrindinylmethoxy)-4H- l-benzopyran-4-one ; Cpd 115 8-methyl-2-(4-morpholinyl)-7- (2-quinoxalinylmethoxy)- 4H-l-benzopyran-4-one; Cpd 116 8-methyl-2-(4-morpholinyl)-7-(pyrazinlymethoxy)-4H-l- benzopyran-4-one ; Cpd 117 8-methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- l-benzopyran-4-one N-oxide; Cpd 118 8-methyl-2-(4-morpholinyl)-7-(3-pyridinylmethoxy)-4H- 1 -benzopyran- 4 -one N-oxide; Cpd 119 8-Iodo-2-(4-morpholinyl)-7- (3 -pyrindinylmethoxy) -4H-1- benzopyran-4-one ; Cpd 120 3,3-Dimethyl-l-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1 -benzopyran- 7 -yl ] oxy ] -butan- 2 - one ; Cpd 121 1- [ [8 -Methyl-2- (4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy] -propan-2-one; Cpd 122 1- [ [8 -Methyl-2- (4-morpholinyl) -4-oxo-4H-l-benzopyran- 7-yl]oxy] -butan- 2 -one; Cpd 123 8 -Me thyl - 2 - ( 4 - morpho liny 1 ) -7 - (2-oxo- 2- (2 - naphthyl) ethoxy) -4H-l-benzopyran-4-one ; Cpd 125 2- (4-Morpholinyl) -7- (2 -pyrindinylmethoxy) -4H-1- benzopyran-4-one; Cpd 126 2-(4-Morpholinyl)-7-(3-pyrindinylmethoxy)-4H-l- benzopyran-4-one ; Cpd 127 2-(4-Morpholinyl) - 8- (2-pyrindinylmethoxy) -4H-1- benzopyran-4- one ; Cpd 128 2- (4-Morpholinyl) -8- (3 -pyrindinylmethoxy) -4H-1- benzopyran-4-one ; Cpd 129 8-methyl-2-(4-morpholinyl)-7-(2-quinolinylmethoxy)-4H- 1 -benzopyran- 4 - one ; Cpd 130 7,8-(Bis) -phenylme thoxy- 2- (4-morpholinyl) -4H-1- benzopyran-4-one; Cpd 131 7,8-(Bis)-acetyloxy-2-(4-morpholinyl)-4H-l-benzopyran- 4 -one; Cpd 132 7,8-(Bis)-hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4- one; Cpd 133 7-Hydroxy-2- (4-morpholinyl) -8-phenylmethoxy-4H-l- benzopyran- 4- one ; Cpd 135 8 - Hydroxy - 2 - ( 4 -morpholinyl ) - 7 - ( 3 - trif luorome thyl ) phenylmethoxy- 4H - 1 -benzopyran- 4 - one ; Cpd 136 7 - Hydroxy - 2 - (4 -morpholinyl ) - 8 - ( 3 - trifluoromethyl)phenylmethoxy-4H-l-benzopyran-4-one; Cpd 137 7-[3-(l-cyclohexyl-lH-tetrazol-5-yl)propoxyl-8-methyl- 2- (4-morpholinyl) -4H-l-benzopyran-4-one; Cpd 138 8-[3-(l-cyclohexyl-lH-tetrazol-5-yl)propoxy]-2-(4-mor- pholinyl) -4H«l-benzopyran-4-one; Cpd 139 7-[(l-cyclohexyl-lH-tetrazol-5-yl)methoxy]-8-methyl-2- (4 -morpholinyl) -4H-l-benzopyran-4-one ; Cpd 140 8-[(l-cyclohexyl-lH-tetrazol-5-yl)methoxy]-2-(4-mor- pholinyl) -4H-l-benzopyran-4-one; Cpd 141 2-(4-morpholinyl)-8-[(l-phenyl-lH-tetrazol-5-yl)oxy]- 4H-l-benzopyran-4-one; Cpd 142 N-cyclohexyl-2- [ [2- (4-morpholinyl) -4-OXO-4H-1- benzopyran- 8 -yl] oxy] -acetamide ; Cpd 143 N-(l,l-dimethylethyl)-2-[[2-(4-morpholinyl)-4-oxo-4H- l-benzopyran-8-yl]oxy] -acetamide; Cpd 144 2- [ [2- (4-morpholinyl)-4-oxo-4H-l-benzopyran-8-yl] -N- phenyl-acetamide ; Cpd 145 2-[ [2-(4-morpholinyl)-4-oxo-4H-l-benzopyran-8-yl]oxy] - N- (1-phenylethyl) -acetamide; N-[[ [8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]acetyl] -phenyalanine, ethyl ester; 8-methyl-2-(4-morpholinyl)-7-[(l-phenyl-lH-tetrazol-5- yl)oxy] -4H-l-Benzopyran-4-one; 2- [ [8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy] -N-3-pyridinyl-acetamide; N-[ [ [8-methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7-yl]oxy]acetyl] -Phenylalanine; 7-(2,2-dimethoxyethoxy)-8-methyl-2-(4-morpholinyl)-4H- 1-Benzop ran-4-one; 2- (4-Morpholinyl) -8- (2-propenyl)-4H-l-benzopyran-4- one; 2- (4-Morpholinyl) -8- (1-propenyl)-4H-l-benzopyran-4- one; 8-Formyl-2- (4-Morpholinyl) -4H-l-benzopyran-4-one; 2- (4- morpholinyl) -8- (phenylamino)methyl-4H- 1 - benzopyran-4-one; 2-(4-morpholinyl)-8- (2E- phenyl) ethenyl-4H- 1- benzopyran- 4 - one ; 8 -Hydroxymethyl- 2- ( 4 -Morpholinyl) -4H-1 -benzopyran- 4- one; 8-methyl-7- [ (l-methyl-3-piperidinyl)me thoxy] -2- (4-mor- pholinyl) -4H-l-Benzopyran-4-one; 8 -Methyl -2 - ( 4 -morpholinyl ) -7-(2-(l-piperi- dinyl ) ethyl) oxy-4H-l-benzopyran-4- one; 8 -Methyl - 2 - (4-morpholinyl) -7- (2- (l- pyrrolidinyl) ethyl) oxy-4H-l-benzopyran-4- one; 8-Methyl-2- (4-morpholinyl) -7- (2- (4-morpholinyl) ethyl) - oxy-4H- 1 -benzopyran- 4 - one ; 8 -Methyl -2-(4-morpholinyl)-7-(3-(l-piperi- dino) propyl) oxy-4H-l-benzopyran-4- one; 7- (2-Diethylaminoethyl)oxy-8-methyl-2-(4-morpholinyl) - 4H-l-benzopyran-4-one; 7- [2- ( e thy lphenylamino) ethoxy] -8 -methyl- 2- (4 -mor¬ pholinyl) -4H-l-Benzopyran-4-one; 7-(2-Diisopropylaminoethyl)oxy-8 -methyl - 2 - (4- morpholinyl) -4H-l-benzopyran-4-one; 7-Hydroxy- 8-methyl-2- (1-piperidinyl) -4H-l-benzopyran- 4- one; Cpd 171 8-Methyl-2-(l-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one; Cpd 172 7-(2-(4-Benzyl-(l-piperizinyl))ethyl)oxy-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 173 7-Acetoxy-3,8-dimethyl-2-(4-morpholinyl)-4H-l-ben- zopyran-4-one ; Cpd 174 3, 8-dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpd 175 7 -benzyloxy- 3,8 -dimethyl-2- (4-morpholinyl) -4H-1- benzopyran-4- one ; Cpd 176 3 , 8-Dimethyl-2- (4-morpholinyl) -7- (naphthyl-1- methyloxy) -4H-l-benzopyran-4-one ; Cpd 177 3 , 8-Dimethyl-7- (4-methoxy-benzyloxy) -2- (4-morpho- linyl) -4H-l-benzopyran-4-one ; Cpd 178 3,8-Dimethyl-2-(4-morpholinyl)-7-(2-phenyl-ethyloxy)- 4H-l-benzopyran-4-one; Cpd 179 3 , 8-Dimethyl-7-(4-chlorobenzyloxy)-2-(4-morpholinyl)- 4H-l-benzopyran-4-one ; Cpd 180 3, 8-Dimethyl-2-(4-morpholinyl) -7- (3- trifluoromethyl - benzyloxy) -4H-l-benzopyran-4-one; Cpd 181 7 - (Carbomethoxy-methoxyl) -3 , 8 -dimethyl-2- (4- morpholinyl) -4H-l-benzopyran-4-one ; Cpd 182 8-Hydroxy-3-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one, Cpd 183 8 -Benzyloxy- 3 -methyl- 2- (4-morpholinyl) -4H-l-benzo- pyran-4-one; Cpd 184 3-methyl-2- (4 -morpholinyl) -8- (m-trif luoromethyl- benzyloxy ) - 4H- 1 -benzopyran- 4 - one , Cpd 185 8-methyl-7-(2-phenyl)ethynyl-2-(4-morpholinyl)-4H-l- benzopyran-4-one; Cpd 186 8-methyl-2-(4-morpholinyl)-7-(2-phenyl)ethyl-4H-l- benzopyran- 4- one ; Cpd 187 2-(4-Morpholinyl)-8-(2-phenyl)ethynyl-4H-l-benzopyran- 4 -one; Cpd 188 2-(4-Morpholinyl)-8-(2-phenyl)ethyl-4H-l-benzopyran-4- one; Cpd 189 2-(4-Morpholinyl)-8- (2- ( 3 - trifluoromethyl - )phenyl)ethynyl-4H-l-benzopyran-4-one; Cpd 190 2-(4-Morpholinyl)-8-(2-(3-trifluoromethyl)phenyl)- ethyl-4H-l-benzopyran-4-one; Cpd 192 8-Methyl-2-(4-morpholinyl)-7-(2-(l-naphthyl))ethyl-4H- 1-benzopyran-4-one; Cpd 193 8-Methyl-2-(4-morpholinyl)-7-phenyl-4H-l-benzopyran-4- one; Cpd 194 7-acetyloxy-8-iodo-2-(4-morpholinyl)-4H-l-benzopyran- 4-one; Cpd 195 8-ethyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1 -benzopyran-4 - one ; Cpd 196 8-Ethyl-2- (4-morpholinyl) -7-phenylmethoxy-4H-l- b enz opyr an - 4 - one ; Cpd 197 8 - Iodo- 2 - (4-morpholinyl) - 7 -phenylmethoxy-4H-l- benzopyran-4-one; Cpd 198 8-Ethyl-2- (4-morpholinyl)-7-(2-(l-piperi- dinyl)ethyl)oxy-4H-1-benzopyran-4-one; Cpd 199 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-l- benzopyran-4-one; Cpd 200 8-Iodo-7-hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4- one; Cpd 202 7-(3-pyridinylmethoxy)-2-(l-piperidinyl)-8-methyl-4H- l-benzopyran-4-one ; Cpd 204 8-Methyl-2-(4-morpholinylmethyl) -7- (phenylmethoxy) -4H- 1 -benzopyran- 4 -one; Cpd 205 7 -hydroxy- 2- (4-morpholinylmethyl) -8-methyl-4H-l- benzopyran-4-one ; Cpd 206 7- [ (l-cyclohexyl-lH-tetrazol-5-yl)methyoxy] -8-methyl- 2- (4-morpholinylmethy) -4H-1 -benzopyran- 4 -one ; Cpd 207 8 -Methyl - 2 - (4-morpholinylmethyl) -7- (3- pyridiny lme thoxy )-4H-l-benzopyran-4- one or a pharmaceutically acceptable salt or hydrate thereof. 10. A compound according to Claim 1 selected from the group consisting of: Cpd 2 2 -( -morpholinyl) -4H-benzopyran-4-one; Cpd 3 8 -Methyl- 2 - (4 -morpholinyl) - (7 -phenylmethoxy) -4H- benzopyran-4-one ; 6 - ( [ [Phenylmethoxy] carbonyl] amino) -2- (4-morpholinyl) - 4H- l-benzopyran-4-on ; 8 -Methyl-2- (4 -morpholinyl) -7- (2-pyridinylmethoxy) -4H- 1 -benzopyran- 4 -one ; 8 - (4-Methoxy-benzyloxy) - 2- (4 -morpholinyl) -4H-1- b enz opyran- 4 - one ; 8 -Methyl-2- (4-morpho linyl) -7- (naphthyl-1-methyloxy) - 4H-l-benzopyran-4-one ; 8 -Methyl-2- (4-morpholinyl) - 7 - ( 3 -pyrindinylmethoxy) -4H- l-benzopyran-4-one ; 7- [ (l-cyclohexyl-lH-tetrazol-5-yl)methoxy] -8-methyl-2- (4-morpholinyl) -4H-1 -benzopyran- 4 -one ; 8 -Methyl- 2- (4- morpholinyl) -7- (2- ( 1 -piper i- dinyl) ethyl) oxy-4H- l-benzopyran-4- one ; 8 -Methyl- 2 - (4-morpholinyl) -7- (2- (l- pyrrolidinyl) ethyl) oxy-4H-l-benzopyran-4- one; 8-Methyl-2- (1-piperidinyl) -7- (3 -pyrindinylmethoxy) -4H- l-be zopyran-4-one ; or a pharmaceutically acceptable salt or hydrate thereof. 11. Use of a compound selected from the group consisting of a compound of Formula I wherein X is N, or CZ where Z is H, C ~~- alkyl, amino (-NH2) or a halogen atom; when X is CZ, Y is selected from the group consisting of -(CH2) n NR Rιo wherein Rg and Rιo > being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Rg and RIQ are not both hydrogen; (b) c l- c 12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 C 1 -C4al yl) ; (d) -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or carboCχ-C4 alkoxy), (e) -(CH 2 ) n pyridinyl or (f) wherein Rg and Rιo > taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C - C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperldine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH 2 )qOH, -C0 2 H, -C0 2 CH3 -C0 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-l-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C -C4 alkoxy, halo, trifluoromethyl, -CH 2 0 H , -C0 2 H, -C0 2 CH 3 or -C0 2 CH 2 CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3, -tetrahydroisoquinoline or imidazole; and R5, Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, Ci-Cg alkyl, -(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C alkoxy, halo, OH, trifluoromethyl or -C02(C -C 4 alkyl)], -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH 2 )q RgRιo, -CH-CH-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C alkyl)] , -CH 2 -CH-CH 2 , -CH-CH-CH3,- O-CH2-CH-CH2, -CβC-phenyl [wherein phenyl is optionally sub- stituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -Cθ2(Cι-C4alkyl)] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -O-(CH 2 )pNRgRι 0 , -0-CH2CH ( 0CH 3 ) 2 , -0-(CH 2 )pORι 5 , -(CH 2 ) n C(0)-(CH 2 ) n Rg, -(CH 2 ) n C(0)0-(CH 2 ) p Rg, -(CH )n C(0)0- (CH 2 ) p NRgRι 0 , -(CH 2 ) n C(0)(CH 2 ) n NRgRi 0 , N0 2 ,-0-(CH 2 ) n C(0)- (CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 , -NR 9 R 10 , -N(Rg)(CH 2 ) n C(0)-(CH 2 ) n R 10 , -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n R 10 , N(Rg)(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 . -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι- C 4 alkyl)] , -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(Rg)(CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg-(CH 2 ) n naphthyl, halo (fluoro, chloro, bromo, iodo) , OH, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q 0C(0)-NRgR Q, .(1-cyclohexyl-lH-tetrazol- 5-yl)C ~C4 alkoxy, -[l-(Cι-C 5 alkyl)-lH-tetrazol-5-yl]C -C4 alkoxy, -[l-( p henyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C^-C4 alkyl, G l- C 4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl)] , -[1-(pyridinyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -[1-(1-phenylethyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -C1-C4 alkoxyl, a group of Formula II wherein R' is methyl or carboxy, R' ' is hydrogen and R' ' ' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], Cι~ C 5 alkyl, -(CH ) n C0 2 H, -CH 2 SH, -CH 2 SCH 3 , imidazolinylmethylene, indolinylmethylene, CH 3 CH(0H) , CH 2 0H, H 2 N(CH 2 ) 4 -(optionally in protected form) or H 2 NC(NH)NH(CH 2 )3 (optionally in protected form) ; with the overall proviso that when Y is other than -(CH 2 ) n morpholinyl, at least one member of R 5 , Rg, R7 or Rg is other than hydrogen, C -Cg alkyl, N0 2 , OH, C^-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH 2 , or dimethyamino; with the further proviso that when Y is 4- morpholinyl, the compound is other than: 6,7-dimethoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpho1iny1)-4H-1-benzopyran-4-one, N-cyclohexyl-2- [ [8-methyl-2- (4-morpholinyl)-4-oxo-4H-l- benzopyran-7-yl]oxy] -acetamide, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-1-benzopyran-7- yl]oxy] -N-phenyl-acetamide, 6- [ (1-cyclohexyl-lH-tetrazol-5-yl)methoxy] -2- (4-mor¬ pholinyl)-4H-l-Benzopyran-4-one, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-1-benzopyran-7- yl]oxy] -N-(l-phenylethyl)-acetamide; with the further provisio that when Y is dimethylamino, the compound is other than: 2- (Dimethylamino)-8-methyl-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester, (Dimethylamino)-4-oxo-4H-l-benzopyran-6-yl carbamic acid dimethyl ester, 2-(Dimethylamino)-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester; when X is N, Y is selected from the group consisting of -NRgRio wherein Rg and Rχθ ι being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Rg and RIQ are not both hydrogen; (b) C -C"L 2 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl) ; (d) -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or carboCι-C4 alkoxy), (e) -(CH 2 ) n pyridinyl or (f) wherein Rg and Rχo. taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Cι~ C4 alkyl, C -C alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C -C4 alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C^-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH 2 )qOH, -C0 2 H, -C0 2 CH3 -C0 2 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-l-piperazine, -phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH 2 0 jj , -C0 2 H, -C0 2 CH 3 or -C0 2 CH 2 CH3,. and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-l,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5. Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, Ci-Cg alkyl, -(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 (Cι-C4alkyl)] , -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH2)qNRgRiQ. -CH-CH-phenyl [wherein phenyl is optionally sub- stituted with one, 2 or 3 C -C alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C 4 alkyl) ] , -CH 2 -CH-CH 2 , -CH-CH-CH 3 , -O-CH2-CH-CH2, -C«C-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl)] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -O-(CH 2 )pNR 9 R 10 , -O-CH2CH(0CH 3 ) 2 , -0- (CH 2 )pOR 15 , -(CH 2 ) n C(0)-(CH 2 ) n Rg, - (CH 2 ) n C(0)0-(CH 2 ) p Rg, -(CH )n C(0)0- (CH 2 ) p NRgRι 0 , -(CH 2 ) n C(0) (CH 2 ) n NRgR 10 . N0 2 , -0- (CH 2 ) n C(0) - . (CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p R 9 , -0-(CH 2 ) n C(0) - (CH 2 ) n NRgR I0 , -NR 9 R 10 , -N(Rg)(CH 2 ) n C(0)-(CH 2 ) n Rιo, -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n Rιo. N(R 9 )(CH 2 ) n C(0)-(CH2) n NR9Rιo, -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι- C 4 alkyl)], -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0) - (CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0) -N(Rg) (CH 2 ) n pyridine, -0-(CH ) n quinoxalinyl, -0- (CH 2 ) n quinolinyl, -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthy1, -0- (CH 2 ) n C(0)-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg- (CH 2 ) n naphthyl, halo (fluoro, chloro, bromo, iodo) , OH, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q OC(O)-NR 9 R 10 , .(1-cyclohexyl-lH-tetrazol- 5-yl)Cχ-C4 alkoxy, - [l-(C -C 5 alkyl)-lH-tetrazol-5-yl]C -C4 alkoxy, - [1- ( p henyl)-lH-tetrazol-5-yl]C -C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl) ] , -[1-(pyridinyl)-lH-tetrazol-5-yl]C 1 -C4 alkoxy, . [i_.(i_ phenylethyl)-lH-tetrazol-5-yl]C -C4 alkoxy, or -C1-C4 alkoxyl; R 5 is selected from C1-C5 alkyl, -(CH 2 ) n phenyl [phenyl optionally substituted with one, 2 or 3 C1-C alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C -C4al yl) ] , -(CH 2 ) n pyridin-l-yl or - (CH2) p piperidin-l-yl] n is 0-5; p is 2-5 q is 1-5, and pharmaceutically acceptable salts or hydrates thereof; to prepare a medicament for preventing or treating atherosclerosis. 12. A method according to Claim 11 where Y is selected from the group consiting of -(CH 2 ) n NRgRιo wherein Rg and R Q, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of: (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, c l" c 4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Cι~ C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, c l' c 4 alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH 2 )qOH, -C0 2 H, -C0 2 CH3 -C0 2 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) , (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-l-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH 2 0 H , -C0 2 H, -C0 CH 3 or -C0 2 CH 2 CH 3 . 13. A method according to Claim 12 wherein X is CZ where Z is H or methyl. 14. A method according to Claim 12 wherein X is N. 15. A method according to Claim 13 or 14 wherein R5, R , R7 and Rg are selected from the following groups: (i) R 5 , Rg, R7 and Rg each hydrogen; (ii) R5, Rg, and Rg are each hydrogen, and R7 is selected from: -0-(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo or tri¬ fluoromethyl) , -C^C-phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), or -(CH ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, Ci- C alkoxy, halo or trifluoromethyl); (iii) R5 and Rg are hydrogen, Rg is hydrogen, halo or C -C5 alkyl, and R7 is selected from: -0-(CH ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), -0-(CH ) n pyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -0-(CH ) n naphthyl, -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 c l _c 4 alkyl, C -C4 alkoxy, halo or trifluoromethyl), -(CH 2 ) p pyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH 2 )p(l-pyrrolidinyl) or -[(1- cyclohexyl-lH-tetrazol-5-yl)Cι-C4 alkoxy; or (iv) R5, R7 and Rg are each hydrogen, and Rg is -NH-C(0)-0-CH 2 phenyl. 16. The method according to Claim 11 where the compound is selected from the group consisting of: Cpd 1 6-Chloro-2-(4-morpholinyl)-4H-l-benzo pyran-4-one; Cpd 2 2-(4-morpholinyl)-4H-benzopyran-4-one; Cpd 3 8-Methyl-2- ( 4 -morpholinyl) - (7 -phenylmethoxy) -4H- benzopyran-4-one ; Cpd 4 7-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 5 8-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 6 6-Bromo-2-(4-morpholinyl) -4H-l-benzopyran-4-one; Cpd 7 6-Fluoro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 7-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 8-Methyl-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-Methoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 7-Methoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 6-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one; 8-(Phenylmethoxy)-2-(4-morpholinyl)-4H-l-benzopyran-4- one; [2-(4-morpholinyl) -4-oxo-4H-l-benzopyran-6-yl] -1,1- dimethylethyl carbamic acid ester; 6- (3-pyridinecarboxamide)-2- (4-morpholinyl) -4H-1- benzopyran-4-one; 2-(4-Morpholinyl)-6-nitro-4H-l-benzopyran-4-one; 6-([ [Phenylmethoxy]carbonyl]amino)-2-( -morpholinyl)- 4H-l-benzopyran-4-one; 8-Methoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one; 3-Amino-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 3-Chloro-2-(4-morpholinyl)-4H-l-benzopyran-4-one; 3-Bromo-2- (4-morpholinyl) -4H-l-benzopyran-4-one ; 8 -Methyl - 2- (4-morpholinyl) - 7 - (phenylmethoxy) -4H-1- benzopyran-4-one ; Cpd 25 2 - (4-Morpholinyl) - 5 - (phenylmethoxy) -4H- l-benzopyran-4- one ; 7 , 8-Dimethoxy-2- (4-morpholinyl) -4H-l-benzopyran-4-one ; 2-(4-Methyl-2-piperazinyl)-4H-l-benzopyran-4-one; 8-Methyl-7- (phenylmethoxy) -2- [4- (2-pyridinyl) -1- piperazinyl]-4H-benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(1-piperazinyl)-4H- benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(1-pyrrolidinyl)-4H- benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(1-piperidinyl)-4H- benzopyran-4-one; 8-Methyl-2-(4-methyl-l-piperazinyl)-7-(phenylmethoxy)- 4H-benzopyran-4-one; 8-Methyl-7-(phenylmethoxy)-2-(2,6-dimethyl-4- morpholinyl)-4H-benzopyran-4-one; Cpd 34 2-[4-(Hydroxyethyl)-1-piperazinyl] -8-methyl-7-(phenyl¬ methoxy)-4H-benzopyran-4-one onohydrochloride; Cpd 35 2- [4-(Diphenylmethyl)-l-piperazinyl] -8-methyl-7- (phenylmethoxy)-4H-benzopyran-4-one; Cpd 36 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperidinyl)- 4H-benzopyran-4-one; Cpd 37 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-l-piperazinyl)- 4H-benzopyran-4-one; Cpd 38 2-(4-Hydroxy-l-piperdinyl)-8-methyl-7-(phenylmethoxy)- 4H-benzopyran-4-one; Cpd 39 7-Hydroxy-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one; Cpd 40 6-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 41 7-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 42 5-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 43 8-Hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 44 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4-one; Cpd 45 [(8-methyl-2-(4-morpholinyl)-4H-l-benzopyran-7-yl)oxy] acetic acid lithium salt; Cpd 46 [ [8-Methyl-2-(4-morpholinyl)-4-oxy-4H-l-benzopyran-7- yl]oxy]acetic acid methyl ester; Cpd 47 7- [(4-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 48 8 * -Methyl-7-[(4-methylphenyl)methoxy]-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 49 7-[(4-Chlorophenyl)methoxy] -8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 50 7- [ (4, 5-Dichlorophenyl)methoxy] -8-methyl-2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 51 8-Methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- l-benzopyran-4-one; Cpd 52 8-Methyl-7- [ [ (phenyl)carbonyl]oxy] -2-(4-morpho linyl)-4H-l-benzopyran-4-one; Cpd 53 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-l-benzopyran- 4 -one ; Cpd 54 7 - [ [ 4- (l , l-Dimethylethyl)phenyl]methoxy] -8-methyl-2- (4-morpholinyl) -4H-l-benzopyran-4-one ; Cpd 55 8-Methyl-2- (4 -morpholinyl) -7- [ [4- phenylme thoxy) - phenyl] me thoxy] -4H-l-benzopyran-4-one ; Cpd 56 7- [(3-Methoxyphenyl) methoxy] -8-methyl-2- (4-morpho- linyl) -4H-l-benzopyran-4-one; Cpd 57 7-[(4-Nitroρhenyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-l-benzopyran-4-one ; Cpd 58 7-[(2-Phenylethyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-l-benzopyran-4-one ; Cpd 59 7- [ (2-Methoxyphenyl)methoxy] -8-methyl-2- (4-morpho- linyl) -4H-l-benzopyran-4-one; Cpd 60 7- [ (4 -Ethoxyphenyl) methoxy] -8-methyl-2- (4-morpho- linyl) -4H-l-benzopyran-4-one; Cpd 61 8- (4-Ethoxy-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpd 62 2-(4-Morpholinyl)-8-(4-nitro-benzyloxy)-4H-l-benzo- pyran-4-one; Cpd 63 8- (2-Methoxy-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4-one ; Cpd 64 2-(4-Morpholinyl)-8-(2-phenyl-ethoxy)-4H-l-benzopyran- 4-one; Cpd 65 2- (4 -Morpholinyl )- (2- oxo -2 -phenyl- ethoxy) -4H-1- benzopy ran- 4 - one ; Cpd 66 8- (4-Benzyloxy -benzyloxy) -2- (4 -morpholinyl) -4H-1- benzopyran-4-one ; Cpd 67 8 -(4-Chloro -benzyloxy) -2- (4-morpholinyl) -4H-l-benzo- pyran-4-one; Cpg 68 8- (4-t-Butyl-benzyloxy) -2- (4-morpholinyl) -4H-1- benzopyran-4- one ; Cpd 69 8- (3-Methoxy-benzyloxy) - 2- (4-morpholinyl) -4H-1- benzopyran- 4- one; Cpd 70 8-(3,4-Dichloro-benzyloxy)-2-(4-morpholinyl)-4H-l- benzopyran-4-one ; Cpd 71 8-(4-Methyl-benzyloxy)-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpd 72 8- (4-Methoxy-benzyloxy ) -2- (4-morpholinyl) -4H-1- benzopyran-4-one; Cpd 73 2- (4-Morpholinyl)-8-(naphthyl-2-methyloxy)-4H-l- benzopyran-4-one; 2 - ( 4 -Morphol inyl) - 8 - (naphthyl - 1 -methyloxy) -4H- 1 - benzopyran-4-one ; 8 - Me thy 1 - 2 - ( 4 - morpho linyl) - 7 - (naphthyl - 2 -me thylox ) - 4H-l-benzopyran-4-one ; 8-Methy1-2- (4-morpholiny1)-7-(naphthyl-1-methylox )- 4H-l-benzopyran-4-one; 2-(Dimethylamino)-4H-l-benzopyran-4-one; and 2- (Dimethylamino)-8-methyl-7-(phenylmethoxy)-4H-1- benzopyran-4-one; Cpd 83 6-Methyl-2-(4-morpholinyl)-4H-l,3- benzoxazin-4-one; 8-Methyl-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one; 6-Bromo-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one; 7-Chloro-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one; 6,8-Bis(l-methylethyl)-2-(4-morpholinyl)-4H-l,3- benzoxazin-4-one; 6-Fluoro-2-(4-morpholinyl)-4H-l,3-benzoxazin-4-one; 6-Dimethoxymethyl-2-(4-morpholinyl)-4H-l,3-benzoxazin- -one; Cpd 90 7-Methoxy-2-(4-morpholinyl)-4H-l,3-benzoxazin- 4-one; 6-(Morpholin-l-yl)-pyrido(2,3-e)-l,3-oxazine-8-one; 8-Methyl-2-(l-piperidinyl)-4H-l,3-benzoxazin-4-one; 8-Methyl-2-(l-pyrrolidinyl)-4H-l,3-benzoxazin-4-one; 2- (1-pyrrolidinyl) -4H-1 , 3-benzoxazin-4-one ; 2- (1- (4-Thiomorpholinyl) ) -4H-1 , 3-benzoxazin-4-one ; 2- (4-Methyl-l-piperazinyl) -4H-l , 3-benzoxazin-4-one ; 2- (4-Morpholinyl) -4H-l , 3-benzoxazin-4-one ; [ 8 -methyl- 2 - (4 -morpholinyl) -4-oxo-4H-l-benzopyran-7- yl] 4 -morpholinyl carboxylic acid ester; 2- (4-morpholinyl) -7- (phenylmethoxy) -4H-l-benzopyran-4- one; 8 -Methyl- 2 - ( -morpholinyl) -7- (2-oxo-2- phenyl ethoxy) - 4H-l-benzopyran-4-one ; 6 -Chloro -8-methyl-2- (4 -morpholinyl) - 7- (phenylmethoxy) - 4H-1 -benzopyran- 4 -one ; [ [ 2 - (4 -Morpholinyl ) -4-oxo-4H-l-benzopyran-8 -yl] oxy] - acetic acid methyl ester; Cpd 105 4-[ [[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-l-benzopyran- 7 -yl] oxy] methyl] -benzoic acid methyl ester; Cpd 106 4- [ [ [2- (4-Morpholinyl) -4-oxo-4H-l-benzopyran-8- yl] oxy] methyl] -benzoic acid methyl ester; Cpd 107 8 -Me thyl - 2 - (4 -morpholinyl) - 7 - [ [ 3 - (trifluoromethyl)phenyl] methoxy] -4H-l-benzopyr n-4- one; Cpd 108 2- (4-Morpholinyl) -8- [[ 3- (trifluoromethyl) - phenyl] methoxy] -4H-l-benzopyran-4-one; Cpd 109 7-(Cyclohexylmethoxy)-8-methyl-2-(4-morpholinyl)-4H-l- benzopyran-4-one ; Cpd 110 8-Methyl-2-(4-morpholinyl) -7- (2-propenyloxy)-4H-l- benzopyran-4-one ; Cpd 111 2- (4 -Morpholinyl) -7- (1-naphthalenylmethoxy) -4H-1- benzopyran-4-one; Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- l-benzopyran-4-one; Cpd 113 8-Methyl-2-(4-morpholinyl)-7-(4-pyrindinylmethoxy)-4H- l-benzopyran-4-one; Cpd 115 8-methyl-2-(4-morpholinyl)-7-(2-quinoxalinylmethoxy)- 4H-l-benzopyran-4-one; Cpd 116 8-methyl-2-(4-morpholinyl)-7-(pyrazinlymethoxy)-4H-l- benzopyran-4-one; Cpd 117 8-methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- l-benzopyran-4-one N-oxide; Cpd 118 8-methyl-2-(4-morpholinyl)-7-(3-pyridinylmethoxy)-4H- 1 -benzopyran- 4 -one N-oxide; Cpd 119 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-l- benzopyran-4 - one ; Cpd 120 3,3-Dimethyl-l-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1 -benzopyran- 7 -y 1 ] oxy] -butan- 2 - one ; Cpd 121 1- [ [8 -Methyl-2- (4-morpholinyl)-4-oxo-4H-l-benzopyran- 7 -yl ] oxy] -propan- 2 - one ; Cpd 122 1- [ [ 8 -Methyl-2- (4-morpholinyl) -4-oxo-4H-l-benzoρyran- 7 -yl ] oxy] -butan- 2 - one ; Cpd 123 8 -Methyl- 2 - ( 4 -morpholinyl) -7 - (2- oxo- 2- (2- naphthyl) ethoxy) -4H-l-benzopyran-4-one ; Cpd 125 2- (4-Morpholinyl) -7 - (2 -pyrindinylmethoxy) -4H-1- benzopyran-4-one ; Cpd 126 2- (4-Morpholinyl) -7- ( 3 -pyrindinylmethoxy) -4H-1- benzopyran-4-one ; Cpd 127 2- (4-Morpholinyl) -8- (2 -pyrindinylmethoxy) -4H-1- benzopyran-4-one; Cpd 128 2-(4-Morpholinyl)-8-(3-pyrindinylmethoxy)-4H-l- benzopyran-4-one; Cpd 129 8-methyl-2-(4-morpholinyl)-7-(2-quinolinylmethoxy)-4H- 1 -benzopyran- 4- one ; Cpd 130 7, 8- (Bis) -phenylmethoxy- 2- (4-morpholinyl) -4H-1- benzopyran-4-one ; Cpd 131 7,8- (Bis)-acetyloxy-2-(4-morpholinyl)-4H-l-benzopyran- 4-one; Cpd 132 7,8- (Bis) -hydroxy- 2 - (4-morpholinyl) -4H-l-benzopyran-4- one; Cpd 133 7 -Hydroxy-2- (4 -morpholinyl) -8 -phenylmethoxy- H-1- benzopyran-4-one ; Cpd 135 8 - Hydroxy - 2 - ( 4 - morpholinyl ) - 7 - ( 3 - trif luoromethyl) phenylmethoxy- 4H- 1 -benzopyran-4 - one ; Cpd 136 7 - Hydroxy - 2 - (4 - lorpholinyl) • 8 - ( 3 ■ t r if luo rome thy 1 ) phenylme thoxy - 4H - 1 - b enz opy ran - 4 - one ; Cpd 137 7-[3-(l-cyclohexyl-lH-tetrazol-5-yl)propoxyl-8-methyl- 2- (4-morpholinyl) -4H-l-benzopyran-4-one ; Cpd 138 8-[3-(l-cyclohexyl-lH-tetrazol-5-yl)propoxy]-2-(4-mor- pholinyl)-4H-l-benzopyran-4-one; Cpd 139 7- [(1-cyclohexyl-lH- tetrazol- 5 -yl)methoxy] -8-methyl-2- (4-morpholinyl) -4H-l-benzopyran-4-one ; Cpd 140 8- [(l-cyclohexyl-lH-tetrazol-5-yl)methoxy]-2-(4-mor- pholinyl) -4H-l-benzopyran-4-one ; Cpd 141 2- (4-morpholinyl)-8-[(l-phenyl-lH-tetrazol-5-yl)oxy]- 4H-l-benzoρyran-4-one ; Cpd 142 N-cyclohexyl-2- [ [2- (4-morpholinyl) -4-OXO-4H-1- benzopyran-8-yl] oxy] -acetamide ; Cpd 143 N- (l,l-dimethylethyl)-2-[ [2- (4-morpholinyl) -4-oxo-4H- 1 -benzopyran- 8 -yl] oxy] -acetamide; Cpd 144 2- [ [ 2- (4-morpholinyl) -4-oxo-4H-l-benzopyran-8-yl] -N- pheny 1 - acetamide ; Cpd 145 2- [ [2- (4-morpholinyl)-4-oxo-4H-l-benzopyran-8-yl]oxy] - N- (1-phenylethyl) - acetamide ; N- [ [ [8-methyl-2-(4-morpholinyl) -4-oxo-4H-l-benzopyran- 7-yl]oxy] acetyl] -phenyalanine, ethyl ester; 8-methyl-2- (4-morpholinyl) -7- [ (1-phenyl-lH- tetrazol-5- yl)oxy] -4H-l-Benzopyran-4-one; 2- [ [8 -methyl-2- (4-morpholinyl)-4-oxo-4H-l-benzopyran- 7 -yl] oxy] -N- 3 -pyridinyl -acetamide ; N- [ [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-l-benzopyran- 7 -yl ] oxy ] cetyl ] -Phenylalanine ; 7-(2 . 2-dimethoxyethoxy)-8-methyl-2-(4-morpholinyl)-4H- l-Benzopyran-4-one ; 2- (4-Morpholinyl) -8- (2-propenyl)-4H-l-benzopyran-4- one; 2- (4 -Morpholinyl) -8- (l-propenyl)-4H-l-benzopyran-4- one ; 8-Formyl-2- (4-Morpholinyl) -4H-l-benzopyran-4-one; 2 - (4 -morpholinyl) - 8 - (phenyl amino) me thy 1-4H- 1- benzopyran- 4 - one ; 2- (4 -morpholinyl) -8- ( 2E -phenyl ) ethenyl-4H-l - benzopyran-4-one; 8 -Hydroxymethyl- 2- (4 -Morpholinyl) -4H-l-benzopyran-4- one; 8-methyl-7- [ (l-methyl-3-piperidinyl)me thoxy] -2- (4-mor- pholinyl) -4H-l-Benzopyran-4-one ; 8-Methyl-2- (4-morpholinyl) -7-(2- (1-piperi- dinyl) ethyl) oxy-4H- l-benzopyran-4- one ; 8 -Methyl- 2 - (4-morpholinyl) - 7- (2- (l- pyrrolidinyl) ethyl) oxy-4H- l-benzopyran-4-one ; 8-Methyl-2- (4-morpholinyl) -7- (2- (4 -morpholinyl) ethyl) - oxy-4H-l -benzopyran- 4- one; 8 -Methyl- 2- (4- morpholinyl) -7- (3- (1-piper i- dino)propyl)oxy-4H-l-benzopyran-4-one; 7-(2-Diethylaminoethyl)oxy-8-methyl-2- (4-morpholinyl) - 4H-l-benzopyran-4-one ; 7- [2- (ethylphenylamino)ethoxy] -8-methyl-2- (4-mor- pholinyl) -4H-l-Benzopyran-4-one ; 7 - (2-Diisopropylaminoethyl)oxy-8 -methyl-2- (4- morpholinyl) -4H-l-benzopyran-4-one ; Cpd 170 7-Hydroxy-8-methyl-2-(l-piperidinyl)-4H-l-benzopyran- 4-one; Cpd 171 8-Methyl-2-(l-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- l-benzopyran-4-one ; Cpd 172 7-(2-(4-Benzyl-(l-piperizinyl))ethyl)oxy-8-methyl-2- (4-morpholinyl)-4H-l-benzopyran-4-one; Cpd 173 7-Acetoxy-3, 8-dimethyl-2- (4-morpholinyl) -4H-l-ben- z opy ran - 4 - one ; Cpd 174 3,8-dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-l-benzo- pyran-4-one; Cpd 175 7-benzyloxy-3 , 8-dimethyl-2- (4-morρholinyl) -4H-1- benzopyran- 4 - one ; Cpd 176 3 , 8-Dimethyl-2- (4-morpholinyl) -7- (naphthyl-1- methyloxy)-4H-l-benzopyran-4-one; Cpd 177 3 , 8-Dimethyl-7- (4-methoxy-benzyloxy) -2- (4-morpho- linyl) -4H-l-benzopyran-4-one; Cpd 178 3,8-Dimethyl-2-(4-morpholinyl)-7-(2-phenyl-ethyloxy)- 4H-1 -benzopyran- 4 -one; Cpd 179 3, 8-Dimethyl-7-(4-chlorobenzyloxy)-2-(4-morpholinyl)- 4H-l-benzopyran-4-one; Cpd 180 3,8-Dimethyl-2-(4-morpholinyl)-7-(3-trifluoromethyl- benzyloxy) -4H-l-benzopyran-4-one ; Cpd 181 7 - (Carbomethoxy-methoxyl) -3 , 8 -dimethyl - 2 - (4- morpholinyl) -4H-l-benzopyran-4-one ; Cpd 182 8 -Hydroxy- 3-methyl-2- (4-morpholinyl) -4H-l-benzopyran- 4-one, Cpd 183 8-Benzyloxy-3-methyl-2- (4-morpholinyl) -4H-l-benzo- ρyran-4-one; Cpd 184 3 -methyl - 2 - (4 -morpholinyl) -8- (m- trifluoromethyl - benzyloxy) -4H-l-benzopyran-4-one, Cpd 185 8-methyl-7-(2-phenyl)ethynyl-2-(4-morpholinyl)-4H-l- benzopyran-4-one ; Cpd 186 8-methyl-2-(4-morpholinyl)-7-(2-phenyl)ethyl-4H-l- benzopyran-4-one ; Cpd 187 2-(4-Morpholinyl)-8-(2-phenyl)ethynyl-4H-l-benzopyran- 4-one; Cpd 188 2-(4-Morpholinyl)-8-(2-phenyl)ethyl-4H-l-benzopyran-4- one; Cpd 189 2- (4-Morpholinyl) -8- (2- (3- tr i luoromethyl- ) henyl) ethynyl-4H-l-benzopyran-4-one; Cpd 190 2-(4-Morpholinyl)-8-(2-(3-trifluoromethyl)phenyl)- ethyl-4H-l-benzopyran-4-one ; Cpd 192 8-Methyl-2-(4-morpholinyl)-7-(2-(l-naphthyl))ethyl-4H- ■ 1 -benzopyran- 4- one ; Cpd 193 8-Methyl-2-(4-morpholinyl)-7-phenyl-4H-l-benzopyran-4- one; Cpd 194 7-acetyloxy-8-iodo-2-(4-morpholinyl)-4H-l-benzopyran- 4- one; Cpd 195 8-ethyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- l-benzopyran-4-one ; Cpd 196 8-Ethyl-2-(4-morpholinyl)-7-phenylmethoxy-4H-l- benzopyran-4-one ; Cpd 197 8-Iodo-2- (4-morpholinyl) -7-phenylmethoxy-4H-l- benzopyran-4-one ; Cpd 198 8 -Ethyl- 2- (4 -morpholinyl ) -7-(2-(l-piperi- dinyl) ethyl) oxy-4H- 1 -benzopyran-4- one ; Cpd 199 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-l- benzopyran- 4 -one; Cpd 200 8-Iodo-7-hydroxy-2-(4-morpholinyl)-4H-l-benzopyran-4- one; Cpd 202 7- (3-pyridinylmethyleneoxy)-2-(l-piperidinyl)-8- methyl-4H-1-benzopyran-4-one; Cpd 204 8-Methyl-2-(4-morpholinylmethyl)-7-(phenylmethoxy)-4H- l-benzopyran-4-one; Cpd 205 7-hydroxy-2- (4-morpholinylmethyl) -8-methyl-4H-1- benzopyran-4-one; Cpd 206 7- [(l-cyclohexyl-lH-tetrazol-5-yl)methyoxy]-8-methyl- 2-(4-morpholinylmethy)-4H-l-benzopyran-4-one; Cpd 207 8-Methyl-2- (4-morpholinylmethyl) -7-(3- pyridinylmethoxy)-4H-l-benzopyran-4-one; or a pharmaceutically acceptable salt thereof. 17. A pharmaceutical composition comprising a compound selected from the group consisting of compounds of Formula I wherein X is N, or CZ where Z is H, C1-C5 alkyl, amino -NH2) or a halogen atom; when X is CZ, Y is selected from the group consisting of -(CH2) n NRgR o wherein Rg and ιo > being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R Q are not both hydrogen; (b) c l _c 12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl) ; (d)- (CH 2 ) n ρhenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, tri- fluoromethyl or ] , (e) -(CH2) n pyridinyl or (f) wherein Rg and Rχo > taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C1-C alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Ci- C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-1-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C alkyl, C1-C4 alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C alkyl, alkoxy, halo, trifluoromethyl, - CH2 qOH, -C0 2 H, -C0 2 CH3 -C0 2 CH 2 CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C alkoxy, halo or trifluoromethyl) , (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-l-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C -C4 alkoxy, halo, trifluoromethyl, -CH 2 0g, -C0 2 H, -C0 2 CH3 or -C0 2 CH 2 CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- ethylhomopiperazine, 4-phenyl-l,2-3,6- tetrahydropyridine, proline, tetra- hydro urylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5, Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, Ci-Cg alkyl, -(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C -C4alkyl ] , -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH 2 ) q NRgRi Q , -CH-CH-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Ci-C 4 alkyl)] , -CH 2 -CH-CH 2 , -CH-CH-CH 3 , -0-CH 2 -CH-CH 2 , -C=C-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl ] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -O-(CH 2 )pNR 9 Rι 0 , -O-CH2CH ( 0CH 3 ) 2 , -0-(CH 2 )p0R 15 , -(CH 2 ) n C(0)-(CH 2 ) n Rg, -(CH 2 ) n C(0)0-(CH 2 ) p Rg. -(CH )n C(0)0- (CH 2 ) p NRgRι 0 , -(CH 2 ) n C(0)(CH 2 ) n NRgR 10 , N0 2 ,-0-(CH 2 ) n C(0)- (CH 2 ) p Rg. -0-(CH 2 ) n C(0)0-(CH 2 ) p Rg, -O-(CH 2 ) n C(O)-(CH2) n NRgRι 0 , -NRgR 10 , -N(Rg)(CH 2 ) n C(0)-(CH 2 ) n R 10 , -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n Rι 0> N(Rg)(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 ' -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 " -C^ alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 - C 4 alkyl)], -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine. -0(CH 2 ) n C(0)-N(Rg) (CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl, -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthy1, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthy1, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg-(CH2) n naphthyl, halo (fluoro, chloro, bromo, iodo) , OH, -(CH2) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q 0C(0)-NR Ri Q , _(1-cyclohexyl-lH-tetrazol- 5-yl)Cι-C 4 alkoxy, - [l-(C -C 5 alkyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -[l-( p henyl)-lH-tetrazol-5-yl]C -C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C alkyl)] , -[1-(pyridinyl)-lH-tetrazol-5-yl]Cι-C 4 alkoxy, -[1-(1- phenylethyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -C1-C4 alkoxyl, a group of Formula II wherein R' is methyl or carboxy, R' ' is hydrogen and R' ' ' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C -C5 alkyl, - (CH 2 ) n C0 2 H, -CH 2 SH, -CH 2 SCH 3 , imidazolinylmethylene, indolinylmethylene, CH 3 CH(0H) , CH 2 0H, H 2 N(CH 2 )4-(optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form) ; with the overall proviso that when Y is other than -(CH 2 ) n morpholinyl, at least one member of R5, Rg, R7 or Rg is other than hydrogen, C -Cg alkyl, N0 2 , OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH2, or dimethyamino; with the further proviso that when Y is morpholinyl, the compound is other than: 6,7-dimethoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-l-benzopyran-4-one, N-cyclohexyl-2- [ [8-methyl-2- (4-morpholinyl)-4-oxo-4H-l- benzopyran-7-yl]oxy] -acetamide, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-1-benzopyran-7- yl]oxy]-N-phenyl-acetamide, 6 - [ (1-cyclohexyl- 1H-tetrazol-5-yl)methoxy] -2- (4-mor¬ pholinyl)-4H-l-Benzopyran-4-one, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-1-benzopyran-7- yljoxy] -N-(1-phenylethyl)-acetamide; with the further provisio that when Y is dimethylamino, the compound is other than: 2- (Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester, (Dimethylamino)-4-oxo-4H-l-benzopyran-6-yl carbamic acid dimethyl ester, 2-(Dimethylamino)-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester; when X is N, Y is selected from the group consisting of - R R o wherein Rg and io. being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Rg and RIQ are not both hydrogen; (b) Cχ-C alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C 4 alkyl) ; (d) -(CH 2 ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or carboC -C4 alkoxy), (e) -(CH 2 ) n pyridinyl or (f) wherein R9 and o. taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C -C4 alkyl, C 1"C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Ci- C alkyl, C1-C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH 2 0H, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, 0^-04 alkoxy, halo, trifluoromethyl, -(CH 2 )q0H, -C0 2 H, -C0 2 CH3 -C0 2 CH 2 CH 3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C^-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine, 4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C -C4 alkoxy, halo, trifluoromethyl, -CH 2 0 jj ,- C0 2 H, -C0 2 CH 3 or -C0 2 CH 2 CH 3 , and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5, Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, C^-C alkyl, -(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl)] , -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH ) q NRgRi Q . -CH-CH-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl)] , -CH2-CH-CH 2 , -CH-CH-CH3, -0-CH 2 -CH-CH 2 , -CβC-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C4alkyl)] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -0-(CH 2 )pNR 9 Rιo, -O-CH2CH ( 0CH 3 ) 2 , -0-(CH 2 )p0R 15 , -(CH 2 ) n C(0)-(CH 2 ) n Rg. -(CH 2 ) n C(0)0-(CH 2 ) p Rg, -(CH )n C(0)0- (CH 2 ) p NRgR 10 , -(CH 2 ) n C(O)(CH 2 ) n NRgR 10> N0 2 , -O-(CH 2 ) n C(0)- (CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p Rg, -0-(CH 2 ) n C(0)- (CH 2 ) n NRgR 10 , -NR 9 R 10 , -N(R 9 )(CH 2 ) n C(O)-(CH 2 ) n R 10 , -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n Rι 0 , N(R9)(CH 2 ) n C(O)-(CH 2 ) n NR 9 R 10 . -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι- C 4 alkyl)], -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(Rg) (CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl, -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)"(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg-(CH 2 ) n naphthyl, halo (fluoro, chloro, bromo, iodo) , OH, -(CH 2 ) q -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q 0C(0)-NRgRi Q , .(1-cyclohexyl-1H-tetrazol- - 5-yl)Cι-C 4 alkoxy, -[l-(Cι-C 5 alkyl)-lH-tetrazol-5-yl]Cι-C 4 alkoxy, -[l-( p henyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C -C alkyl)] , -[1-(pyridinyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -[l-(l-phenylethyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, or -C 1 -C 4 alkoxyl; Rl5 is selected from C1-C5. alkyl, -(CH 2 ) n phenyl [phenyl optionally substituted with one, 2 or 3 C -C alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 Cι-C4al yl ] , -(CH 2 ) n pyridin-l-yl or -(CH 2 ) p piperidin-l-yl] ; n is 0-5; p is 2-5; q is 1-5; and pharmaceutically acceptable salts and hydrates thereof, in association with a pharmaceutcal carrier. 21. A process for the preparation of a compound of Formula I wherein X is CZ where Z is H, C1-C5 alkyl, amino (-NH 2 ) or a halogen atom; Y is selected from the group consisting of -(CH 2 ) n NRgRiQ wherein Rg and R^Q, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that Rg and RIQ are not both hydrogen; (b) Cχ-Cι 2 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C alkoxy, halo, OH, trifluoromethyl or -C0 2 (C1-C4alkyl) ; (d)- (CH ) n phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, ^-04 alkoxy, halo, OH, tri¬ fluoromethyl or carboCι«C4 alkoxy), (e) -(CH 2 ) n pyridinyl or (f) wherein Rg and Rχo, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of Ci- C4 alkyl, C -C4 alkoxy, halo or trifluoromethyl (cc) 3-amino-l-pyrrolidine, (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH 2 OH, or trifluoromethyl (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH 2 )qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-l-piperazine, 4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-l- piperazine optionally substituted with one or two members selected from the group consisting of Cτ-C alkyl, C -C4 alkoxy, halo, trifluoromethyl, -CH 2 0 H ,- C0 2 H, -C0 2 CH 3 or -C0 2 CH 2 CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- me hylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetra- hydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3, -tetrahydroisoquinoline or imidazole; and R5, Rg, R7 and Rg, being the same or different, are selected from the group consisting of hydrogen, C -C alkyl, -(CH 2 ) n ρhenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Cι-C alkyl)], -(CH 2 ) n naphthyl, -(CH 2 ) n pyridinyl, -(CH ) q NRgRi Q , -CH-CH-phenyl [wherein phenyl is optionally sub¬ stituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (Ci-C 4 alkyl)] , -CH 2 -CH-CH 2 , -CH-CH-CH3, -0-CH 2 -CH-CH2, -C»C-phenyl [wherein phenyl is optionally sub- stituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C 1 -C4alkyl)] , -0(CH 2 )p(N-methylpiperdin- 3-yl), -0-(CH 2 )pNRgR 10 , -O-CH2CH ( 0CH 3 ) 2 , -0-(CH 2 )p0R 15 , -(CH 2 ) n C(0)-(CH 2 ) n R 9 , -(CH 2 ) n C(0)0-(CH 2 ) p R 9f -(CH )n C(0)0- (CH 2 ) p NRgRιo, -(CH 2 ) n C(0)(CH 2 ) n NRgRι 0 , N0 2 , -0-(CH 2 ) n C(0)- (CH 2 ) p Rg, -0-(CH 2 ) n C(0)0-(CH 2 ) p R 9 , -0-(CH 2 ) n C(0)-(CH 2 ) n NR g R 10 , - 9R10, -N(Rg)(CH 2 ) n C(0)-(CH 2 ) n Ri 0 , -N(Rg)-(CH 2 ) n C(0)0- (CH 2 ) n R 10 , N(Rg)(CH 2 ) n C(0)-(CH 2 ) n NRgR 10 , -0-(CH 2 ) n phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C -C4 alkyl, G1-C alkoxy, halo, OH, trifluoromethyl or -C0 2 (C - C 4 alkyl)], -0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-(CH 2 ) n pyridine, -0-(CH 2 ) n C(0)0-(CH 2 ) n pyridine, -0(CH 2 ) n C(0)-N(Rg)(CH 2 ) n pyridine, -0-(CH 2 ) n quinoxalinyl, -0-(CH 2 ) n quinolinyl, -0-(CH 2 ) n pyrazinyl, -0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)0-(CH 2 ) n naphthyl, -0-(CH 2 ) n C(0)NRg-(CH 2 ) n naphthyl, halo (fluoro, chloro, bromo, . iodo), OH, -(CH 2 ) α -0H, (CH 2 ) q 0C(0)Rg, -(CH 2 ) q 0C(0)-NRgRi Q . .(1-cyclohexyl-lH-tetrazol- 5-yl)Cι-C 4 alkoxy, - [l-(Cι-C 5 alkyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -[l-( p henyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C 1" G 4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C -C alkyl)] , -[1-(pyridinyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -[1-(1- phenylethyl)-lH-tetrazol-5-yl]Cι-C4 alkoxy, -C -C alkoxyl, or a group of Formula II (see Formula Sheet) wherein R' is methyl or carboxy, R' ' is hydrogen and R' ' ' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], Ci- C 5 alkyl, -(CH 2 ) n C0 H, -CH 2 SH, -CH 2 SCH 3 , imidazolinylmethylene, indolinylmethylene, CH 3 CH(0H) , CH 2 0H, H 2 N(CH 2 ) 4 -(optionally in protected form) or H 2 NC(NH)NH(CH2)3 (optionally in protected form) ; with the overall proviso that when Y is other than -(CH 2 ) n morpholinyl, at least one member of R5, Rg, R7 or Rg is other than hydrogen, C -Cg alkyl, NO2. OH, C -C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH 2 , or dimethyamino; with the further proviso that when Y is 4- morpholinyl, the compound is other than: 6,7-dimethoxy-2-(4-morpholinyl)-4H-l-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-1-benzopyran-4-one, N-cyclohexyl-2- [ [8-methyl-2- (4-morpholinyl)-4-oxo-4H-l- benzopyran-7-yl]oxy] -acetamide, 2- [ [8-methyl-2- (4-morpholinyl) -4-oxo-4H-l-benzopyran-7- yl]oxy] -N-phenyl-acetamide, 6- [ (1-cyclohexyl-lH-tetrazol-5-yl)methoxy] -2- (4-mor- pholinyl)-4H-l-Benzopyran-4-one, 2- [ [8-methyl-2-(4-morpholinyl) -4-oxo-4H-1-benzopyran-7- yl]oxy]-N-(1-phenylethyl)-acetamide; with the further provisio that when Y is dimethylamino, the compound is other than: 2- (Dimethylamino) -8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester, (Dimethylamino)-4-oxo-4H-l-benzopyran-6-yl carbamic acid dimethyl ester, 2-(Dimethylamino)-4-oxo-4H-l-benzopyran-7-yl carbamic acid dimethyl ester; R 5 is selected from C^-Cg alkyl, -(CH 2 ) n phenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C -C4 alkoxy, halo, OH, trifluoromethyl or -C0 2 (C -C4alkyl ] , -(CH 2 ) n pyridin-l-yl or -(CH 2 ) p piperidin-l-yl] ; n is 0-5; p is 2-5; q is 1-5; which comprises reacting a salicylic acid ester of Formula A with an ynamine of Formula B I N / \ Rg χo

Inventors: GAMMILL RONALD B, JUDGE THOMAS M, MORRIS JOEL, GAMMILL, RONALD, B., JUDGE, THOMAS, M., MORRIS, JOEL
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1989
Main classification: C07D405
IPC codes: A61K31, A61P9, C07D265, C07D311, C07D405, C07D413, C07D417